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“La clef de toutes les sciences est sans contredit le point d'interrogation ; 
nous devons la plupart des grandes découvertes au comment ? 
Et la sagesse dans la vie consiste peut-être à se demander, 
à tout propos, pourquoi ?” 
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Abstract 
 
Various epidemiological surveys have recently demonstrated that the incidence and mortality rates of 
cutaneous malignant melanoma are still increasing in western countries. Incidence rates have dramatically 
increased during the last 70 years, raising from 1:1,500 in 1935 to 1:68 in 2002. Although its morbidity 
rates in certain population groups have slightly declined lately, it remains the most common malignancy 
among young adults. Malignant melanoma represents 5% of all skin cancers, but 71% of all skin cancer 
deaths in Caucasian populations. Unless primary melanoma tumors are detected early enough and 
adequate surgery can be performed, the prognosis of the disease is very poor, particularly, because of its 
high metastasizing potential and the difficulty to detect and to treat either the primary or the secondary 
lesions. 
 
Ionizing radiation is one of the major means to kill tumor cells in patients suffering from cancer. Specific 
targeting of radioisotopes to the surface of cancer cells, with the purpose of exposing them to in situ 
generated radiation, was initially studied with antibodies as vehicles. Radiopeptides for targeting began to 
interest radiochemists and nuclear oncologists later, when structural peptide analogues with excellent 
biostability and bioactivity became available; in addition, these analogues carried suitable chemical groups 
for incorporation of a variety of different isotopes. The idea, however, to apply radioactive peptides to 
receptor-mediated targeting of tumor cells dates back to the early 1970s, when peptide hormone receptors 
(i.e. binding sites) had been identified on cell membranes. Radiopeptides are attractive tools for cancer 
diagnosis and therapy because a variety of human tumors overexpress surface receptors for regulatory 
peptides or peptide hormones. The best examples illustrating the rationale of this strategy are radiolabeled 
somatostatin (SST) analogs, which are commercially available (OctreoScan® and OctreoTher®) and 
routinely used in clinics to image or even treat neuroendocrine tumors and tumors of the nervous system 
expressing SST receptors.  
 
Melanocortin type 1 receptors (MC1R) are overexpressed at the surface of melanoma cells. The hormone 
!-MSH is the native ligand of MC1R, and !-MSH analogs bind with great affinity as well. Therefore, !-MSH 
derivatives with improved in vivo stability and behavior and bearing chelates able to incorporate various 
radionuclides have been developed. Nevertheless, the side-effects of nonspecific retention in the kidneys 
limits the therapeutic efficacy of most radiopeptides, as nephrotoxicity is the dose-limiting factor. 
Simultaneously, diagnosis of tumors localized in the renal region can be markedly compromised. 
 
Elevated renal uptake and prolonged retention of radiolabeled antibody fragments and peptides in this and 
other organs represent a major issue for the therapeutic application of such agents. Over recent years, one 
of the focuses of research has therefore been to find new methods to reduce renal uptake. Several 
strategies have been investigated without sufficient success. Whether variations in the net charge of the 
peptide itself, use of chelator complexes other than DOTA, study of different isotopes, the position of the 
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chelator complexes in the peptide molecule or of various regulating elements within the peptide sequence 
such as, e.g., cyclization of the peptide, none of these approaches resulted in substantial satisfaction. 
Therefore, new strategies are needed to potentially solve the kidney uptake issue, or at least to improve the 
ratio between tumor uptake and kidney uptake of radioactivity. 
 
Dimerization of peptides has been studied in the field of MSH derivatives since 1977, when several MSH 
molecules (up to 300) were attached to the tobacco mosaic virus (TMV), yielding a complex that displayed 
a 1,500-fold higher potency than !-MSH. Other dimeric !-MSH derivative synthesized later showed 
increased in vitro affinity. Finally, various dimeric ACTH derivatives displayed increased potencies 
compared to their monomeric equivalents. Thus, this approach was tempting to test new dimeric peptides 
derived from known efficient sequences, taking latest findings about peptide sequences and key structural 
elements into account. The idea was not to hit simultaneously two receptors, but to increase the 
concentration of the binding motif in the vicinity of the receptor in order to potentially improve tumor uptake 
of the peptides in vivo. Three dimeric peptides were successfully synthesized, labeled with 111In and tested, 
and although they exhibited excellent receptor binding affinities in the subnanomolar range and good 
internalization properties, the in vivo data did not match the expectations. Indeed, no increase in tumor 
uptake could be observed, and the dimeric derivatives suffered from very high kidney uptake, making them 
unsuitable for diagnostic or therapeutic purposes. 
 
A new type of 111In-labeled !-MSH glycopeptide analogs was then investigated. Glycopeptides were initially 
introduced to improve drug delivery to target tissues, either by taking advantage of specific uptake 
mechanisms or by enhancing the bioavailability of peptides. Glycopeptides were shown to exhibit 
prolonged effects (glycosylated enkephalin peptides) due to better delivery to the target tissue, enhanced 
renal peptide uptake from blood (glycosylated Arg8-vasopressin), an improved stability toward enzymatic 
degradation in vivo, or a better intestinal absorption, thus enhancing the bioavailability of the peptides. 
Other effects of glycation on peptide properties appeared later, including higher or lower accumulation in 
the proximal tubules of the renal cortex, depending on the coupled sugar. Structure-activity relationship 
studies could describe structural features to exploit or avoid in order to target the kidney. It was observed 
that the affinity of peptides for kidney membrane cells could be modulated by attaching different types of 
sugars to the molecules, and this led to systematic SAR studies confirming the observations. Other studies 
also mention that after carbohydration of somatostatin derivatives, a switch in the excretion way could be 
observed. It appeared that the glycopeptides tended to exhibit a switch from the hepato-biliary towards the 
renal excretion way, without affecting the uptake in targeted tissues. 
 
This was the basis for the development of carbohydrated !-MSH derivatives in this thesis. Six glycated !-
MSH derivatives, based on the sequence of DOTA-NAPamide (one of the peptides exhibiting the best 
pharmacokinetic profile to date) were synthesized and tested. Various carbohydrate moieties were coupled 
at different positions along the peptide sequence, in order to determine the influence of the type of sugar or 
its position on the in vitro and in vivo properties of !-MSH analogs. Competitive binding assays displayed 
results in accordance with the data obtained for the reference peptide, indicating that carbohydration does 
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not affect target receptor affinity. Biodistribution experiments with melanoma-bearing mice delivered 
interesting results. While C-terminal glycation enhanced kidney uptake and retention time, side-chain-
glycation seemed only to increase kidney uptake. The N-terminal end, on the other hand, is apparently the 
best position for carbohydration. Indeed, two of the three peptides displayed promising results. Introduction 
of a galactose moiety was particularly favorable, as it delivered a better tumor-to-kidney ratio of the area 
under the curve (4-48h) than the reference peptide DOTA-NAPamide. Thus, carbohydration was shown to 
exhibit a high impact on the pharmacokinetics of !-MSH analogs. Some major tendencies on the biological 
characteristics after glycation could be drawn, and a new candidate with good potential as lead for further 
derivation could be developed. 
 
Finally, novel analogs of negatively charged !-MSH were investigated in this work. It has been shown in 
the past that the surface of tubular cells is negatively charged and that anionic molecules are excreted 
more easily than cationic molecules, probably because of repulsive electrostatic effects. Therefore, 
derivatives carrying an overall negative charge were synthesized and tested. One of them bore two 
negatively-charged D-Asp and the chelate at its C-terminal end, in order to enhance the renal excretion of a 
potential metabolite. The peptide yielded poor results, both in vitro and in vivo. Affinity of the peptide for the 
receptor was lost. In another peptide, DOTA was coupled over a Gly-spacer to a phosphorylated Tyr 
located at the N-terminal end of the peptide. While the new derivative displayed average results in vitro, its 
in vivo data were excellent. Indeed, an even better tumor-to-kidney ratio of the area under the curve (4-48h) 
than DOTA-Gal-NAPamide was reached, delivering the best linear 111In-labeled !-MSH analog to date. 
 
Although this study encompasses only a limited panel of derivatives from each group of peptides 
investigated, some important trends for the development of further derivatives could be established. 
Complete sets of in vitro and in vivo data were collected for all the peptides, providing valuable information 
for the elucidation of structural features required to improve the pharmacokinetic behavior of peptides for 
targeting the MC1R. Two new lead candidates provided excellent data; they could be further optimized by 
combining features of both of them. Indeed, no linear 111In-labeled !-MSH analog exhibited such interesting 
tumor-to-kidney ratios as DOTA-Gal-NAPamide and DOTA-phospho-MSH2-9 to date. 
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1 Introduction 
1.1 MSH and skin 
 
The skin is the largest organ of the body, and its first line of defense against heat, sunlight, injury and 
infection through various pathogens. In addition to its ability to communicate internal physiological 
information, like the presence of fever, the skin also reacts to external stimuli, such as sun exposure, 
toxins, and even psychological stimuli. From poison indication and warning, to the "cold sweats" and 
"goosebumps", the skin is a constant and dynamic interface between the body and its environment. It also 
helps to regulate the temperature and the water and electrolyte contents of the body. Additionally, it helps 
to protect the underlying organs and muscles. Skin also contains various sensory organs or receptors and 
contributes to the synthesis of vitamins B and D. Finally, the skin is involved in breathing and gas exchange 
processes. 
 
 
Figure 1: Anatomy of the skin (modified from H. Leonhardt, Histologie, Zytologie und Mikroanatomie des 
Menschen, Thieme Verlag 1990). 
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The skin has an average surface of about 1.5-2 m2, and to the greater extent it is 2-3 mm thick. It consists 
of three main layers, subdivided into several others. These layers are differentiated by their respective 
amounts of hair follicles, pigmentation, cell formation, gland makeup, and blood supply. Moreover, these 
layers are present in the two general types of skin, thin and hairy, and thick and hairless. The former is 
more prevalent on the body, while the latter is found on parts of the body that are used heavily and 
experience extreme friction, like the palm and the heel. Underneath the dermis lies subcutaneous tissue, or 
hypodermis. 
 
Figure 1 describes the anatomy of the skin, and its major components can be easily observed. The 
epidermis represents the outermost layer and is subdivided into 5 sublayers. Under the epidermis lies the 
dermis, which is divided into two regions. Finally, the hypodermis, which is not really part of the skin, but 
more an important component of the whole integumentary system, is responsible for the attachment of the 
skin to muscles and bones, and for the blood supply to the skin. 
 
• Epidermis:  - stratum corneum 
   - stratum lucidum 
   - stratum granulosum 
   - stratum spinosum 
   - stratum basale 
 
• Dermis:  - papillary dermis 
   - reticular dermis 
 
• Hypodermis:  - subcutaneous tissue 
 
 
In the epidermis, our main region of interest, cells called keratinocytes are formed through mitosis in the 
innermost layer (stratum basale). They move up the various strata changing shape and composition as 
they go through the process of differentiation, fill themselves with keratin (from whence their name is 
derived), develop into cornocytes and die due to lack of blood supply. The epidermis contains no blood 
vessels, and only the lower cell layers are nourished by diffusion from blood capillaries reaching the upper 
layers of the dermis. Therefore, cells die as they differentiate and move up the strata towards the stratum 
corneum, consisting of dead cells that will detach in a process called desquamation. The whole process is 
called keratinization and takes place within weeks. The outermost sublayer of the epidermis, stratum 
corneum, consists of 25 to 30 layers of dead cells, and this keratinized layer is responsible for sparing body 
hydration and protection against harmful chemicals and pathogens. 
Langerhans cells represent around 3 to 8% of the epidermal cells. They belong to the group of T-
lymphocyte antigen-presenting dendritic cells, and are trans-epithelial. They are particularly scattered 
between the keratinocytes of the stratum spinosum of the epidermis. E-cadherin probably plays an 
important role in their adhesion to keratinocytes. Langerhans cells are known to initiate and spread immune 
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responses against antigens on the skin surface. Their role is to capture exo-antigens via endosomes, to 
process them and to re-express them on the surface with class II molecules of the MHC (major 
histocompatibility complex)295. After catching the antigen, activated Langerhans cells leave the epidermis 
and head for the satellite lymph nodes where they present antigenic determinants to T-lymphocytes. 
 
 
Figure 2: Detailed view of the epidermis (from Sobotta Lehrbuch Histologie, 2
nd
 edition (2006), Urban & 
Fischer, München) 
 
 
Melanocytes are the cells mainly responsible for skin pigmentation, and therefore will be of major interest in 
this work. There are typically between 1000 and 2500 melanocytes per square millimeter of skin. Although 
their size can vary, melanocytes typically measure 7 micrometers in length. Melanocytes can be found at 
many locations throughout the body. In the skin they are usually associated with the hair follicle, and in 
some mammals (including humans), they are found in the basal layer (stratum basale) of the interfollicular 
epidermis as well. Mature melanocytes form long dendritic processes that ramify around the neighboring 
keratinocytes. Each melanocyte typically makes contact with about 30 to 40 keratinocytes and forms the 
so-called epidermal melanin unit, described later in this work (1.2.2). Melanin is transferred from those 
melanocytes to the keratinocytes, where it contributes to the determination of skin color and helps 
protecting the skin against the damaging UV radiation278. 
 
!-Melanocyte-stimulating hormone (!-MSH) is the native ligand of melanocortin receptors type 1 (MC1R), 
which are located at the surface of melanocytes and induce signals triggering melanogenesis. !-MSH is 
Merkel cells 
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Basal layer 
Melanocyte 
Stratum corneum 
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Stratum spinosum 
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generated by post-translational enzymatic cleavage of the precursor molecule proopiomelanocortin 
(POMC), which occurs primarily in the pituitary gland (=hypophysis)87, in both the anterior and the 
intermediate lobe. !-MSH itself is produced in the intermediate lobe, located between the adenohypophysis 
(anterior lobe) and the neurohypophysis (posterior lobe). Although it is mainly located in the hypophysis, 
POMC and production of POMC-derived peptides is not confined to this organ. It was shown in several 
studies that POMC-derived peptides could be detected in significant levels in various tissues, such as 
lymphocytes and monocytes, and more particularly in the skin (Langerhans cells)36. !-MSH was isolated 
from the skin of various species (including humans), and it was proven that this !-MSH could not be 
pituitary-derived. In the skin, it is usually produced by melanocytes, but was also shown to be produced by 
keratinocytes269. POMC expression could also be detected in the dermis in vitro. Human papilla cells 
(regulating hair follicle activity) also exhibited immunoreactivity for ACTH, !-MSH and "-endorphin, and 
expressed both the MC1R and the MC4R. Additionally, immunoreactivity for both receptors could be 
detected in human dermal papilla cells in situ. The data collected in this study suggest a regulatory role of 
!-MSH within the dermal papilla. Deregulation of the system may lead to abnormal immune and 
inflammatory responses of the hair follicle, and could have an implication in inflammatory forms of 
alopecia41. 
 
Other components of the skin comprise the so-called appendages. These are usually located in the dermis 
(see Figure 1). Sweat glands, for example, are distributed almost over the whole body at a density of 
approximately 400 glands/cm2. Their function is to decrease skin temperature by secreting a nearly isotonic 
solution. Hair follicles extend from less than 1 mm into the dermis to more than 3 mm into the hypodermis. 
The average density is about 40-50/cm2, which is less than the density of sweat glands, but their average 
surface area may be larger. A sebaceous gland is associated with each hair follicle. The ducts of 
sebaceous glands join the hair follicles approximately 0.5 mm below the surface of the skin. In the initial 
diffusion state, hair follicles are one of the most important sites for percutaneous penetration. The inner root 
sheath surrounding the hair shaft presents an opportunity for molecules to diffuse along the hair follicle. 
This compartment is filled with sebum, which does not form a barrier to diffusion. When a steady diffusion 
state has been reached, diffusion through the stratum corneum becomes the dominant pathway66. 
 
Sebaceous glands are found in all regions of the body except on the palms of the hands and sole of the 
feet. They are connected with a duct to the hair follicle where they deliver the sebum. The sebum is 
composed primarily of triglycerides and free fatty acids with fewer amounts of squalene and waxes. It is 
generally accepted that sebum does not participate in the barrier function of the skin. Among these 
appendages, the sebaceous glands are of great interest, as MC1R expression was detected both in vitro 
and in situ in human sebocytes40, and as !-MSH has long been known to target the sebaceous gland as 
well. By modulating interleukin-8 secretion307, !-MSH is thought to modulate the inflammatory response in 
the pilosebaceous unit. 
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1.2 Melanocytes, epidermal melanin unit and melanogenesis 
 
In order to understand the process of normal physiologic pigment production or of its disorders such as 
hyper- and hypopigmentation, an appreciation of the structure and functions of melanocytes, briefly 
described in the previous chapter, is required. 
 
1.2.1 Melanocytes 
 
Histologically, melanocytes are derived from the neural crest. During embryogenesis, they migrate from the 
lateral ridges of the neural plate as the ridges join to form the neural tube. During further development, 
presumptive melanocytes (undifferentiated melanoblasts) migrate to various sites including the skin, where 
they proliferate and then differentiate into melanin-producing cells239. The uveal tract of the eye (choroids, 
ciliary body and iris), the leptomeninges (the two innermost membranes of the meninges) and the inner ear 
(cochlea) constitute additional sites of melanocyte migration. In the inner ear, melanocytes play a role in 
developing the ability to hear. Thus, the lack of migration or survival of melanocytes in the inner ear, the 
iris, and parts of the forehead and extremities may explain the expression of congenital deafness, 
heterochromia irides (two differently colored irises), and patches of leukoderma (synonym of vitiligo: an 
auto-immune disorder in which the body destroys its own melanocytes) in patients with Waardenburg 
syndrome (rare disorder resulting from an autosomal dominant mutation involving disorders in the neural 
crest-derived tissue). 
 
During embryogenesis, melanin-producing melanocytes are found diffusely spread throughout the dermis. 
With the help of the monoclonal antibody HMB-45, melanoblasts have been identified in human fetal skin at 
approximately 7 weeks of gestation147. After 10 weeks, they appear for the first time in the head and neck 
region. They then become numerous between the 12th and the 14th week of fetal development104. These 
dermal melanocytes disappear after birth either by migration to the epidermal tissues or through cell death 
(given the difference in the absolute numbers of cells in the dermis and in the epidermis), except in three 
anatomic locations: the head and neck, the dorsal part of the distal extremities, and the presacral area337. 
In addition, these three sites coincide with the most common sites for dermal melanocytoses and dermal 
melanocytomas (blue nevi). 
 
As mentioned earlier, the basal layer of the hair matrix and the outer root sheath of hair follicles are also 
main migration destinations of melanocytes. Cells located in the matrix produce melanin, whereas 
melanocytes of the outer root sheath usually are amelanotic, and therefore more difficult to identify. It is 
also thought that there are two populations of melanocytes, one in the hair follicle and one in the 
interfollicular epidermis308. Based on clinical observations and antigen expression, the latter seems to be 
more sensitive to the destructive effect of vitiligo. Melanocytes usually reside in the basal layer of the 
epidermis, where they will remain during their whole life. They allow their dendrites to make contact with 
keratinocytes, building the epidermal melanin unit described later in 1.2.2. 
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Under normal conditions, it is more the level of activity of the melanocytes than their number that 
determines the degree of pigmentation of the skin44. Although some regional variations occur in the density 
of epidermal melanocytes, their amount remains more or less equal even in different skin types and ethnic 
groups. Normally, their density in the genital region lies around 1500 melanocytes/mm2 and is higher than 
on the back (~900/mm2). Usually the number of melanocytes in humans varies from about 900 to 2800 per 
cm2, and there are smaller differences between individuals when the same anatomic part is examined. 
Therefore, skin pigmentation is considered to depend on the level of melanogenic activity and the transfer 
of melanin to the neighboring keratinocytes. Hence, even people suffering from the most severe form of 
oculo-cutaneous albinism show normal amounts and densities of epidermal melanocytes. Several factors 
contribute to the melanogenic activity of the cells, including specific characteristics of the melanosomes 
(e.g. diameter), the organelle where melanin is synthesized, as well as constitutive and stimulated levels of 
activity of enzymes involved in the melanin synthesis. These enzymes are influenced by receptor-mediated 
interactions with extracellular ligands, e.g. !-melanocyte-stimulating hormone (!-MSH), that will be 
described later on. 
 
 
1.2.2 Epidermal melanin unit 
 
The function of melanocytes in mammalian skin is to form and maintain dendrites, to synthesize and 
mature melanosomes and to secrete these into keratinocytes with which they are associated. In the human 
epidermis, each melanocyte secretes melanosomes to approximately 36 keratinocytes, forming an 
epidermal melanin unit. The epidermal melanin unit is the structural and functional unit allowing a color 
adaptation. Skin and hair pigmentation is clearly related to the amount of melanin contained in the 
keratinocytes. Several sequential processes can be distinguished233,278. 
 
1. Formation of structural proteins and the enzyme tyrosinase, and their assembly in the 
melanosomes; 
2. Melanization of the melanosomes through enzymatic oxidation of tyrosine to melanin; 
3. Migration of the melanosomes from the perikaryon into the dendrites of the melanocytes; 
4. Transfer of the melanosomes to the keratinocytes; 
5. Incorporation of melanosomes by the keratinocytes either as single particles or as melanosome 
complexes; 
6. Degradation of the protein matrix of melanosomes within keratinocytes. 
 
These processes are described in the following figure: 
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Figure 3: Epidermal Melanin Unit in human skin and process involved in melanogenesis (from A.N. 
Eberle, The Melanotropins. 1988, Karger Verlag, Basel)
87
. 
1-3: Steps in melanocyte development. 4-10: Stages in melanin formation (tyrosinase is synthesized by RER 
and then transported to Golgi). Abnormalities in pigmentation may be caused by a defect at any of these steps. 
I-IV: The four stages of melanosome development as differentiated by electron microscopy: I = Large spherical, 
membrane limited vesicle formed by fusion of tyrosinase-containing Golgi-vesicle and RER-derived vesicle; no 
melanin deposition. II = Oval; obvious matrix in the form of parallel longitudinal filaments; minimal deposition of 
melanin; high tyrosinase activity. III = Oval; moderate deposition of melanin; high tyrosinase activity. IV = Oval; 
heavy deposition of melanin; electron-opaque; minimal tyrosinase activity.  
 
 
1.2.3 Melanogenesis 
 
Melanogenesis is the process leading to the synthesis of two chemically distinct kinds of melanin: the 
lighter yellow-red phaeomelanins and the darker brown-black eumelanins. The type of melanin produced is 
also important for the level of skin pigmentation, and it is recognized that both types of melanin are 
synthesized in human melanocytes152. Phaeomelanin is the major type of melanin in red hair and also 
predominates in skin types I and II. Humans with red hair will tend to produce more pheomelanin in hair 
and skin and/or have a reduced ability to produce eumelanin, thus explaining the lack of tanning and higher 
sensitivity to harmful UV-radiation315. Eumelanin is present in larger amounts in individuals with darker skin 
and hair (types III and IV). Eumelanin provides a better protection against damaging UV radiation. 
 
The process of skin pigmentation can be divided into two components. The first is the pigmentation 
genetically determined in the absence of stimulatory influences, affecting, e.g., the level of pigmentation of 
parts of the body normally not UV-radiation exposed. It is called “constitutive pigmentation”. The second is 
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the level of pigmentation (or tanning) occurring in response to stimuli like UV-radiation or even, to a certain 
degree, hormones, and is called “facultative pigmentation”. These external stimuli are converted into 
intracellular messenger molecules that then affect melanogenesis. 
 
Following a single exposure to UV irradiation, an increase in the size of melanocytes can be observed, 
along with an increase in tyrosinase activity44. Repeated exposures to UV irradiation lead to an increase in 
the number of stage IV melanosomes transferred to keratinocytes, as well as an increase in the number of 
active melanocytes. Density of melanocytes is roughly twofold higher in the chronically exposed (e.g. the 
upper outer arm) than in the non-sun-exposed (e.g. the upper inner arm) skin at all ages127. An immediate 
pigmentary darkening occurs within minutes after UVA exposure, and fades away after 6-8 hours. It is more 
easily observed in darker skin types, and therefore is thought to illustrate oxidation of pre-existing melanin 
or melanin precursors. A new pigment production (via an increase in tyrosinase activity) happens and 
becomes visible 48-72 hours after exposure to UVB and UVA radiation. It is called delayed tanning. The 
majority of red-haired individuals are unable to develop a tan after UV exposure. Dysfunctional MC1-R on 
their melanocytes can partly explain this inability. This phenomenon, along with the production of free 
oxygen radicals following the UV irradiation of phaeomelanins, probably contributes to the increased 
incidence of both cutaneous melanoma and nonmelanoma skin cancers in red-haired persons45. 
 
The synthesis of melanin takes place in the melanosomes, organelles located in the cytoplasm of 
melanocytes and that are closely related to lysosomes. Indeed, in the same way the cell is protected from 
proenzymes and proteinases contained in the lysosomes, melanosomes home the melanogenesis process 
in order to protect the inner part of the cell against various harmful melanin precursors (e.g. phenols, 
quinines, catechols) generated during melanogenesis, and able to oxidize lipid membranes99. The 
melanosomes contain matrix proteins, which form a scaffold to deposit the melanin itself, and enzymes that 
regulate the biosynthesis of melanin (e.g. tyrosinase). Many of these enzymes are glycoproteins, requiring 
carbohydrate ligand binding in order to gain full function141. For example, after synthesis and release of pre-
tyrosinase in the lumen of the rough endoplasmic reticulum (RER), the enzyme migrates via the smooth 
surface membrane to the Golgi apparatus where terminal carbohydrates, such as sialic acid, are bound. 
Then it joins the matrix proteins to form the melanosomes. Targeting enzymes to the plasma membrane via 
intracytoplasmic organelles requires “helper”-proteins. The adaptor protein 3 (AP3) carries this function, 
and is involved in the budding of vesicles from the trans Golgi network, and therefore plays a role in the 
melanosome formation141. 
 
After tyrosinase is transported to the Golgi apparatus and the melanosome matrix is synthesized, the 
maturation process of the melanocytes reaches its final stages. The melanization of the melanosome 
occurs in several steps. Tyrosinase activity reaches a peak and then decreases as melanization of 
melanosomes increases. As soon as melanin is deposited, the melanosomes migrate via microtubules into 
the dendrites of the melanocyte for the transfer into the neighboring keratinocytes. Microtubules and the 
motor proteins kinesin and dynein are involved in the movement. Within the dendrites, a specialized myosin 
protein is contributing to the process by forming a bridge between the actin cytoskeleton beneath the 
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plasma membrane and the organelle itself, each end of the myosin connecting both structures 
together140,141. 
 
 
Figure 4: Melanogenesis pathway (modified and completed from Wikberg et al.
325
 and from V.J. Hearing
140
). 
 
As shown in Figure 4, pigmentation regulation involves several layers of control: UV irradiation of the 
dermis increases production of melanocortic peptides. These first bind to the MC1 receptor, thus 
stimulating adenylyl cyclase (C) and hence the production of cAMP. Protein kinase A (PKA) is then 
activated by this cAMP, leading to the phosphorylation of CREB (cAMP-responsive element-binding 
protein) and cis-activation of the microphthalmia-associated transcription factor (MITF) promoter. MITF 
therefore regulates the transcription of the tyrosinase gene. MITF belongs to the basic-helix-loop-helix-
zipper family and is known to interact with a specific DNA sequence termed M-Box with the sequence 
GTCATGTGGCT present in the promoter region of the tyrosinase gene35. The intracellular second 
messenger cAMP increases tyrosinase gene expression by enhancing the interaction between MITF and 
the M-Box. MITF finally induces expression of tyrosinase, TRP1 and TRP2 (tyrosinase-related proteins 1 
and 2), and likely other genes as well. These proteins in turn influence differentiation, proliferation, 
formation of pigment and inhibit apoptosis. The system is positively coupled: activation of cAMP leads to 
increased formation of MC1 receptors, which in turn allow to form even more cAMP. Therefore, the 
increased MC1 receptors production causes an increased sensitivity to melanocortic peptides325. The 
actual biochemical synthesis really starts after expression by MITF-mRNA of the several genes mentioned 
earlier. Negative regulation is achieved by agouti protein, which acts as an inverse agonist on MC1R4. 
Agouti leads to the preferential formation of pheomelanins (details see below). 
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The brown-black eumelanin and the yellow-reddish pheomelanin mainly differ in their biochemical structure 
and ultrastructural appearance within melanosomes268. Both are derived from the naturally occurring amino 
acid tyrosine, and the whole melanin biosynthesis pathway itself is mainly regulated by the enzyme 
tyrosinase, which catalyses multiple steps in the biosynthesis of melanin through tyrosine hydroxylase, 
DOPA oxidase and dihydroxyindole oxidase activities. 
 
The early steps on the melanogenic pathway, i.e. the O-hydroxylation of L-Tyr to L-3,4-
dihydroxyphenylalanine (DOPA) in presence of elementary oxygen (O2), as well as the oxidation of L-DOPA 
to L-dopaquinone, are catalyzed by the enzyme tyrosinase184,199. Tyrosinase is an important key enzyme of 
65 kDa (75 kDa when glycosylated), is the rate-limiting enzyme in the melanin biosynthesis and requires 
copper on two binding sites. All tyrosinases have in common a binuclear type III copper centre within their 
active site, where two copper atoms are each coordinated with three histidine residues. The two copper 
atoms within the active site of tyrosinase enzymes interact with dioxygen to form a highly reactive chemical 
intermediate that then oxidizes the substrate292. The activity of tyrosinase is similar to catechol oxidase, a 
related class of copper oxidase. Tyrosinases and catechol oxidases are collectively termed polyphenol 
oxidases. The uniqueness of tyrosinase lies in the fact that it requires DOPA as cofactor for the tyrosine 
hydroxylase reaction142. The product is therefore the cofactor for the synthesis of the product. Rates of 
tyrosine hydroxylation in the absence of the cofactor are negligible, raising the question of where the 
cofactor comes from, since DOPA is not a normal amino acid available within the cell. This interesting 
question is to date still unsolved. The kinetics of reduction and oxidation of the active site iron in tyrosine 
hydroxylase may have an influence on the regulation of the reaction107. 
 
Tyrosinase can be divided into three domains: an inner domain that resides inside the melanosome, a 
transmembrane domain and a cytoplasmatic domain. The larger part of the enzyme resides inside the 
melanosome and only 10% or 30 amino acids belong to the cytoplasmatic domain280. The activity of 
tyrosinase is enhanced by DOPA and is stabilized by tyrosinase-related protein 1 (TRP1) in human and 
mouse. The regulation of the activity of tyrosinase is managed by phosphorylation of the enzyme by protein 
kinase C-"230. 
 
DOPA can spontaneously autooxidize to dopaquinone in the absence of tyrosinase, but at slower rates 
than in presence of the enzyme. Dopaquinone is an extremely reactive compound that undergoes an 
irreversible intramolecular cyclization, the nitrogen of the side chain attaching itself to the 6-position of the 
benzene nucleus, leading to the formation of leucodopachrome and then dopachrome in the absence of 
thiols (e.g. from cystein) in the vicinity. Dopachrome is able to decarboxylate spontaneously to 
dihydroxyindole (DHI). In the presence of divalent cations and the enzyme DOPAchrome tautomerase (also 
called tyrosinase-related protein 2, TRP2) though, the intermediate 5,6-dihydroxyindole-2-carboxylic acid 
(DHICA) is formed. DHI is then oxidized to indole-5,6-quinone and DHICA is oxidized to indole-5,6-
quinone-carboxylic acid. It was speculated that the oxidation of DHICA was catalyzed by an enzyme called 
DHICA oxidase. There was also a speculation that TRP1 mRNA expression would be correlated with 
DHICA oxidase activity, which has been confirmed for the murine model but not for the human43. TRP1, at 
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least in mice167, is able to promote the oxidation of DHICA but in humans, this catalytic function of TRP1 
seems to be lost. Human tyrosinase seems capable to accelerate DHICA consumption. 
Further investigations have shown that human tyrosinase actually functions as DHICA oxidase, as opposed 
to the mouse enzyme. Therefore, human tyrosinase displays a less specific substrate specificity than its 
murine counterpart, and thus might be responsible, at least partially, for incorporation of DHICA units into 
human eumelanins224. This leads to a much slower further oxidation and polymerization than for DHI-
eumelanin, resulting in a more soluble, lower molecular weight and lighter colored melanin known as 
DHICA-eumelanin. On the other side, DHI is rapidly cyclized, decarboxylated, oxidized and polymerized to 
form a very black, insoluble and high molecular weight pigment, the previously mentioned DHI-eumelanin. 
Both types of melanin bear an indole non-repeating scaffold and their exact structure remains unknown. 
The quinones are thought to be responsible for this oxidative polymerization. Whether this polymerization 
step lies under enzymatic control is not yet clear. It is thought that peroxidase or the melanocyte-specific 
protein Pmel-17 play a role in this step of melanin synthesis. 
 
Table 1: Characteristics of melanogenic enzymes 
 Tyrosinase TRP1 TRP2 
Synonym 
Monophenol 
monooxygenase 
DHICA oxidase 
Catalase B 
Glycoprotein-75 
Melanoma antigen gp75 
Dopachrome tautomerase 
Dopachrome 
deltaisomerase 
Specificity Melanocyte Melanocyte Melanocyte 
Catalytic 
Activity 
Tyrosine ! DOPA 
DOPA ! Dopaquinone 
DHI ! Indolquinone 
DHICA ! Indolquinone 
carboxylic acid 
Dopachrome ! DHICA 
Miscellaneous 
Heat-stable 
Protease-stable 
Chelator-sensitive 
Glycosylated 
Membrane-bound 
DOPA cofactor-dependant 
Glycosylated 
Membrane-bound 
Heat-sensitive 
Protease-sensitive 
Chelator-insensitive 
Glycosylated 
Membrane-bound 
DOPA cofactor independent 
 
 
The various steps of the synthesis are also likely to be regulated specifically, due to the variety of factors 
involved. One more regulation mechanism possibly involving the P gene is under investigation. The P 
protein (encoded by the P gene), a transmembrane protein in the melanosomes, is most likely involved in 
the transport of tyrosine as initial precursor of the synthesis. The observation that melanosomes isolated 
from melanocytes with mutations in both copies of the P gene will produce more pigment when incubated 
in concentrated solutions of tyrosine could be a possible proof117. Another hypothesis is that the P protein is 
involved in maintaining a low pH within the melanosomes, as a low pH is required for normal tyrosinase 
activity241,243. Stimulations from outside the cell via MC1R increase the production of eumelanin at the 
expense of pheomelanin. Competitive inhibitors of tyrosinase activity include hydroquinone and L-
phenylalanine. 
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The biosynthesis of pheomelanin is different from that of eumelanin in various aspects:  
 
1. It is less dependent on tyrosinase activity than eumelanin synthesis, as pheomelanin is even 
produced when the levels of tyrosinase activity are virtually undetectable50. 
2. Pheomelanins follow another main route of biosynthesis from the dopaquinone key step. In the 
presence of thiol donors like cysteine, dopaquinone is converted to cysteinyl-DOPA by nucleophilic 
addition. Following the same kind of sequence as for eumelanin biosynthesis, cysteinyl-DOPA 
undergoes oxidation by peroxidase, cyclization to form alanyl-hydroxyl-benzothiazine, and finally a 
polymerization step leading to the formation of pheomelanin. Pheomelanins have a yellow-reddish 
color, are soluble in alkali and have a rather low molecular weight. 
 
These various types of melanin are responsible for hair color variations in mammals (humans included). In 
humans, yellow to bright red hair results from the production of pheomelanin, whereas brownish, black, 
grey and blond hair have their origin in eumelanin production156,226. It is not clear how the switch from 
eumelanin production to pheomelanin production, or vice-versa, is controlled. Mutations in genes coding for 
certain proteins may produce phenotypic modifications leading to variations in coat color in the mouse and 
to different hues in the hair and skin of humans27,28. Additionally, it is known that in mice the interactions of 
MSH and agouti protein play a major role in this regulation. In contrast to the human, mouse coat color 
genetic analyses provided explanations for red hair other than through MC1R allelic variation. The key 
player is the agouti protein, a paracrine signaling molecule inhibiting the effects of melanocortin signaling. 
Agouti protein is the only known native competitive antagonist of the MC1R. It inhibits the binding of 
melanocortins and therefore their ability to activate the MC1R. The modulation of the signaling by altering 
the levels of antagonist against a constant background level of melanocortin ligand avoids the necessity for 
a mechanism adjusting !-MSH levels independently of other POMC-derived products, such as ACTH and 
"-endorphin. The existence of MC1R gene sequence variations was also reported in humans. For example, 
variations were found in over 80% of individuals with red hair and/or fair skin, but in less than 20% of 
individuals with brown or black hair, and in less than 4% of those showing a good tanning response. These 
findings suggested that MC1R in humans (as in other mammals) is a switch regulating the pigmentation 
cascade. Additionally, variations in this protein may lead to a poor tanning response315. 
 
Keratinocytes also play an important role in the regulation of melanocyte growth and differentiation. They 
produce a whole variety of factors acting on melanocytes. Under normal conditions, melanocytes do not 
produce their own growth factors and their proliferation is regulated by keratinocytes through the production 
of the autocrine basic fibroblast growth factor (bFGF). Other melanocyte growth factors include mast cell 
growth factor (MGF) and hepatocyte growth factor (HGF), but their effects are not specific to melanocytes. 
Cytokines and other inflammatory mediators are locally produced factors regulating melanocytes. It has 
been suspected that some of these substances may mediate the effects of UV-radiation and post-
inflammatory pigmentary responses. The cytokines interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor-! (TNF-!) have been reported to inhibit both melanogenesis and melanocyte proliferation. 
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These, together with tumor necrosis factor-" (TNF-"), interleukin-7 (IL-7) and interferon-# (INF-#) also 
induce the expression of intercellular adhesion molecule-1 (ICAM-1). 
 
Endothelins also play a role in melanocyte development, growth, melanogenesis, motility and dendricity. 
Studies show that endothelin-1 (ET-1) affects melanocyte dendricity136, proliferation329 and 
melanogenesis155, while endothelin-3 (ET-3) plays an important part in regulation of progenitor number and 
differentiation in melanocyte development245. 
 
Beside their ability to distribute melanin to surrounding keratinocytes, melanocytes are also able to produce 
a wide range of signal molecules, such as cytokines, melanocortin peptides, catecholamines, serotonin, 
eicosanoids, and nitric oxide (NO). Upon UV radiation (UVR) and other stimuli they secrete for example NO 
as a signaling molecule. Human melanocytes produce NO that can be effected by !-MSH, in response to 
UV radiation and bacterial lipopolysaccharides (LPS)310. Why the melanocytes and melanoma cells 
produce NO is not quite clear. It was shown that NO stimulates melanin production and, as it is released by 
keratinocytes in response to UV radiation, it could serve as a paracrine factor in UVR-induced 
melanogenesis257. But melanocytes are capable of producing higher amounts of NO than keratinocytes, 
indicating the possibility that NO acts as an autocrine factor to regulate melanogenesis. However, the main 
importance of NO in melanocytes appears not to be its function as an autocrine mediator, but as a 
signaling molecule linking the melanocyte with other systems in the skin. NO could be related to a 
phagocytotic property of melanocytes as they produce a number of cytokines. !-MSH also plays a role in 
the modulation of the immune system. There is evidence that it has potent anti-inflammatory and 
immunomodulatory properties through its ability of being a competitor for proinflammatory cytokines310,311. 
These examples make it quite clear that melanocytes have various functions beside their ability of 
producing and distributing melanin. 
 
 
1.3 !-Melanocyte-stimulating hormone (!-MSH) 
 
The “melanophore stimulants” have a long history. They were discovered about ninety years ago, when it 
was shown that !-MSH induces skin darkening in amphibians, from whence its name derived. Surgical 
ablation experiments showed that the pituitary gland is involved in the control of skin color, and was one of 
the first observations of its decisive role in endocrine function. 
 
 
1.3.1 The pituitary gland or hypophysis 
 
The pituitary gland, commonly called hypophysis, is an endocrine gland located in a small bony cavity 
(sella turcica) covered by a dural (from the dura mater) fold at the base of the brain. The pituitary fossa, in 
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which the pituitary gland sits, is situated in the sphenoid bone in the middle cranial fossa at the base of the 
brain. The pituitary gland secretes hormones regulating homeostasis, including trophic hormones that 
stimulate other endocrine glands. It is functionally connected to the hypothalamus by the median eminence. 
The pituitary is functionally linked to the hypothalamus. In the adult human, it is composed of two main 
lobes, the adenohypophysis and neurohypophysis, whereas in most other vertebrates, an intermediate lobe 
is present as well. 
 
 
Figure 5: Pituitary anatomy (from S.L. Asa and S. Ezzat)
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. 
The normal pituitary is a bean-shaped gland that has two components. The neurohypophysis, also known as the 
posterior lobe, is an extension of the hypothalamus that descends into the sella turcica. It is composed of neuronal 
processes that secrete hormones that are produced in the cell bodies of hypothalamic ganglion cells of the 
infundibulum; these cell processes are supported by glial cells known as pituicytes. The adenohypophysis is 
composed of hormone-secreting epithelial cells, known as adenohypophysial cells, which are derived from the oral 
ectoderm and ascend as Rathke!s pouch during development. They lose contact with the oral ectoderm where the 
bone of the sella forms. The bulk of this tissue is the anterior lobe or pars distalis of the gland. The intermediate lobe, 
or pars intermedia, is composed of epithelial cells from the posterior limb of Rathke!s pouch. This structure is 
composed mainly of corticotrophs and is well developed in most mammals, but is only rudimentary in humans. The 
pars tuberalis is a small rim of the adenohypophysis that is wrapped around the pituitary stalk; it is composed mainly 
of gonadotrophs. 
 
 
The adenohypophysis, also referred to as the anterior pituitary, is divided into anatomical regions known as 
the pars tuberalis and pars distalis. The adenohypophysis synthesizes and secretes important endocrine 
hormones, such as ACTH, TSH, prolactin, growth hormone, endorphins, FSH, and LH. These hormones 
are released from the anterior pituitary under the influence of hypothalamic hormones. The hypothalamic 
hormones travel to the anterior lobe by way of a special capillary system, called the hypothalamic-
hypophyseal portal system. The neurohypophysis is also referred to as the posterior pituitary. It is 
functionally linked to the hypothalamus by the pituitary stalk, whereby hypothalamic releasing factors are 
released and in turn stimulate the release of posterior pituitary hormones. Hormones are made in nerve cell 
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bodies positioned in the hypothalamus, and these hormones are then transported down the nerve cell's 
axons to the posterior pituitary. The hormones secreted by the posterior pituitary are: 
 
• Oxytocin, which is released from the paraventricular nucleus in the hypothalamus. 
• Antidiuretic hormone (ADH, also known as vasopressin and AVP, arginine vasopressin), is 
released from the supraoptic nucleus in the hypothalamus. 
 
As mentioned, there is also an intermediate lobe in many animals. For instance, in fish, it is believed to 
control physiological color change. In adult humans it is just a thin layer of cells between the anterior and 
posterior pituitary. The intermediate lobe produces MSH, although this function is often (imprecisely) 
attributed to the anterior pituitary. 
 
 
1.3.2 Melanocortins and !-MSH 
 
In the 1930s and 1940s, various bioassays were developed, allowing the quantitative isolation of the 
“melanophore stimulants”. However, these could only be characterized in the 1950s with the development 
of an isolated frog skin bioassay and better purification and sequencing methods. These allowed molecular 
characterization and sequence determination of !-MSH and other MSHs from pig. Isolations from bovine, 
equine, ovine, as well as macaque, camel, dogfish and salmon pituitary glands followed. Later, a functional 
relationship between the so-called melanocortins and adrenocorticotropin, lipotropin and endorphin could 
be proven. Shortly after the isolation of MSH peptides, peptide chemistry adopted new concepts enabling 
the synthesis of these peptides, as well as the synthesis of numerous peptide hormone analogues. In the 
last 40 years, the mode of action of melanotropins could be partly elucidated thanks to the pharmacological 
structure-activity studies developed since then. And these contributions and discoveries, associated with 
the functional relationship shown earlier, culminated in the isolation and sequence analysis of the common 
precursor to all melanotropins, proopiomelanocortin (POMC), in 1979. The first melanocortins to be purified 
and sequenced were !-MSH, "-MSH and ACTH. The !- and "-MSH were initially known as basic and 
acidic melanocyte-stimulating principles due to the difference in their isoelectric points. Once the 
sequences were established, !-MSH was found to share the sequence of ACTH1-13, but carrying a N-
terminal acetyl group and bearing an amidation at the C-terminus. The sequence of "-MSH was different, 
but also shared a common partial sequence with ACTH and !-MSH.  
 
!-MSH consists of a 13-amino acid residue and, as mentioned, carries either a free or acetylated N-
terminal serine and the C-terminal valine contains in most cases a carboxamide group: 
 
Ac – Ser1 – Tyr2 – Ser3 – Met4 – Glu5 – His6 – Phe7 – Arg8 – Trp9 – Gly10 – Lys11 – Pro12 – Val13 – NH2 
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These C- and N-terminal modifications give !-MSH more stability, as they inhibit degradation by 
exopeptidases. In addition, they increase the potency of the peptide in many bioassays87. The C-terminus 
of mammalian !-MSH is amidated. The N!-amino group of Ser1 is either free or blocked with an acetyl 
group, depending on the tissue. In some cases, !-MSH occurs in its diacetylated form, the second 
acetylation being found on the side-chain hydroxyl group of the N-terminal serine, forming the [N,O-
bisacetyl-Ser1]-!-MSH. Acetylation of !-MSH and "-endorphin is an important process in the regulation of 
the biological activity of these peptides77. Acetylation in melanotrophs (cells of the intermediate lobe of the 
hypophysis producing melanocyte-stimulating hormone) of the pars intermedia takes place in secretory 
granules by opiomelanotropin N-acetyltransferase (NAT)56. This enzyme uses acetyl coenzyme A as acetyl 
donor and differs from the soluble acetyltransferase.  The preferential acetylation reaction is that of ACTH1-
14 or ACTH1-13, and to a lesser degree that of "-endorphin. The double acetylation of N-terminal Ser
1 may 
result from an O-acetylation, followed by a spontaneous O!N-shift of the acetyl group. This process is 
often observed during coupling reactions in peptide synthesis. A possible evidence for the increased 
potency of diacetylated !-MSH was shown by recruitment of lactotrope cells secreting prolactin in a primary 
culture of rat anterior pituitary cells by !-MSH, diacetyl-!-MSH, or N-acetylated "-endorphin. The secretion 
of prolactin was significantly increased by the latter two peptides316. 
 
 
Figure 6: Sites of cleavage in POMC of human. Pattern of processing of POMC in melanotrophs of the pars intermedia
87
. 
 
The mammalian !-MSH is a basic peptide with a pI of 10.5-11.0 and has a molecular weight of 1664.93 Da 
(acetylated N-terminus, C-terminal amide group, without counterions). It is more or less heat stable (can be 
heated up to 80°C under physiological conditions for a short period) but very prone to oxidation of the Met4 
residue. Oxidation dramatically decreases the biological activity of !-MSH. It is thought that !-MSH 
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occurred in an early phase of evolution because its sequence is preserved in many different species with 
only slight differences. For example Xenopus !-MSH differs from mammalian peptide only by a single 
mutation at the N-terminus, where Ser1 is replaced by Ala (88). 
 
As mentioned earlier, all melanocortin peptides are derived from a large (31-36kDa) precursor called 
proopiomelanocortin (POMC). POMC is mainly synthesized in the pars intermedia and pars distalis of the 
pituitary gland, but also in other regions of the brain and in several peripheral tissues (e.g. skin, testes, 
ovaries, placenta, adrenal medulla, gastrointestinal tract, cells of the immune system and tumor cells), 
where the precursor is also processed. Induction of corticotropin releasing hormone (CRH) in the 
hypothalamus-pituitary-axis activates CRH-receptors and induces production and secretion of POMC. 
Proteolytical cleavage of the large precursor converts the prohormone into its bioactive form. All the 
melanocortins (!-, "-, #-MSH and ACTH) share a common MSH core sequence bearing the amino acids 
His–Phe–Arg–Trp. Interestingly, investigations about the relative levels of the different POMC-derived 
peptides and thus the processing level of POMC showed predominant presence of the unprocessed 
hormone in the blood, indicating that POMC is inefficiently processed in the pituitary125. Similarly, POMC 
processing seems to be incomplete in the skin as well. It has been shown that cultured human 
keratinocytes and melanocytes secrete high levels of unprocessed POMC260. These observations lead to 
the conclusion that an excess of POMC is synthesized in the hypophysis and the skin. This may happen to 
ensure sufficient stocks of ligands for the melanocortin receptors that can be secreted instantly in response 
to physiological demand. Clearly, only a small proportion of POMC is proteolytically converted to ACTH and 
MSH peptides, the excess being secreted. Therefore, the levels of POMC processing may be the limiting 
factor in the signaling pathway. 
 
The biosynthesis of POMC seems to be controlled by MSH release-inhibiting factors, such as dopamine, 
neuropeptide Y (NPY), or #-aminobutyric acid (GABA). They lower the cAMP levels of melanotrophic cells, 
which results in a reduced capacity of the cell to synthesize POMC mRNA. In contrast, POMC transcription 
is enhanced by MSH releasing factors such as adrenalin by elevating the cAMP levels in the cell. Adrenalin 
is released in stress situations. 
 
!-MSH has various physiological functions and acts as a pleiotropic peptide affecting many different kinds 
of cells in the nervous system and many peripheral organs. As mentioned earlier, it interacts with several 
subtypes of melanocortin receptors. In lower vertebrates such as Xenopus or Rana, it is responsible for the 
adaptation of skin color to the light intensity and the pattern of the environment. In the mammal, !-MSH 
was found to be present in the skin, where it is localized in keratinocytes, melanocytes, and Langerhans 
cells318. In the skin it normally acts together with ACTH, which shows an even greater occurrence than !-
MSH. In human melanomas, the extent of its production and release could be correlated with the 
expression of MC1 receptors. !-MSH apparently decreases expression levels of tumor necrosis factor 
(TNF-!), which normally stimulates synthesis of the intercellular adhesion molecule-1 (ICAM-1)213, 
supposedly mainly responsible for tumor aggressiveness and metastatic potential. As a further function, 
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!-MSH is thought to regulate inflammation and hyperproliferative skin diseases. The following scheme 
(Figure 7) describes the pleiotropic actions of !-MSH in various human skin cell types. 
 
 
 
Figure 7: Pleiotropic actions of !-MSH in human skin cells
42
. 
Depicted are the various skin cell types (from left to right: epidermal melanocytes and keratinocytes, endothelial cells, mast 
cells, adipocytes, fibroblasts, and cells of the pilosebaceous unit, that is, follicular melanocytes and keratinocytes, dermal 
papilla cells, and sebocytes), which were shown to express MCRs and to react with !-MSH. Note that generation of !-MSH 
is not limited to the epidermis but can be induced in many other cutaneous cell types upon exposure to prototypical stressors. 
In addition, MC peptides can be delivered to the skin via the classical endocrine pathway. 
 
In the brain, !-MSH exhibits a trophic effect on the outgrowth of neuritis from PNS and CNS, and exerts a 
positive effect on short-term memory, activates sexual behavior, stimulates aggression and social behavior, 
grooming, stretching and yawning. Most of these effects are mediated over the MC3 or MC4 receptors. 
MC4R and !-MSH also exert a tonic inhibition on food intake (anorexigenic effect) that plays an important 
role in diseases like obesity, insulin resistance and type II diabetes. Many other effects of !-MSH are 
known, such as stimulation of the activity of sebaceous glands, increase of prolactin release in lactotrophs, 
modulation of the neuroactivity of the retina, increase in permeability of the blood-aqueous barrier of the 
eye, and stimulation of the release of progesterone from prepubertal ovaries in females. 
 
 
1.4 The melanocortin-1 receptor (MC1R) 
 
Communication of living cells with their environment is really critical. It is so critical that some entire protein 
families are totally and exclusively dedicated to the reception of external stimuli, such as chemical 
messengers or physical stimuli. They are then capable of giving an adaptive response to these triggers. 
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1.4.1 GPCRs and the MC1R as superfamily member 
 
The G protein-coupled receptor (GPCR) superfamily is the largest with over 1000 members. GPCRs 
mediate responses to a whole variety of stimuli, including light, odorants, taste molecules, ions, 
neurotransmitters and hormones. Consequently, they involve a whole collection of responses implying a 
wide range of physiological functions, including stress and immune response, sexual behavior, 
cardiovascular regulation, energy homeostasis and of course skin pigmentation through regulation of the 
activity of metabolic enzymes and pathways, ion channels and membrane transporters. This variety of 
functions may be the reason why they are the most investigated group of target proteins for drug 
development187. 
 
Ligand-binding studies by Donatien et al.81, Ghanem et al.122 and Siegrist et al.284 demonstrated that MC1R 
is a GPCR expressed in melanocytes and melanoma cells. MC1R is a major regulator of pigmentation of 
the skin (type and amount of pigment) and thus one of the determinants of the skin!s phototype and 
sensitivity. As mentioned in the previous chapter, POMC-derived small peptide hormones (the 
melanocortins) act as physiological agonists. MC1R belongs to a five-member subfamily of GPCRs, the 
melanocortin receptors (MCRs), which mediate the physiologic actions of melanocortins by a Gs-protein-
dependent activation of the cAMP signaling pathway. MC1R was cloned and mapped to a locus known to 
influence pigmentation in the mouse276. Since then, genetic analysis, phenotypic association and structure-
function studies opened new perspectives for the assignment of its function as a key regulator of skin 
biological events. 
 
This receptor is a member of the large superfamily of seven transmembrane-domains receptors64,121,214,291, 
and it has 39-61% homology with a family of GPCRs that all bind melanocortin peptides. This family also 
includes MC2-, MC3-, MC4- and MC5-receptors. mRNA expression of the five receptors allowed for their 
localization in various tissues, summarized in Table 2. Eberle described the whole variety of their related 
effects, ranging from food intake regulation and energy homeostasis to cortisol secretion, sexual behavior, 
exocrine gland secretion and of course pigment production and regulation87. 
 
Table 2: Melanocortin receptors and their tissue localizations 
Receptor Tissues or cell types 
MC1-R Melanocytes, melanoma, macrophage, brain 
MC2-R Adrenal cortex, adipose tissue 
MC3-R Brain, placenta, duodenum, pancreas, stomach 
MC4-R Brain, spinal cord 
MC5-R Skin, adrenal cortex, adipose tissue, skeletal muscle 
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MC1R is expressed with the highest density on melanocytes191. As GPCR, it activates G proteins that bind 
GTP and GDP as intermediary messengers. G proteins are usually named after their !-subunits. Four 
distinct types of !-subunits are known: 
 
• Gs proteins, which stimulate adenylyl cyclase;  
• Gi proteins, which inhibit adenylyl cyclase and activate G protein-coupled inwardly rectifying 
potassium (GIRK) channels as well; 
• Gq proteins, which activate phospholipase C"; 
• G12 proteins, which activate Rho guanine-nucleotide exchange factors (GEFs). 
 
The MCRs signal primarily by activation of the heterotrimeric Gs protein and stimulation of adenylyl cyclase. 
The resulting increase in intracellular cAMP is responsible for most, if not all, melanogenic actions of !-
MSH52. The pathway following adenylyl cyclase stimulation has been described earlier in chapter 1.2.3 and 
in Figure 4. Agonistic activation of the receptors induces conformational changes, which seem to involve 
rearrangements of the transmembrane domains III and VI. This “activated receptor” can interact with the 
heterotrimeric G protein, and serves as guanine-nucleotide exchange factor to promote GDP dissociation, 
and GTP binding and activation. The activated heterotrimer then dissociates into an !-subunit and a "#-
dimer. Both these subunits have an independent capacity to trigger cell response through separate 
effectors. After hydrolysis of GTP to GDP, the heterotrimer is reassociated and the activation cycle is 
terminated235. The whole physical dissociation process of ! from "# is though contested and remains an 
issue165. As already mentioned, Gs! with bound GTP is able to activate adenylyl cyclase, leading to an 
increased production of cAMP. This increase in cAMP levels result in the activation of tyrosinase via PKA. 
Evidence suggests that the expression, de novo synthesis and activation of tyrosinase are increased by the 
binding of a ligand. It has been shown in B16 mouse melanoma cells that inhibition of phosphatidylinositol-
3-kinase (PI3-kinase) and its target, the serine/threonine kinase p70S6, increases the melanin content of 
these cells51, as well as their dendrite outgrowth (PI3-kinase only). Therefore, the PI3-kinase pathway may 
be involved in regulating melanogenesis as well. In contrast, the melanocyte-specific activation of the MAP-
kinase pathway by cAMP may in some cases downregulate melanogenesis: MAP kinase ERK2 
phosphorylates MITF, thereby targeting the transcription factor to proteasomes for degradation52. 
 
 
1.4.2 Agouti protein, agouti signaling protein and agouti-related protein 
 
Agouti is a paracrine signaling molecule whose expression in rodents is normally limited to skin and whose 
biological function in that tissue is to act at the hair follicle melanocyte to modulate eumelanin synthesis211. 
It blocks the actions of !-MSH on melanocytes of the hair follicle. This antagonism forces the melanocyte to 
switch from eumelanin to pheomelanin biosynthesis. Control over time of agouti expression leads to the 
typical banding observed on the coat of several animals189. Although no similar phenotypic property can be 
observed in the human hair color, a human counterpart of agouti protein has been cloned and 
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characterized: the agouti signaling protein (ASIP)326. As observed for most melanocortin peptides, ASIP 
mRNA was also detected in a wide range of tissues, such as heart, ovaries and testis or adipose tissue. 
The physiological functions of ASIP in these tissues remains mostly unclear. It is widely accepted that ASIP 
antagonizes the effect of melanocortins by directly binding to target MCRs and may thus play a role in the 
regulation of human pigmentation by inhibiting melanogenesis300. Its role appears to be comparable to that 
of agouti in the murine model. Agouti-related protein (AGRP) is a more recently discovered neuropeptide of 
the central nervous system. Various evidences suggest a major role in the regulation of mammalian 
feeding behavior225,282. AGRP was identified because of its sequence similarity to the agouti protein332. 
 
Ubiquitous expression of agouti in mice generates several pleiotropic effects, such as yellow coat, obesity, 
insulin resistance, increased body length and premature infertility182. Obesity and diabetes caused by 
ectopic agouti expression are explained by its ability to mimic AGRP, since ubiquitous expression of AGRP 
in transgenic mice causes an increased weight gain and body length phenotype identical to that produced 
by ubiquitous expression of agouti. Structurally, however, the similarity between agouti and AGRP is 
confined almost entirely to their 40-residue carboxyl termini where a total of 20 residues, including 10 
cysteine residues, are identical. Both agouti and AGRP have been shown to antagonize the action of 
melanocortic peptides such as !-MSH and ACTH at specific melanocortin receptor subtypes332. Whether it 
was competitive antagonism, inverse agonism or activation of an effector other than adenylyl cyclase, was 
not easy to assess. Studies in several laboratories proved that these molecules bind to MCRs in a 
competitive mechanism and function as inverse agonists332. 
 
1.4.3 Structure of the MC1R and ligand binding 
 
Structure 
MCRs are not closely related to any other G protein-coupled receptor, even though they can be classified 
as class A GPCRs (whose prototype is rhodopsin) after analysis of the sequence similarity. GPCRs cannot 
readily be crystallized, and the only templates available delivering information about their secondary and 
tertiary structures are a low-resolution electron microscopy structure of bacteriorhodopsin296 and the 
famous crystal structure of rhodopsin by Palczewski et al. in 2000229. MCR was computer-modeled 
according to this structure149,240, from which it was concluded that MCR shares homologies with GPCRs 
such as the extracellular N-terminus, the seven-transmembrane helical core domain joined by three 
intracellular and three extracellular loops, and the intracellular C-terminal extension. Human MC1R is 
composed of 317 amino acids and murine MC1R of 315. The human MC1R gene coding for the receptor 
was first cloned independently by Chhajlani and Wikberg64 and by Mountjoy et al.214, both in 1992. Many 
particularities of the different parts of MC1R are or have been discussed120. Some of them are though of 
higher interest for ligand binding. 
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Figure 8: Structure of the human melanocortin-1 receptor
120
. 
The positions for TM helices are drawn according to the two-dimensional model of Ringholm et al.
253
. The amino acid 
sequence corresponds to the wild type consensus (GenBank accession number AF326275). Positions for natural non-
synonymous mutations are shown in red (for RHC alleles) or orange. Potential post-translational modification sites are also 
highlighted.  
 
 
The extracellular loops 
For instance, binding affinity of agonists has been shown to be weaker in the case of a mutation of Glu269 
and Thr272 for Ala in the third extracellular loop65, but whether these residues provide contact and are really 
implicated in the binding affinity, is discussed. Indeed, transmembrane domain 6 (TM6) is connected to the 
extracellular loop 3, and the binding of agonists is mostly accounted for by a network of charged and 
aromatic residues located in several transmembrane domains, including TM6. Glu269 and Thr272 might just 
induce a change in the position of TM6 and alter the configuration of the binding pouch. As mentioned by 
García-Borrón et al., Cys267 and Cys275 might form an essential intramolecular disulfide bond between TM6 
and TM7, as mutations of both of them to Gly or Ala leads to loss of function106,120. Also, all three Cys 
residues of the extracellular loop 3 are conserved in all MCRs, indicating a probable crucial functional role 
for one intraloop and one interloop disulfide bonds. 
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The intracellular loops 
The intracellular loops of GPCRs usually contain all phosphorylation targets that are important for 
internalization, cycling and thus the regulation of signaling. They mostly provide the binding interfaces for 
the heterotrimeric G proteins120. The second intracellular loop also contains conserved phosphorylation 
sites of protein kinase A (PKA), as well as a target for protein kinase C (PKC). The third intracellular loop is 
poorly conserved in MCRs. 
 
The transmembrane domains 
The transmembrane domains are positioned almost perpendicularly to the plane of the membrane. Several 
transmembrane domains contribute to form the ligand-binding pocket located, for class A GPCRs, below 
the interface formed by the plasma membrane and the extracellular medium. The Arg residue in the core 
sequence His-Phe-Arg-Trp (HFRW) shared by natural melanocortins presumably interacts with a highly 
charged region containing Glu94 (TM2), Asp117 and Asp121 (TM3), according to three-dimensional models of 
ligand-receptor complexes by Haskell-Luevano et al.138. The positive charge of the arginine is supposed to 
change the arrangement of TM2 and TM3. The induced movement, especially on TM3, is thought to induce 
a conformational change of the second intracellular loop. This region, containing the conserved DRY 
tripeptide (characteristic of class A receptors) at the interface between TM3 and the second intracellular 
loop, is known to be important for functional coupling. Its rearrangement is supposed to allow for interaction 
with the Gs protein
190. Also, TM4, 5 and 6 contain aromatic residues and may form interactions with the 
aromatic residues of potential ligands, thus contributing to the binding affinity331. 
 
Quaternary structure 
The quaternary structure of MC1R probably plays a role in the various properties displayed by the receptor. 
The ligand binding and the coupling efficiency can be dramatically influenced by dimerization or 
oligomerization. A BRET assay (bioluminescence resonance energy transfer) by Mandrika et al.196 
suggested a constitutive dimerization process in cells overexpressing the receptor. This dimerization 
appears early in the biosynthesis of MC1R and seems to be constitutive, but MC1R was not found to show 
cooperativity in agonist binding120. 
 
 
1.4.4 Selectivity 
 
The MCRs share some common properties, including recognition of the HFRW pharmacophore pattern, 
giving the MCRs the ability to bind several melanocortins, but with different affinities288. Most of these 
results were obtained by transfection of human MC1R into cultured cells. MC1R shows high affinity for !-
MSH and slightly lower affinity for the other melanocortins. MC1R binds several ligands, both natural and 
synthetic. The order of potency is: Nle4-D-Phe7-!-MSH (synthetic) > !-MSH > ACTH > "-MSH > #-MSH. 
MC2R displays a strong selectivity for ACTH only. MC3R is the least selective receptor and binds all 
natural melanocortins, but has a slightly higher affinity for #-MSH. MC4R has a very slight preference for "-
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MSH over !-MSH, but a very low affinity to #-MSH. MC1R and MC4R are not able to distinguish well 
between ACTH and !-MSH. MC5R binds melanocortins in the same potency sequence as MC1R (!-MSH 
> ACTH > "-MSH > #-MSH), though with much lower affinities271.  
 
Table 3: Specificity of melanocortin receptor subtypes. 
Receptor subtype (human) Ligand Specificity 
MC1R !-MSH > ACTH > "-MSH > #-MSH 
MC2R ACTH only 
MC3R !-MSH = "-MSH = #-MSH = ACTH 
MC4R !-MSH = ACTH = "-MSH >> #-MSH 
MC5R !-MSH > ACTH > "-MSH > #-MSH 
 
ACTH was reported to bind to MC1R with a potency between that of !-MSH and of "-MSH, but Schiöth et 
al. pointed out that this may be due to degradation of ACTH to !-MSH139,270. Nevertheless, conclusions 
(especially those regarding cutaneous pigmentation) drawn from transfection of human MC1R into cultured 
cells are limited. Several factors can limit the credibility of the results139: 
 
• !-MSH may stimulate pigmentation via the protein kinase C pathway in addition to the adenylyl 
cyclase pathway. 
• POMC breakdown products are produced in different ratios in melanocytes and keratinocytes for 
example, and thus the concentrations used for in vitro studies may differ from the ones used in vivo 
for ligand binding and receptor activation. 
• There are potential phosphorylation sites on PKA and PKC of MC1R, but the effect of 
phosphorylation and whether ligand binding is influenced is not known. 
 
These findings show that absolute receptor subtype selectivity is not to be expected from the 
melanocortins, and thus that a strategy aiming at targeting one or the other receptor subtype may not be 
successful or result in severe side or adverse effects. Nevertheless, in the case of MC1R, it was proven 
that the receptor is overexpressed at the surface of human melanocytes (though only 700-1000 receptors 
per cell81 are found), and even more at the surface of human melanoma cells (a few thousands per cell284), 
but these amounts remain quite low compared to MC1R on mouse melanocytes (approximately 10,000 per 
cell285). MC1R is also expressed in numerous other cell types such as keratinocytes, fibroblasts, 
endothelial cells, sebocytes, Langerhans cells, monocytes, dendritic cells, neutrophils, granulocytes, 
natural killer cells, osteoclasts and others255. However, quantitative comparisons have shown that MC1R 
mRNA is much lower in non-melanocytic cells. Roberts et al. showed that levels of MC1R mRNA in various 
cultured human skin cells were at least 11-fold lower than that within melanocytes254. Additionally, only the 
higher amounts found in these studies resulted in clearly detectable protein. Thus, the conclusion can be 
drawn that MC1R protein in cell types other than melanocytes is not expressed at physiologically relevant 
levels. This shows that even though MC1R is expressed throughout the body, relevant expression is only 
found in melanocytes or melanoma cells. In concert with the high and quite specific affinity of MC1R for !-
MSH, it is reasonable to think that a targeting strategy mimicking !-MSH would be successful and might be 
exempt of severe adverse effects. 
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1.5 Melanoma 
 
1.5.1 Overview of cancer 
 
1.5.1.1 Historical considerations 
 
Cancer 
 
Cancer has plagued all multicellular organisms since the beginning of time. In fact, paleopathologists have 
found melanotic masses of tissues and diffuse metastases in pre-Colombian Inca mummies being more 
than 2,400 years old313. Indeed, cancer has always proven to be an elusive adversary in the field of 
medicine. The Greek physician Galen (128-200 A.D.), among others, noted similarities between crabs and 
some tumors with swollen veins, and called tumors “karkinos”, Greek word meaning either crab, tumor or 
the zodiac constellation. Later, the Roman physician Celsus (28 B.C.-50 A.D.) translated the word 
“karkinos” into “cancer”, Latin word with the same meanings. 
 
Oncology 
 
Oncology (from the Greek words onkos (mass or tumor), and logos (study) is the study of neoplastic 
diseases. Early authors suggested that certain families, races, and working classes were predisposed to 
neoplastic transformations. In 1862, Edwin Smith, an American Egyptologist, discovered the apparently 
earliest recordings of the surgical treatment of cancer. Written in Egypt circa 1600 B.C., this treatise was 
based on teachings possibly dating back to 3000 B.C. The Egyptian author advised surgeons to contend 
with tumors that might be cured by surgery but no to treat those lesions that might be fatal. 
 
Hippocrates (460-375 B.C.) was the first to describe the clinical symptoms associated with cancer. He 
advised against treating terminal patients, who would enjoy a better quality of life without surgical 
intervention145. He also coined the terms carcinoma (crab legs tumor) and sarcoma (fleshy mass). In the 
second century A.D., Galen published his classification of tumors, describing cancer as a systemic disease 
caused by an excess of black bile14. Galen cautioned that as a systemic disease, cancer was not amenable 
to cure by surgery, which was often promptly followed by patient death. This strong admonition against 
surgery persisted for more than 1500 years until in the eighteenth century pathologists discovered that 
cancer often grew locally before spreading to other anatomic sites148. 
 
Various other discoveries helped physicians understand underlying cancer mechanisms as well as develop 
appropriate surgical techniques and anesthesia, but surgical oncology was still associated with high patient 
mortality rates. The main issue was that cancer was rarely diagnosed early enough. However, several 
important developments in this era (such as the microscope, gentle tissue handling, meticulous surgical 
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technique) led to rapid advancements in surgical oncology. Ongoing innovations continue to advance 
effective surgical primary tumor control linked to improved surgical outcomes and better quality of life. 
Enhanced biomedical monitoring and the emergence of critical care medicine have made it possible to 
safely undertake increasingly complicated surgical procedures. A more sophisticated awareness of the 
patterns of tumor progression have made possible less-invasive surgical approaches (sentinel node biopsy 
instead of formal lymphadenectomy in early stage breast carcinoma, radiofrequency ablation with 
ultrasonography guidance, etc.)148. 
 
 
1.5.1.2 General pathophysiology of cancer 
 
Cancer is the common term for neoplasms, or tumors, that are malignant. Nearly all cancers are caused by 
abnormalities in the genetic material of the transformed cells. Tumors arise from a large number of 
sequential mutations within a cell!s genome that are often prompted by cellular or environmental stress 
(carcinogens like tobacco smoke, radiations, chemicals or infectious agents) on the cells. Complex 
interactions between carcinogens and the host genome may explain why only some develop cancer after 
exposure to a known carcinogen. New aspects of the genetics of cancer pathogenesis, such as DNA 
methylation and microRNAs are increasingly being recognized as important. Simple mutations are common 
and regular within the genome of any living organism. Several mechanisms are in place to detect and to 
correct all these mistakes happening during the DNA replication and transcription processes, but once 
these mechanisms are overcome, the cells may lose their ability to regulate cellular growth and 
proliferation. In addition, cancer cells, unlike normal cells, lack contact inhibition usually limiting their ability 
to control growth via intra-cell communication. 
 
A number of key cancer-promoting oncogenes and tumor suppressor genes are present in all cells. These 
regulate key mechanisms for the cells! survival, such as senescence, cell cycle, or for the programmed cell 
death. Inherently, these genes serve as gatekeepers to disease progression. If a mutation occurs on an 
oncogene and for instance permanently activates it, cells may acquire new properties, such as hyperactive 
growth and division, protection against programmed cell death, loss of respect for normal tissue 
boundaries, and the ability to become established in diverse tissue environments. If a tumor suppressor 
gene is inactivated, cells may lose their normal functions, such as accurate DNA replication, control over 
the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune 
system. In both cases, cells lose their innate ability to communicate, to autoregulate or to autodestruct, 
which leads to the formation of tumors.  
Cancer is actually more a group of diseases, in which cells are aggressive (grow and divide without respect 
to normal limits), invasive (invade and destroy adjacent tissues), and/or metastatic (spread to other 
locations in the body). These three malignant properties of cancers differentiate them from the benign 
tumors, which are self-limited in their growth and do not invade or metastasize (although some benign 
tumor types are capable of becoming malignant). Unlike benign tumors, malignant tumors consist of 
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undifferentiated cells that show an atypical cell structure and do not function like the normal cells of the 
organ they originate from148. 
 
Basically, there are more than 100 different types of cancer. The main categories include216: 
 
• Carcinoma: cancer that begins in the skin or in tissues that line or cover internal organs. 
• Sarcoma: cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or 
supportive tissue. 
• Leukemia: cancer that starts in blood-forming tissue such as the bone marrow and causes large 
numbers of abnormal blood cells to be produced and enter the blood. Circulating tumor cells. 
• Lymphoma and myeloma: cancers that begin in the cells of the immune system. Solid tumor state. 
• Central nervous system cancers: cancers that begin in the tissues of the brain and spinal cord. 
 
Usually the various cancer types are classified according to the tissue from which the cancerous cells 
originate (location), as well as the normal cell type they most resemble (histology). Histological examination 
of a tissue biopsy is required to establish a definitive diagnosis, even though initial suspicion of malignancy 
can come from symptoms or radiographic imaging abnormalities3. 
 
Once detected, cancer is usually treated with a combination of surgery, chemotherapy and radiotherapy. 
Some can be cured depending on the type, location and stage. Treatments are also becoming more 
specific for some types of cancer with the development of targeted therapies acting specifically on 
molecular defects in certain tumors, thus sparing healthy cells and therefore involving less side effects or 
toxicity-related limitations. 
 
 
1.5.1.3 Challenges 
 
The advances in medicine of the last 50 years have had a dramatic impact on most common diseases. 
However, although those advances have drastically helped increase patients! life span, cancer death rates 
have remained more or less unchanged, as shown in Figure 9 below3. Three major shortcomings in the 
field of oncology may be responsible for this issue: 
 
- insufficient detection methods; 
- a lack of preventive treatment options; 
- relapse of the disease. 
 
There is currently no accurate early screening method for cancer, leaving detection up to the patient in the 
form of obvious signs of disease, often meaning it is already too late. Improved detection methods would 
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be very profitable for both early and late stage cancers, as they would allow an earlier treatment start, 
thereby improving the general prognosis of the patient. 
 
 
 
Figure 9: U.S. death rates of various diseases per 100'000 inhabitants from 1950 to 2003
3
. 
 
 
Then, there is a lack of preventive treatment options to cut or slow the disease progression from the 
beginning294. Various studies have been conducted concerning natural products and dietary 
phytochemicals containing anti-oxidative molecules and free radicals scavengers such as plant oils, 
flavonoids, glutathione, vitamins C and E and various enzymes such as peroxidases. Low levels of 
antioxidants, or inhibition of the antioxidative enzymes causes oxidative stress and may damage cellular 
components such as DNA, proteins or lipids289,317, which may lead to mutagenesis. Although there is no 
real chemopreventive treatment (such as e.g. atorvastatin against cardiovascular diseases, a drug 
generating $12 billion per year)294, some relatively simple preventive habits have though been proven to 
dramatically lower the incidence of cancer. More than 250 population-based studies, including case-control 
and cohort studies, show that people eating about five servings of fruits and vegetables a day have 
approximately half of the risk of developing cancer (particularly cancers of the digestive and respiratory 
tracts) compared to those eating less than two servings a day. Substances as lycopenes (tomato), 
catechins (green tea) gingerol (ginger), curcumin (turmeric) and many more are known chemopreventive 
phytochemicals299. The change probably has to happen in the population!s dietary habits, as this type of 
chemoprevention can now be considered to be an inexpensive, readily applicable, acceptable and 
accessible approach to cancer prevention. Additionally, with healthcare costs being a key issue today, 
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promotion of the awareness and of the consumption of fruits and vegetables (and thus of phytochemicals) 
would be a simple and cost-effective measure to deploy299. 
 
Another major problem to overcome is relapse. Recurrence of disease following primary treatments 
remains capital for physicians and patients. This recurrence results from disseminated or metastatic cells 
that have broken off of the primary tumor site and relocated at a distant site. Relapse often occurs after 
successful treatment of the primary disease, however, cancer finally remains the cause of death. 
 
These are only a few of the numerous obstacles still to be overcome in order to improve the final prognosis 
for the patient. This work attempts to provide an improved method, based on earlier research in the field of 
melanoma, for the detection and eventual treatment of malignant melanoma and early metastases, with the 
hope of eventually meeting some of the challenges set forth by cancer today, specifically that of early 
detection and detection of potential relapse of disease. 
 
 
1.5.2 Melanoma 
 
1.5.2.1 Overview and epidemiology 
 
Cutaneous malignant melanoma (CMM) is a tumor derived from transformed genetically altered epidermal 
melanocytes in the skin, as a result of complex interactions between genetics and environmental factors. It 
is the most serious type of skin cancer. It is one of the rarer types of skin cancer (4% of skin cancer cases, 
according to the American Cancer Society) but causes the majority of skin cancer-related deaths232. It also 
tends to occur at a younger age than most cancers with half of all melanomas found in people under the 
age of 57. It is actually the most common malignancy among young adults as well. Its incidence has 
substantially increased among all Caucasian populations in the last few decades80. The number of 
melanoma cases worldwide is increasing faster than any other cancer. Its incidence rate showed a general 
increase of 3-7% per year for fair-skinned Caucasian populations, with estimated doubling incidence rates 
every 10-20 years119. Australia is probably the most affected country, with very high incidence rates. In 
Australia, CMM has become the fourth most common cancer among males and the third most common 
among females75. As shown in Figure 10, the lifetime risk of developing malignant melanoma in the U.S.A. 
has also dramatically increased during the last 70 years183, probably due to new socio-cultural behaviors 
such as tanning and the excessive use of solarium booths in order to meet the new beauty standards. The 
widening gap in the earth!s ozone layer might play a big role as well, especially in Australia. It will be 
interesting to observe if newer findings that the ozone layer gap is slowly stabilizing, and that it may 
probably recover by 2050327, will involve a diminution of UV-exposition-related skin cancers. 
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Figure 10: Evolution of the lifetime risk of developing malignant melanoma in the U.S.A. since 1935
183
. 
 
 
Malignant melanoma is the most dangerous type of human skin cancer, as it may be very difficult to detect. 
Indeed, the lesions are usually very small at the beginning, and approximately 10% of melanomas are 
amelanotic, meaning that they do not produce (or overproduce) melanin and are thus almost invisible. 
Additionally, their metastasizing potential is really high and they are extremely resistant to current systemic 
therapies. 
 
 
1.5.2.2 Etiology 
 
Although the etiology of melanoma is unknown, case-control studies have identified a number of 
characteristics present in populations presenting the highest risk for melanoma development83,194. These 
studies have shown that melanoma is largely a disease of individuals with fair complexions. Individuals with 
red or blond hair and fair skin, who usually do not tan well and burn easily even after short exposures, or 
have a history of severe sunburn, are at substantially higher risk of developing melanoma than more darkly 
pigmented, age-matched controls. Individuals bearing more nevi or having a tendency to develop freckles 
are also at increased risk for developing melanoma194. 
 
A review from Longstreth188 suggests that ultraviolet light may be a critical factor for the development of 
cutaneous melanoma. There is an increasing incidence of melanoma in fair-skinned populations and a 
correlation with increasing distance from the poles. Also, adults migrating to sunny climates are at lower 
risk of developing melanoma than similar individuals born there, emphasizing the importance of the 
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duration of exposure to UV radiation. Freckles and nevi are induced by solar exposition and are risk factors 
for the development of melanoma. Solar radiation induces acute and chronic reactions in both human and 
animal skin. Chronic and repeated exposures to UV radiation are the major cause of malignant skin tumors, 
partially including malignant melanoma (not only after cumulative exposure, see below), via gene mutations 
and immunosuppresion. UVB radiation (290-320 nm), especially, has been reported to be much more 
mutagenic and carcinogenic in animal experiments than UVA radiation (320-400 nm). DNA damage is 
mainly caused by UV radiation through mutations in p53 and ras. UVB is also known to upregulate gene 
expression through intracellular signal transduction pathways contributing to the development of skin 
cancer at the tumor promotion stage. Furthermore, it is proven that UVB suppresses immune reactions, 
leading to antigen tolerance. Additionally, indirect stress through DNA repair mechanisms and reactive 
oxygen species (ROS) such as peroxides and superoxides, mostly formed through UVA exposure, has 
been discussed and proven154. These free radicals can cause damage to cellular proteins, lipids and 
saccharides. 
 
Observations suggest that sun exposure may not be the only risk factor in the development of melanoma. 
Indeed, melanoma can occur in relatively unexposed areas of skin, such as the palms and soles. Another 
observation is that melanoma is not directly related to cumulative sun exposure, as are squamous and 
basal cell carcinoma. Individuals having an outdoor occupation are less at risk than white-collar workers, 
confirming findings in animal experiments that the risk of developing melanoma is not only related to the 
cumulative level of sun exposure, but also to acute, intense and intermittent exposure associated with 
blistering sunburn83. Changes in socio-cultural behaviors of the western populations are also to blame. 
Indeed, changes in clothing styles and materials, as well as in the recreational habits and in beauty criteria 
(tanning) have without a doubt contributed to increase melanoma incidence: incidence has dramatically 
increased on the legs in females and the trunk in males. Additionally, it appears that some forms of 
malignant melanoma are genetically inheritable. Members of certain families are more susceptible to the 
development of the genetic abnormalities associated with melanoma. As a result, these family members 
have an exceedingly high risk of developing melanoma, with around 8 to 12% of all cutaneous melanomas 
occurring in individuals with familial predisposition. Familial human melanoma is characterized by an 
increased risk of developing primary melanoma, a higher incidence of multiple primary lesions and an 
earlier age at onset193. Finally, two major types of precursor lesions may increase incidence of melanoma, 
but they will not be extensively discussed here. 
 
• Dysplastic nevus syndrome (DNS) is a familial form of malignant melanoma distinguished by 
multiple, large (>5 mm diameter) macular moles with irregular borders and often variable shades of 
brown, black and red. Melanoma may arise from dysplastic nevi or from apparently normal skin 
remote from nevi in patients with DNS. 
• Congenital nevi are present at birth and usually classified as small or giant congenital nevi, bearing 
a grossly irregular surface, increased pigmentation in varying shades of brown, and hypertrichosis. 
Although melanoma may arise de novo, it arises in association with congenital nevi at increased 
frequency, and all congenital nevi should be viewed with suspicion252. 
INTRODUCTION 
36
1.5.2.3 Melanoma classification 
 
Various forms of melanoma can be observed, depending of their different clinical and biological 
characteristics, and are described by the American Joint Committee on Cancer (AJCC)6. There are five 
distinct kinds: 
 
- Superficial spreading melanoma (SSM): it is the most common form of melanoma, 
accounting for approximately 70% of all melanomas. SSM generally arises in a preexisting 
lesion, and usually appears flat with irregular borders. The lesions are generally 
multicolored with shades of tan, brown, black, red and white. An irregular surface may 
appear as the lesion grows. SSM usually appears on the head, neck and trunk in males 
and on the extremities in females throughout adulthood with a peak in the fifth decade of 
life. 
- Lentigo maligna melanoma (LMM): it represents about 10% of all melanomas. It arises 
from lentigo maligna (melanotic freckle of Hutchinson or precancerous melanosis of 
Dubreuilh). LMM is most commonly found on sun-exposed skin in elderly patients (median 
age is 70 years). Lesions are large (3-4 cm in diameter) and flat with irregular borders, in 
variable shades of tan to dark brown. The invasive melanoma stage generally has a long 
history of 5-15 years of the precursor lesion (lentigo maligna). 
- Nodular malignant melanoma (NM): with 10-15 % of all melanomas, it accounts for the 
second most common pattern. It is mostly found on the trunk of men, but may arise on any 
body surface. Biologically, it is thought to be more aggressive than SSM. Dark lesions 
uniform in color are its major clinical pattern. One particularity is that melanocytic 
abnormalities in the vicinal epidermis are totally absent, and additionally, around 5% of NM 
are amelanotic. NM does not go through the radial growth phase, its very rapid evolution 
leading quickly to vertical growth and invasion of the dermis. For this reason, nodular 
melanomas tend to be thicker, higher-risk lesions. 
- Acral-lentiginous melanoma (ALM): only 3-5% of melanomas are from the ALM type. It 
usually occurs on the palms, soles and subungual regions, representing a higher 
proportion of all melanomas in dark-skinned individuals such as African Americans, Asians 
and Hispanics. Lesions are large (3 cm in diameter) with irregular borders, and generally 
occurs in older individuals (median age is 59 years). The great toe or thumb are the most 
concerned by subungual melanoma. ALM often appears as a tan to dark brown macule 
with an irregular border, but may be ulcerating in more advanced lesions. Its clinical pattern 
being quite similar to LMM, ALM is though a biologically much more aggressive lesion, with 
a relatively short evolution to the vertical growth phase. 
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- Mucosal lentiginous melanoma (MLM): it is similar in appearance to ALM, but occurs on 
the various mucosae of the body, such as the oral cavity, oesophagus, anus, vagina and 
conjunctiva. 
 
 
1.5.2.4 Melanoma development, progression and staging 
 
Clinical and histological studies have resulted in defining relatively distinct steps of melanoma development 
and progression. 
 
- Step 0: normal melanocytes. 
- Step 1: common acquired and congenital nevi with structurally normal melanocytes. 
- Step 2: dysplastic nevi with structural and architectural atypia. 
- Step 3: melanoma in situ and radial growth phase, nontumorigenic primary melanomas 
without metastatic competence. 
- Step 4: vertical growth phase, tumorigenic primary melanomas with competence for 
metastasis. 
- Step 5: metastatic melanoma. 
 
As in any neoplastic system, melanomas can skip steps in their development, appearing without 
identifiable intermediate lesion. The progression from each stage to the next is strongly associated with 
specific biological changes, and this staging is based on experimental models and clinical and 
histopathological observations. The transition from mature melanocytes to the formation of a nevus can be 
characterized by an interruption of the cross-talk between melanocytes and keratinocytes that leads to loss 
of control of the keratinocytes on the melanocytes. Thus, cells from a nevus show limited proliferation and 
cells in common acquired nevi do not have any apparent chromosomal aberration. Nevi can develop not 
only through stimulatory factors, but through this loss of control as well. Cells then presenting cytological 
atypia may then separate from the basal membrane without undergoing apoptosis, generating architectural 
disorders in the lesion and hence transformation of normal melanocytes or common acquired nevi into 
dysplastic nevi or melanoma with radial growth phase. These radial growth phase melanoma cells have 
biological properties that are sort of “hybrid” between benign and malignant. Vertical growth phase 
melanoma cells, therefore, are highly aneuploidic and relatively plastic, some of them being able to acquire 
metastatic competence. A high level of genetic instability and phenotypic plasticity are the major 
characteristics of metastatic cells. They are highly motile, independent of growth factors, and capable of 
invasion of other tissues or organs. 
 
The following illustration (Figure 11) depicts and describes melanoma progression: 
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Figure 11: Biologic events and molecular changes in the progression of melanoma
210
. 
Malignant melanoma usually arises, as previously mentioned, from precursor lesions such as dysplastic nevi, congenital 
nevi, or simply from cutaneous melanocytes. Melanocytes are usually arranged individually at the epidermal junction or in 
small organized clusters of benign nevi. Some atypical ones may then proliferate to form atypical nevi. Further 
proliferation leads to the stage of early melanoma in radial growth phase, which, if it keeps on proliferating, may reach the 
lower layers of the skin (dermis) and become an invasive melanoma in vertical growth phase. The depth of invasion is 
usually the major determinant of the prognosis. As it reaches the dermis and thus comes closer to the circulatory system, 
it may then start to metastasize throughout the body. 
 
A more precise melanoma staging than the one mentioned above has been described by Clark et al.68 as 
early as 1969, and although other techniques of melanoma staging are in use (such as “Breslow!s 
microstaging method”47, measuring the vertical thickness of the primary tumor and being simpler and more 
reproducible than Clark!s method), it gives a precise description of the various stages. 
 
• Level I Tumor cells are located above the basal membrane (in situ melanoma, quite rare). 
• Level II Neoplastic cells have broken through the basal membrane and spread into the 
papillary dermis but not into the reticular dermis. An individual cell or a small cell 
cluster may reach the reticular dermis, but the tumor will stay a level II lesion. 
• Level III When cells tend to accumulate at the interface between both papillary and reticular 
dermal regions, the tumor is classified as level III. 
• Level IV Neoplastic cells start to appear between the collagen bundles, which are typical of 
the reticular dermis. 
• Level V Invasion of the tumors cells into the subcutaneous tissues and fat. 
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Clark mentions in his paper that his definition of level III melanoma is the only level which is different from 
the ones used by the Australian group from the Queensland Melanoma Project242. He writes that a number 
of melanomas have been observed where the base of the tumor seemed to form almost a straight line and 
impinge upon the upper part of the reticular dermis without showing any significant invasion of the reticular 
dermis68. Currently, depth of invasion of a vertically growing melanoma is usually determined by both 
Clark!s level and Breslow!s thickness, and these both criteria allow to set a prognosis. 
 
 
The TNM Staging System 
 
The TNM Staging System6 is another way of staging cancer in general, and counts for one of the most (if 
not the most) commonly used staging systems. It is also used for melanoma staging. This system was 
developed and is maintained by the American Joint Committee on Cancer (AJCC) and the International 
Union Against Cancer (UICC). The TNM classification system was developed as a tool for physicians to 
allow the staging of different types of cancer based on certain standard criteria. The TNM Staging System 
is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of 
metastasis (M). 
 
The T category describes the primary tumor. 
TX Primary tumor cannot be evaluated 
T0 No evidence of primary tumor 
Tis Carcinoma in situ (early cancer that has not spread to neighboring tissue) 
T1-4 Size and/or extent of the primary tumor 
 
The N category describes whether or not the cancer has reached nearby lymph nodes. 
NX Regional lymph node cannot be evaluated 
N0 No regional lymph node involvement (no cancer found in the lymph nodes) 
N1-N3 Involvement of regional lymph nodes (number and/or extent of spread) 
 
The M category tells whether there are distant metastases.  
MX Distant metastasis cannot be evaluated 
M0 No distant metastasis 
M1 Distant metastasis 
 
Each cancer type has its own classification system, letters and numbers not always meaning the same 
thing for every kind of cancer. Once the T, N, and M are determined, they are combined, and an overall 
"Stage" of I, II, III, IV is assigned. Sometimes these stages are subdivided as well, using letters such as IIIA 
and IIIB6. 
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1.5.3 Metastases 
 
Metastases are the major reason for relapses in cancer patients and the cause of 90% of cancer-related 
deaths. Microscopic or clinically evident metastases are present in 60% of cancer patients at the time of 
primary tumor treatment54. They usually are considered as the most advanced form of cancer (end-stage). 
Although their exact mechanism of formation remains under debate, it is commonly accepted that finding a 
method able to stop the spread of metastasis would have a dramatic and revolutionary impact on cancer 
survival rates. The first step involves of course detection of secondary lesions, which remains one of the 
major issues in this quest. This subchapter describes the general pathways leading to the formation of 
metastases. 
 
 
1.5.3.1 Transformation 
 
A whole cascade of sequential events involving multiple host-tumor interactions leading to dissemination is 
responsible for the metastasizing process126. The unregulated growth and eventual loss of mutual 
adherence of cells presenting multiple abnormalities results in the dissemination of free carcinomic cells. 
Migration of these cells through the tumor membrane and extra-cellular matrix is favored, as well as their 
travel to new sites via the lymphatic and/or circulatory systems126. By entering the lymphatic systems, they 
acquire the ability to migrate to the lymph nodes before rejoining the blood stream. Further progression 
allows for a new focus to undergo neovascularization. However, Chambers55 affirms that a majority of 
tumor cells leaving the primary tumor fail to develop metastases. It results in a large number of single 
disseminated cancer cells in the circulatory system. Chambers noted as well that most of these metastatic 
cells are not destroyed by the immune system, probably due to a lack of recognition signals and pathways 
between tumor cells and antibodies. 
 
 
1.5.3.2 Intravasation and extravasation 
 
Tumor cells have first to lose their mutual adherence capability to initiate the metastasizing process, or they 
have to break bonds or lose the functionality between cadherins and integrins of the extracellular matrix54. 
Cadherins are transmembrane glycoproteins that mediate calcium-dependent cell-cell adhesion in normal 
tissue305. Integrins are a family of heterodimers (VLA-1 to VLA-6) that serve as receptors for extracellular 
matrix components including recognition of vascular cell adhesion molecules and cellular 
communication153. Following detachment from the extracellular matrix, neoplastic cells must penetrate the 
basement membrane and invade the interstitial stroma by active proteolysis. Subsequently, intravasation 
requires tumor cell invasion of the subendothelial basement membrane. In a similar manner, only reversed, 
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tumor cell extravasation occurs, allowing the metastatic disease to exit the blood or lymph streams and 
establish a distant metastatic site. 
 
 
 
 
Figure 12: Metastatic process
54
. 
To initiate the metastatic cascade, 
neoplastic cells must first penetrate the 
basement membrane and then invade 
the interstitial stroma by active 
proteolysis. Subsequently, 
intravasation requires tumor cell 
invasion of the subendothelial 
basement membrane. To successfully 
establish a metastatic colony, 
circulating neoplastic cells must survive 
immunological surveillance, arrest at a 
distant vascular step, and extravasate. 
Finally, cells must invade and 
proliferate in the secondary organ. 
 
 
 
 
1.5.3.3 Secondary tumor formation 
 
Tumor-induced angiogenesis is associated with the development of a distant secondary tumor site. The 
angiogenesis process not only allows tumor growth, but also facilitates access to the vascular 
compartment, thus favoring metastatic spread. Angiogenesis is the process leading to formation of new 
blood vessels around a solid tumor. Although most human cancers may persist in situ for months in a 
prevascular phase, growth beyond 2-3 mm3 requires new blood vessel formation105. Neovascularization 
prompts tumor growth by increasing perfusion and supplying nutrients and oxygen. In addition to these 
events prompting tumor growth, tumor cells are also stimulated in a paracrine fashion by several growth 
factors produced by capillary endothelial cells. The success rate of the metastasizing process seems to 
increase with the size of the primary tumor, so that angiogenesis may play an important role in determining 
cancer spread. Indeed, the degree of angiogenesis has proved to be predictive for metastatic disease in 
some neoplasms, whereas areas with the highest density of microvessels contains cells that are most likely 
to metastasize322. The process of angiogenesis can be divided, paralleling the tumor cell invasion process: 
 
• Proliferation of endothelial cells; 
• Breakdown of the extracellular matrix; 
• Migration of endothelial cells. 
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The induction of this process is mediated by angiogenic factors released by both tumor and host cells and 
depends on the net balance of positive and negative regulators. The major pro-angiogenic factor is of 
course the vascular endothelial growth factor (VEGF). It is a regulator of both physiological and 
pathological neovascularization54. These factors and regulators will not be covered in this work. 
 
 
1.6 Melanoma treatment 
 
As mentioned earlier, the prognosis of malignant melanoma is strongly dependent on the time point, and 
thus at which stage it was detected. Patients with tumors that were diagnosed early and surgically excised 
have a high probability of total remission118,163. However, although many therapeutical efforts have been 
achieved, the 5-year survival rate of patients whose disease has spread to the sentinel lymph node is only 
54%163, only 6% for patients with disseminated melanoma, and a median survival of 7.5 months24. The 
biological and clinical aspects of melanoma progression are relatively well defined. Its molecular 
mechanism, however, is not yet well characterized. Neither are the genetic markers associated to the 
metastatic process. 
 
High-throughput technologies helped a lot to shed light on previously unknown candidate genes (WNT5A, 
BRAF), oncogenes or tumor suppressors (e.g. PTEN, RAS, MYC) that may be involved in melanoma 
pathogenesis. Although most of them have not been attributed to precise melanoma subtypes or validated 
as prognostic markers, some correlations have been observed between molecular biology and clinical 
survival data. For example, the oncogene Akt is a serine/threonine kinase leading to cell cycle progression 
and proliferation. Inhibition of apoptosis is correlated to this oncogene as well. Interestingly, Akt expression 
increases with melanoma progression and invasion. Patient survival, implicitly, is inversely correlated with 
Akt expression, and consequently could serve as independent prognostic marker72. However, little 
consensus currently exists regarding a “standard” therapy, which most likely reflects the low level of activity 
of all available agents. Agents such as dacarbazine and temozolomide are widely used as monotherapies 
or combined therapies. A small randomized trial has demonstrated similar response rates for dacarbazine 
and temozolomide (10-20%)217. 
 
 
1.6.1 Excision 
 
Surgery provides the most effective and longest-lasting therapy for melanoma. The type of surgery that is 
chosen depends on the stage of the melanoma. Primary melanoma (melanoma in situ or stage I or II) is 
treated with surgical excision of the lesion. If the depth of invasion is low and if the surrounding healthy 
tissue is not invaded, complete removal of the lesion usually leads to complete remission. Stage III primary 
melanoma with lymph node involvement is treated with surgery to remove the primary melanoma and 
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lymph nodes in the region of the primary melanoma. This procedure may cure or extend the survival rates. 
The goal of treatment for metastatic melanoma (stage IV) is to relieve symptoms and prolong life. It does 
not usually cure the cancer. Therefore, excision is not applicable to stage IV melanoma. 
 
 
1.6.2 Systemic therapies 
 
There is no standard therapy for the treatment of disseminated melanoma. Patients are treated very 
differently in various clinical trials or cancer centers. Several therapy strategies have been tried out, such 
as mono-chemotherapy, poly-chemotherapy, combined therapies with cytokines, or even complex 
schemes with up to five different drugs. However, real improvement of the patients! survival could not be 
achieved, and most therapies yielded only temporary clinical responses. 
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Dacarbazine is one of the drugs that has been tested as monotherapy in several randomized clinical trials 
and served as reference in most of them. Dacarbazine (also known as DIC or imidazole carboxamide) is an 
antineoplastic chemotherapeutic drug used in the treatment of various cancers, such as Hodgkin 
lymphoma or malignant melanoma. Its cytotoxic effect comes from its antineoplastic activity (interferes with 
cell growth and prevents formation of new (tumor) tissue). Its exact mechanism is not known, but two main 
hypotheses have been proposed. First, dacarbazine belongs to the family of alkylating agents, which are 
drugs attaching an alkyl group to DNA. They stop tumor growth by cross-linking guanine nucleobases in 
DNA double-helix strands. This makes the strands unable to uncoil and separate. Secondly, dacarbazine 
inhibits DNA synthesis by acting as a purine analog, impairing DNA replication261. Both mechanisms 
blocked by the drug are necessary for DNA replication, and consequently the cells can no longer divide. 
This drug acts nonspecifically, but as cancerous cells usually proliferate more than normal cells, they are 
consequently more sensitive to DNA damage163. Dacarbazine remains a standard of care in community 
practice, and has been used as a standard for comparing the efficacy of new regimens. 
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Temozolomide is an imidazotetrazine derivative of dacarbazine and is studied in many trials as first line 
therapy of melanoma. Temozolomide is a prodrug and is not directly active but undergoes rapid 
nonenzymatic conversion at physiologic pH to the reactive compound MTIC (3-methyl-(triazen-1-
yl)imidazole-4-carboxamide). The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. 
Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine. It is normally indicated in 
treatment of recurrent glioma, where it demonstrated activity. In a recent randomized trial, concomitant and 
adjuvant temozolomide chemotherapy with radiation significantly improves progression free survival and 
overall survival in glioblastoma multiforme patients. Temozolomide is highly genotoxic, teratogenic and 
foetotoxic163,261. The probable mechanism of action of temozolomide is described in Figure 13. 
 
 
Figure 13: The putative molecular mechanism of action of temozolomide
73
. 
The first two steps also account for its pH-dependent elimination. Although O6-guanine methylation accounts 
for only 5% of the total DNA-adducts formed, this lesion is regarded as the most cytotoxic. AIC = 5-
aminoimidazole-4-carboxamide; MTIC = methyltriazen-1-ylimidazole-4-carboxamide. 
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Interleukin-2 
Interleukin-2 (IL-2) was approved by the Food and Drug Administration (FDA) for treatment of metastatic 
melanoma in 1998. Physiologically, upon binding to its receptor (IL-2R), IL-2 stimulates the growth, 
differentiation and survival of antigen-selected cytotoxic T cells via the activation of the expression of 
specific genes. Synthetic IL-2 can be used in the treatment of melanoma and kidney cancer. Highly dosed 
intravenous bolus IL-2 treatment resulted in overall objective response rates of about 12-21% in melanoma. 
IL-2 was able to induce durable complete responses in approximately 6% of patients and partial responses 
in 10% of patients with metastatic melanoma, albeit with high levels of toxicity217. 
 
Other systemic therapeutic strategies include chemotherapy, bio-chemotherapy, immune adjuvants, 
cancer-specific vaccines, cytokines, monoclonal antibodies and immunostimulants. Drugs such as 
carmustine (antineoplastic alkylating agent), paclitaxel (mitotic inhibitor; works by interfering with normal 
microtubule growth during cell division by hyperstabilizing the structures of these microtubules) and 
cisplatin (mitotic inhibitor; works by cross-linking with DNA in different ways, thus interfering with cell 
division and triggering DNA repair mechanisms, including apoptosis) have shown single-agent activity in 
metastatic disease161. High-dosed IFN-! and high-dosed IL-2 administered together or in addition to 
temozolomide constitute possible therapy strategies. Curiously, and although only few patients really profit 
from this strategy (less than 20% in average) in terms of long-term survival, it is the only immunological 
approach approved by the FDA. Additionally, both drugs show a very toxic profile and are pricy. 
 
These elements really emphasize the need for innovative treatment alternatives. Some of the most 
promising and viable options investigated at the moment are: antiangiogenic and immunomodulatory drugs, 
Bcl-2 antisense therapy, B-RAF inhibitors, heat shock protein modulators and anti-cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) monoclonal antibody. This list of strategies is of course not comprehensive. 
It consists of a selection of some of the techniques investigated, and there are other strategies under 
ongoing investigation. 
 
 
1.6.2.1 Antiangiogenic and immunomodulatory drugs 
 
The antiangiogenic properties of thalidomide were discovered by inadvertence in the 1960s, when severe 
teratogenicity was reported after children were born with crippled extremities. Indeed, it was found that the 
drug inhibited blood vessel growth in the foetus. The drug, at that time, had been introduced to treat 
sleeping disorders (hypnotic effect) and morning sickness in pregnant women (antiemetic effect). 
Thalidomide is a racemic mixture: it contains both left- and right-handed isomers in equal amounts. In fact, 
only its (R) enantiomer bears these positive effects, its (S) enantiomer being teratogenic. At the time it was 
introduced, this property had not been discovered, as rodent models did not display any drug toxicity (it 
was not even possible to determine a LD50). However, both enantiomers have the ability to convert into 
each other in vivo, thus not reducing the risk of teratogenicity by administrating only one isoform.  
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Figure 14: Both enantiomers of thalidomide. 
 
Thalidomide found its renaissance in the 1990s when it was found to inhibit the basic fibroblast growth 
factor (bFGF) as well as the vascular endothelial growth factor (VEGF)71. Additional effects were observed 
on NF-$B (inhibition), alterations of CD8+ and CD4+ T cell function, stimulation of cytokine production of IL-
2 and IFN-#163. Thalidomide happened to be efficient in multiple myeloma, but less active in solid tumors. 
Nevertheless, promising results were observed in Kaposi!s sarcoma and malignant melanoma. Particularly 
its combination with the previously mentioned temozolomide proved its efficacy in metastatic melanoma in 
several clinical studies163. New derivatives of thalidomide were recently synthesized and displayed less 
severe side-effects. Preliminary results show a relatively good efficacy and a diminution of side-effects with 
lenalidomide (CC-5013), and other results are awaited. 
 
 
Figure 15: Tumor angiogenesis and its inhibition. From Becker et al.
29
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INTRODUCTION 
47
Angiogenesis depends on the expression of specific mediators such as VEGF, FGF (fibroblast growth 
factor), interleukin-8, and angiopoietins. Newly formed tumor-related blood vessels sprout into the 
extracellular matrix (ECM), a process dependent on the ability of proliferating endothelial cells to interact 
with diverse glycoprotein components of this ECM. This interaction is mediated by endothelial 
transmembrane receptors or integrins !v"3 and !v"5. Bevacizumab is a humanized antibody against VEGF, 
and is another drug candidate in the class of antiangiogenic drugs. Several studies are going on at the 
moment and there are no results available yet. Most investigations are combined therapies with 
dacarbazine, paclitaxel or INF-!163. 
 
 
1.6.2.2 Bcl-2 antisense therapy 
 
The tumor of over 80% of patients with several cancer types (including melanoma) overexpresses the Bcl-2 
gene. It was among the first genes identified in the apoptosis pathway169. Oblimersen (G3139, 
Genasense®, Genta Inc.) is a Bcl-2 antisense compound targeting Bcl-2 mRNA and causing a decrease in 
Bcl-2 protein translation and production. Down-regulation of Bcl-2 protein and induction of apoptosis could 
be demonstrated in several preclinical studies163. Positive preclinical data gave way to phase I, II and then 
III studies with dacarbazine and oblimersen, which showed an increase (almost doubling) in the response 
rate in patients that received concomitant injection of oblimersen versus dacarbazine alone. However, even 
if the progression-free survival time was longer, overall survival was not affected163.  
 
 
 
Figure 16: Mechanism of oblimersen (Genasense
®
). Image from www.genta.com. 
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1.6.2.3 B-RAF targeting 
 
RAF proteins are a family of serine/threonine-specific protein kinases that form part of a signaling pathway 
regulating cell proliferation, differentiation and survival. The ras gene encodes these kinases. Mutations of 
the ras gene can lead to continuous cell proliferation and inhibition of apoptosis. There are three isoforms 
(A-RAF, B-RAF and C-RAF), of which B-RAF is mutated in a high proportion (50-70%) of melanomas. A 
review by Gray-Schopfer et al.130 describes its role in melanoma very well. B-RAF is apparently an 
important oncogene in most melanomas, and it plays a major role in the regulation of cellular responses 
(proliferation, survival and metastasizing). Therefore, B-RAF might be an interesting therapeutic target for 
melanoma therapy162,163. 
 
 
Figure 17: Ras/Raf kinase pathway and inhibition of kinase signaling by sorafenib
134
. 
 
Sorafenib (BAY 43-9006, Nexavar®) is a C-RAF and VEGFR inhibitor that also shows activity against 
oncogenic B-RAF and that was found to induce apoptosis. Several studies showed that sorafenib was 
active, but only for part of the patients. And most of the responses were only partial. Still, sorafenib helped 
stabilize the disease without heavy side effects (it only showed skin toxicity and diarrhea). Therefore, new 
studies (in various phases) with sorafenib in combination with other targeted agents (such as paclitaxel, 
carboplatin and CCI-779, an mTOR inhibitor) have just started163. B-RAF inhibitors may develop into an 
important therapeutic tool in melanoma, but further effort is needed in order to find more potent and more 
selective agents163. 
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1.6.2.4 Heat shock protein modulators 
 
Heat shock proteins are usually produced in response to physical, chemical or immunological stress, and 
they are multifunctional. Their abilities range from mediation of apoptosis and regulation of proteasomal 
destruction to binding to other proteins and various immunological properties. HspPC-96 is a protein 
peptide complex consisting of a 96 kDa heat shock protein (HSP), gp96, and an array of gp96-associated 
cellular peptides. Immunization with HspPC-96 induces T-cell specific immunity against these peptides; 
gp96 is not immunogenic per se. It has demonstrated positive preclinical melanoma-specific T cell-
mediated reactions. It shows low toxicity and is therefore relatively well tolerated. Several studies using a 
combination of HspPC-96 with other agents such as granulocyte macrophage colony-stimulating factor 
(GM-CSF) and INF-! have shown interesting rates of stabilized diseases (18-29%). Results from a study 
with patients being treated with HspPC-96 versus “physicians! choice” including IL-2 and/or chemotherapy 
are awaited163. 
 
 
1.6.2.5 Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibition 
 
The immune system is able to recognize and react to various targets and antigens, but has also developed 
tolerances with the time regarding autoimmunity. Indeed, it usually does not respond to self-antigens. But 
unfortunately, many tumor cells express self-antigens, preventing them of being correctly and effectively 
eliminated by the immune system161,163. 
 
CTLA-4 is one of the proteins that induces tolerance and down regulation of immune responses to tumor 
antigens. It is produced by suppressor cells called T regulatory cells. CTLA-4 inhibits T cell responses in an 
ongoing immune response. Blockade of CTLA-4 by antibody was shown to enhance T cell response and to 
help reject established tumors in mouse models. Additionally, a combined therapy with a tumor vaccine has 
been shown to enhance antitumor responses, though with a concomitant induction of autoimmunity. 
Therefore, various antibodies have been developed and are or have been tested in clinical trials in 
humans161. The results from some of the completed studies showed that various monoclonal antibodies 
against CTLA-4 were able to induce an immune response, in various extents though. Again, as with other 
therapy strategies mentioned earlier, combination therapies were more efficient, or at least led to higher 
response rates. However, some severe autoimmune responses have also been observed, which could be 
a limiting factor in the therapy. Among around 10 ongoing clinical trials, several are large phase III studies 
aimed at studying efficacy, drug safety and toxicity. Further developments in drugs leading to CTLA-4 
blockade are awaited and will focus on clinical efficacy and on the reduction of the side effects161,163. 
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1.6.2.6 Targeting of the vasculogenic mimicry 
 
Tumors are able to call up a strategy different from the VEGF pathway to ensure their blood supply. They 
engage in a sort of vasculogenic mimicry requiring the synergistic effects of laminin 5 (Ln-5) #2 chain and 
matrix metalloproteinases (MMPs) MMP-2 and membrane type 1 (MT1)-MMP. Highly aggressive 
melanoma cells have the ability to use this strategy to induce vasculogenic mimicry in poorly aggressive 
tumor cells, thus affecting the whole tumor microenvironment. Moreover, generation of Ln-5 #2 chain 
promigratory fragments by MMP-2 and MT1-MMP proteolysis is necessary for an aggressive tumor cell-
preconditioned matrix to induce this vasculogenic mimicry. These persisting modifications (even after 
removal or destruction of the tumor) of the tumor microenvironment are not taken into account by most 
treatment strategies, usually targeting aggressive tumor cells only, and may lead to a recurrence of the 
tumor. Therapeutic strategies that target endothelial cells have no effect on tumor cells that engage in 
vasculogenic mimicry (VM). Indeed, anginex (betapep-25), TNP-470 and endostatin were effective 
angiogenesis inhibitors against endothelial cells but not against aggressive melanoma tumor cells with VM. 
VM-targeting strategies include suppressing tyrosine kinase activity and using a knockout EphA2 gene, 
downregulating VE-cadherin, using antibodies against human MMPs and the laminin 5 #2-chain, and using 
anti-PI3K therapy335. Some researchers focus on the extracellular matrix, which is involved in VM 
formation. It has been demonstrated that a purified anti-laminin antibody is able to inhibit channel formation 
by tumor cells266. 
 
Another interesting strategy involves tetracycline derivatives. Tetracyclines are a group of broad-spectrum 
antibiotics inhibiting cell growth by inhibiting translation. They bind to the 16S part of the 30S ribosomal 
subunit and prevent the amino-acyl tRNA from binding to the A site of the ribosome. Their general 
usefulness has been reduced with the onset of bacterial resistance. Despite this, they remain the treatment 
of choice for some specific indications. Seftor et al. showed that the addition of a chemically modified 
tetracycline (CMT-3; COL-3) to a three-dimensional culture of aggressive metastatic melanoma cells 
inhibited MMP activity, and thus the vasculogenic mimicry as well as the vasculogenic mimicry-associated 
genes in these cells. Additionally, it also inhibited the induction of vasculogenic mimicry in poorly 
aggressive cells seeded onto an aggressive cell-preconditioned matrix277. Another study in a murine B16 
melanoma model by Sun et al. showed as well lower vasculogenic mimicry and a diminution of the 
expression levels of MMP-2 and MMP-9 after treatment with doxycyclin. A partial suppression of the tumor 
growth was also observed297. 
 
 
1.6.2.7 Adoptive T-cell therapy 
 
Adoptive T-cell therapy is an immune-based therapeutic strategy significantly boosting tumor-specific T-cell 
immunity above that observed by vaccination alone57. It involves the ex vivo selection and expansion of 
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antigen-specific T-cell clones, and is a way of augmenting the antigen-specific immunity without the in vivo 
constraints linked to vaccine-based strategies. The identification of T-cell-defined tumor antigens in 
melanoma has led to clinical trials targeting cancer cells. The immunogenic potential of antigens in the 
vaccination strategy has been used to induce T-cell responses. Adoptive cellular therapy, in which antigen-
specific T-cells are isolated and expanded ex vivo and then infused to increase the number of effector cells 
in vivo, has also been used to trigger an immune response. Unfortunately, most responses were low or 
undetectable, and clinical responses were consequently low as well. Thanks to the adoptive T-cell therapy, 
a higher load of T-cells in circulation was reached than with normal immunization treatments333. 
 
The major advantages of using CD8+ T-cells for adoptive therapy are their ability to specifically target tumor 
cells through the recognition of specific tumor proteins on the cell surface, and their long clonal life span. 
Moreover, T-cells are well suited for genetic manipulations, which have enabled the evaluation of 
genetically enhanced or retargeted T-cells in pilot clinical trials for cancer as well as other diseases160. 
 
 
Figure 18: Schemes for adoptive transfer of autologous, vaccine-primed, in vitro expanded T cells
160
. 
Patients are primed with tumor vaccine followed by lymphocyte harvest. Autologous T cells are harvested from peripheral 
blood (i) or draining lymph nodes (ii), undergo polyclonal in vitro activation and expansion, and are reinfused after 
lymphodepleting chemotherapy. Antigen-specific immune function is measured after the administration of booster vaccines. 
(iii) TILs can be isolated from resected surgical specimens and expanded in vitro for adoptive transfer after lymphodepleting 
chemotherapy. Most adoptive transfer therapy approaches using TILs have involved the use of IL-2 infusion following T cell 
transfer in order to select tumor-specific T cells. 
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T cells engineered to express suicide molecules 
Severe graft-versus-host diseases (GVHD) represent a frequent complication of allogeneic immunotherapy 
and donor lymphocyte infusion (DLI). The interest to develop T cells with an inducible suicide phenotype 
was raised by promising results obtained with DLI. This approach was proven viable by engineered T cells 
expressing herpes simplex virus thymidine kinase (HSV-TK). It was shown that the transduced cells could 
be ablated by administration of aciclovir or ganciclovir143. This strategy has been used in clinical trials and 
its efficiency is now proven, even inducing total remissions in a significant number of patients. Severe 
GVHD could also be avoided thanks to administration of ganciclovir. These advances even allowed the 
planning of a phase III clinical trial. An excellent review by C.H. June describes these strategies in more 
detail160. 
 
Unfortunately, HSV-TK has been shown to generate potent HSV-TK-specific immune responses, leading to 
the elimination of the adoptively transferred T cells despite administration of ganciclovir. HSV-TK might 
confer immunogenicity to the transfused cells, their survival being strongly affected and excluding any 
retreatment eventuality in case of cancer relapse. New approaches using suicide switches expected to be 
nonimmunogenic, because of their endogenous base, are under investigation160. 
 
T cells engineered to express tumor antigen–specific receptors 
The poor antigenicity of tumors leads to a major limitation of adoptive T-cell therapy. Two strategies are 
under investigation and even tested in the clinic to try to circumvent the problem. The first provides T cells 
with novel receptors by introduction of “T bodies”, chimeric receptors that have antibody-based external 
receptor structures and cytosolic domains that encode signal transduction modules of the T-cell receptor160. 
However, most studies showed that even though the approach was safe for the patient, its major issue was 
the poor persistence of the T cells in the body. A technical challenge is now proposed to reduce the host 
immune response causing the elimination of the adoptively transferred T cells. 
 
T cells engineered for enhanced survival 
The low short-term persistence of the CTLs in the host without Th cells (helper cells) and/or cytokine 
infusion is a limitation in adoptive T-cell therapy. One group has transduced human CTLs with chimeric 
granulocyte colony stimulating factor (GM-CSF)-IL-2 receptors delivering an IL-2 signal upon binding GM-
CSF. This modification has the potential to extend the circulating half-life of CTLs, as their stimulation with 
antigens caused GM-CSF secretion and resulted in an autocrine growth loop allowing CTL clones to grow 
even in the absence of cytokines97,160. 
 
The future of the adoptive therapy with engineered T cells is promising. Indeed, new cell culture and gene 
transfer techniques provide new tools for further developments. For instance, retroviral vectors lead to high-
level expression of transgenes, but the upcoming challenge will be the silencing of their expression (for 
their usability in long-term therapies). The efficiency of human T-cell engineering was dramatically 
increased by the evolution of lentiviral vectors, and various preclinical test show that they are less prone to 
insertional mutagenesis, thus minimizing safety concerns with this type of vectors. Nevertheless, long-term 
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observational studies with larger data sets about patient safety are required to assess real safety issues. 
Finally, as mentioned by June is his review160, “a primary issue that could limit the ultimate safety of the 
approach is the immunogenicity of the proteins that the T cells are engineered to express; this is likely to be 
a larger problem in humans than in mice because activated human T cells, unlike mouse T cells, express 
MHC class II molecules and have been shown to function as effective antigen-presenting cells.” 
 
 
1.7 Targeting methods under development 
 
Selective localization of chemotherapeutic compounds at tumor sites is crucial in cancer research, given 
the usually high cytotoxicity of drugs used in cancer treatment. The concept of tumor targeting is 
fundamental in order to reduce or exclude severe side-effects. Indeed, large quantities of drugs are usually 
required to kill a sufficient number of tumor cells, and thus to reach and preserve complete remission. 
These drugs are generally targeted at rapidly proliferating tumor cells, but physiologically proliferating non-
malignant cells can obviously be affected. Therefore, modern anti-cancer research aims at developing 
more selective chemotherapeutics. However, the development of a drug bearing both cytotoxicity and 
tumor selectivity properties in a single molecule is very difficult to reach. 
 
A whole variety of new entities called vehicles has therefore been developed, such as antibodies, peptides, 
globular proteins, small organic molecules or even polymers. The tumor physiology allows different 
targeting strategies through properties shared by all cancerous cells, or by properties shared within the 
specific types of cancers. The approach is modular, as typically two molecules with different functions are 
linked together, allowing different combinations in the case of a very specific “carrier”-molecule for instance. 
Moreover, these agents can be deployed both for diagnosis and for therapy. Some of these techniques are 
described below. 
 
 
1.7.1 Paclitaxel encapsulated in cationic liposomes 
 
Paclitaxel was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 
when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the pacific yew tree, Taxus 
brevifolia, and named it “taxol”. Paclitaxel (Taxol®; commercialized under this name by Bristol-Myers 
Squibb), as mentioned earlier, interferes with the normal function of microtubule growth. It stops their 
function by hyperstabilizing their structure. The cell loses then the flexibility of its cytoskeleton. Paclitaxel 
binds to the "-subunit of tubulin, and the resulting microtubule/paclitaxel complex does not disassemble. 
Cell function is then impaired because the dynamic instability necessary for the transport of other cellular 
components (such as chromosome positioning during mitosis) is not available anymore172. Additionally, 
paclitaxel seems to induce apoptosis in cancer cells by binding to Bcl-2 (B-cell leukemia 2), a proto-
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oncogene known to prolong cellular viability and to antagonize apoptosis279. The highly lipophilic properties 
of paclitaxel create a real galenical problem. Commercially available injection formulations of the drug in 
Cremophor EL® (a non-ionic solubilizer and emulsifier used in aqueous preparations of hydrophobic 
substances) and dehydrated alcohol lead to severe side-effects, as well as difficult handling (Cremophor 
EL® interacts with PVC containers)1. 
 
This issue was addressed by encapsulating paclitaxel in liposomes, thus providing a carrier until the site of 
action. However, a generally rapid clearance of the liposomes by cells of the reticuloendothelial system 
(primarily monocytes and macrophages that accumulate in the lymph nodes and the spleen)164,238 is a 
major drawback. 
 
 
Figure 19: Evolution of liposomes
309
. 
A| Early traditional phospholipids "plain! liposomes with water soluble drug (a) entrapped into the aqueous liposome interior, 
and water-insoluble drug (b) incorporated into the liposomal membrane (these designations are not repeated on other figures). 
B| Antibody-targeted immunoliposome with antibody covalently coupled (c) to the reactive phospholipids in the membrane, or 
hydrophobically anchored (d) into the liposomal membrane after preliminary modification with a hydrophobic moiety. C| Long-
circulating liposome grafted with a protective polymer (e) such as PEG, which shields the liposome surface from the 
interaction with opsonizing (making cells more susceptible to the action of phagocytes) proteins (f). D| Long-circulating 
immunoliposome simultaneously bearing both protective polymer and antibody, which can be attached to the liposome surface 
(g) or, preferably, to the distal end of the grafted polymeric chain (h). E| New-generation liposome, the surface of which can be 
modified (separately or simultaneously) by different ways. Among these modifications are: the attachment of protective 
polymer (i) or protective polymer and targeting ligand, such as antibody (j); the attachment/incorporation of the diagnostic 
label (k); the incorporation of positively charged lipids (l) allowing for the complexation with DNA (m); the incorporation of 
stimuli-sensitive lipids (n); the attachment of stimuli-sensitive polymer (o); the attachment of cell-penetrating peptide (p); the 
incorporation of viral components (q). In addition to a drug, liposome can be loaded with magnetic particles (r) for magnetic 
targeting and/or with colloidal gold or silver particles (s) for electron microscopy. 
 
 
Cationic liposomes are able to escape this degradation and are enriched within vessel walls. Additionally, 
angiogenic endothelial cells show an improved uptake of cationic liposomes compared to normal 
endothelial cells. A study by Kunstfeld et al.174 showed that paclitaxel encapsulated in cationic liposomes 
prevents tumor angiogenesis and melanoma growth, whereas paclitaxel in Cremophor EL® does not, 
although their in vivo antiproliferative effect was comparable. Further studies by Schmitt-Sody et al.272 
showed an interesting retardation in tumor growth with paclitaxel encapsulated in cationic liposomes, 
compared to placebo, Taxol® (paclitaxel solubilized in Cremophor EL®) or unloaded liposomes. Moreover, 
the appearance of regional lymph node metastases was significantly delayed by the treatment. 
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A further development of the liposomal vehicle was achieved with paclitaxel-loaded PEGylated 
immunoliposomes. Immunoliposomes are liposomes designed to actively target solid tumors by virtue of 
the monoclonal or polyclonal antibodies attached to their surface. The ability of immunoliposomes to target 
tumor cells overcomes many limitations of conventional liposomal formulations and provides a novel 
strategy for tumor-targeted drug delivery. PEGylated immunoliposomes are stabilized with PEG, and thus 
show an increased circulation time. Therefore, the drug itself is able to circulate a longer time in the blood, 
increasing its potential efficacy. In addition, the selectivity provided by the antibody can increase the 
therapeutic index of an encapsulated drug by promoting selective delivery to cells overexpressing a 
receptor. An excellent review by Torchilin309 describes new technologies and strategies used for liposomal 
vectors. 
 
 
1.7.2 RGD-liganded carriers 
 
The metastasizing ability of a tumor is due to a cascade of events in the cells themselves, but on a more 
macroscopic level as well. Indeed, other cascades are involved in the spreading of the cancer cells 
throughout the body. As mentioned in 1.5.3, this suite of events includes detachment and intravasation of 
tumor cells from primary tumors (or from existent metastases), adhesion to and invasion of the endothelium 
and subendothelial regions of the target organ, and neoplastic growth at the new location. It was found out 
that opportune interferences in these cascades could be favorable to fight the metastasizing process. 
Selectins and integrins, as adhesion molecules, play a central role in the adhesion process and in the 
invasion process through basement membranes or the extracellular matrix. Additionally, a major 
component of the extracellular matrix, fibronectin, is known to contribute to adhesion and invasion as ligand 
for several integrins175. 
 
Pierschbacher and Ruoslathi discovered the arginine-glycine-aspartic acid (RGD) cell attachment site in 
fibronectin in 1984236, but at that time probably did not expect such a short sequence to be a crucial 
recognition pattern for cells and proteins. RGD-recognition sites were reported in other extracellular matrix 
proteins as well. Moreover, RGD pattern-recognition is also used by viruses and bacteria to gain entry into 
host cells, and RGD-motifs have been found in snake venoms, enabling interference with blood 
coagulation306. Therefore, angiogenesis-associated integrin !v"3, for instance, represents an attractive 
target for therapeutic intervention because it becomes highly upregulated on angiogenic endothelium and 
plays an important role in the survival of endothelial cells. These discoveries helped to figure out a possible 
exploitation of this RGD/integrin system to target cells and contribute to internalization of drug carriers. 
Synthetic molecules, including peptides based on the RGD sequence may inhibit adhesion and invasion of 
tumor cells and hinder the metastasizing process. However, as many peptide derivatives, they undergo 
rapid hydrolysis in vivo and, as a result, their circulation time is quite short due to rapid renal and hepatic 
metabolization. Various strategies have been tried out to circumvent the problem, including cyclization of 
the peptides (conferring rigidity and stability to the structure), insertion of non-natural amino-acids (D-amino 
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acids in particular, or peptidomimetics), macromolecules such as polymers, or therapeutic proteins 
equipped with RGD-motifs, and these modifications yielded increased specificity and affinity306. Finally, 
some specific systems have been developed, such as liposomes, nanoparticles or non-viral gene vectors, 
and even adenoviral vectors, and have been equipped with RGD mostly via extended PEG tethers, to 
prevent unwanted interactions with non-target cells. 
 
RGD-liganded liposomes 
One of the most interesting techniques is the RGD-liganded liposome. They have been shown to impair 
metastasizing on B16BL6 murine melanoma cells. Liposomes can carry thousands of RGD or RGD-related 
peptides on one macroscopic particle, and they are more resistant in the blood stream. Oku et al. 
synthesized such derivatives by grafting hydrophobic molecules onto RGD-related peptides and 
incorporating the resulting RGD analogs into liposomal membranes. They were successful in suppressing 
lung colonization of B16BL6 melanoma cells in both experimental and spontaneous tumor metastases223. 
It is suspected that RGD-related peptides incorporated into liposomal membranes bind strongly to 
metastatic cells by cooperative binding mediated by RGD molecules exposed on the surface of liposomes. 
There is no effect on primary melanoma, indicating that the suppression of metastases is not due to direct 
toxicity against tumor cells175. 
 
Phage display technology 
Phage display allows the presentation of large peptide and protein libraries on the surface of filamentous 
phage, which leads to the selection of peptides and proteins, including antibodies, with high affinity and 
specificity to almost any target. The technology involves the introduction of exogenous peptide sequences 
into a location in the genome of the phage capsid proteins. The encoded peptides are expressed or 
“displayed” on the phage surface as a fusion product with one of the phage coat proteins. In this way, 
instead of having to genetically engineer different proteins or peptides one at a time and then express, 
purify, and analyze each variant, phage display libraries containing up to 1010 variants can be constructed 
simultaneously15. 
An application of this technique has shown good potency of its “expressed” ligand. A cyclic structure 
containing two disulfide bonds (ACDCRGDCFCG), called RGD4C and binding avidly to !V"1 integrin, was 
much more potent than commonly used peptides at inhibiting cell attachment to fibronectin. RGD4C has 
then been exploited as targeting ligand for the delivery of cytostatic drugs. Several other RGD 
peptidomimetics have been reported with further improved binding to !v integrins, but only few have been 
exploited for targeting or diagnostics. This is partly due to the fact that they lack groups suitable for the 
coupling of drug or drug carriers. Likely, peptidomimetics will be applied more often as targeting moiety, 
thanks to their excellent binding properties and their stability. 
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Figure 20: Phage structure
15
. 
Phage structure. PIII, pVI, pVII, pVIII and 
pXIX represent phage proteins. Exogenous 
peptides are expressed or “displayed” usually 
on pIII or pVIII. 
 
 
 
RGD-liganded monoclonal antibodies 
Another interesting !v-integrins targeting approach is the coupling of RGD-related peptides to monoclonal 
antibodies. Their major advantage is also a prolonged circulation time in vivo. This effect could be observed 
for humanized monoclonal antibodies (HuMAb) coupled to cyclic RGD peptides (e.g. cRGDfK). HuMAb 
enables the coupling of multiple RGD-related peptides, and consequently increases their affinity to !v-
integrins compared to free peptides. As well, the size of such a macromolecular construct allows the 
coupling of other molecules along the peptide backbone, such as therapeutic agents. This conjugation may 
reduce the toxicity some drugs exhibit in free form. Immunohistochemistry, though, showed localization of 
the peptide not only in the endothelial cells, but also in the liver and the spleen, which could possibly lead 
to side effects in a long-term therapy. Nevertheless, the construct is apparently internalized and degraded 
via a lysosomal pathway, although this internalization was only shown in primary human umbilical vein 
endothelial cells (HUVEC) and not in tumor cells. 
 
Only some of the major developments of RGD-derived carriers have been described here. Nevertheless, 
they show that carrier systems like liposomes, nanoparticles, proteins and other polymers bearing multiple 
RGD-peptides are more likely to be internalized via receptor-mediated endocytosis than single peptide 
constructs. Several other common advantages are attributable to RGD-equipped macromolecular carriers 
even though they represent a diverse group. 
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These kinds of carriers have some major interesting advantages over single peptide constructs. First, there 
is an inhibition of the renal filtration because of the high molecular size of the carrier, thus preventing 
glomerular filtration. This may lead to longer circulation times and extended presentation of the ligand to 
the target receptor (but also to a higher toxicity due to the delay in excretion). Secondly, the drugs are 
mostly protected by their carrier against the “destructive” action of enzymes present in the blood stream or 
in some tissues. Finally, the high molecular weight of most carriers leads to passive retention in a tumor, 
via the so-called enhanced permeability and retention (EPR) phenomenon. For example, RGD4C-equipped 
polymers accumulated in the course of 3 days, while radioactivity in other organs decreased, resulting in a 
50:1 tumor:blood ratio at day 3. The control polymer without RGD-targeting motif accumulated in the tumor 
to a lesser extent, demonstrating the contribution of RGD-mediated targeting to the EPR effect306. 
 
 
1.7.3 DNA vaccines against VEGF receptor 2 (also called FLK-1) 
 
Angiogenesis plays a central role in various processes of solid tumor progression, including invasion, 
growth and metastasizing. Angiogenesis can even be seen as a rate-limiting step in tumor growth. Indeed, 
tumor growth is generally limited to 1-2 mm3 in the case of a missing vasculature or neovasculature. The 
inhibition of tumor growth by attacking the tumor!s vascular supply provides obviously a primary target for 
anti-angiogenic intervention, and offers several advantages. Firstly, the inhibition of tumor neoangiogenesis 
is a physiological mechanism inherent to the host, and thus should not trigger the development of 
resistance. Then, hundreds of tumor cells are supplied by each capillary, and targeting the vascular system 
of the tumor potentiates the antitumor effect. Thirdly, efficiency of the therapeutic agents is increased by 
the direct contact of the vasculature with the blood stream218. 
 
The vascular endothelial growth factor receptor 2 (VEGFR2 or FLK-1) is a receptor binding five isomers of 
murine VEGF. Its expression on endothelial cells is restricted but it is upregulated in case these cells 
proliferate during angiogenesis in the tumor vasculature. It is necessary for tumor angiogenesis, and 
therefore plays a determinant role in tumor growth (as mentioned earlier), invasion and metastasis, making 
it a very interesting therapeutic target192,218,336. 
 
 
1.7.4 Salmonella delivery system 
 
As mentioned earlier for VEGF, live attenuated Salmonella strains constitute an interesting delivery system 
for heterologous antigens implicated in the construction of DNA vaccines, and allow stable and regulated 
expression of the foreign antigen in the host cell. Indeed, upon penetration of the bacteria in the cell, 
plasmid-encoding antigens under eukaryotic promoters may be transferred to the host cell, resulting in 
expression of the foreign antigen by the host cell228. The preference of Salmonella for macrophages and 
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dendritic cells allowed live bacteria to be used to target immunomodulatory molecules to antigen-presenting 
cells, thus providing an effective way to modulate immune responses259. 
 
More recently, Salmonella strains have been used as vectors for the delivery of cytokine-encoding 
plasmids, and their immunomodulatory effects were studied in experimental models. For instance, they are 
able to influence the immune response against the Frag C antigen (fragment C of tetanus toxin) or the 
specific immune response elicited during a parasitic infection (Echinococcus granulosus). The cytokines 
used in these studies were interleukin-4 (IL-4) and IL-18259. Both of them being known to have antitumoral 
activities, they have been used in experiments aiming at evaluating their efficacy as oral gene therapy for 
cancer in a melanoma mouse model. Cytokine-encoding plasmids were introduced into Salmonella 
enterica serovar Typhi (S. Typhi) or serovar Typhimurium (S. Typhimurium), and the recombinant strains 
were administered to mice by mucosal or systemic route. The results showed that delivery of DNA-
encoding cytokines to the immune system was successful, and that the cytokines markedly influenced the 
host!s immune response259. Recent work from the same group showed extended survival time of mice 
carrying subcutaneous melanoma, as well as higher levels of IFN-#, in experiments with orally administered 
single doses of Salmonella carrying various cytokine-encoding plasmids5. 
 
 
1.7.5 Peptides and peptidomimetics, and their radioactive derivatives 
 
As mentioned earlier, surgery is the major treatment modality for primary tumors and large metastases. 
Chemotherapy, which is used for disseminated tumors and has curative effects in cases of lymphomas, 
testicular tumors and tumors in pediatrics, yields poor results in the treatment of melanoma. There is 
currently no curative treatment against other large groups of tumors, such as breast, prostate, colorectal, 
lung and ovarian tumors, and many more. Only a palliative effect can be achieved with chemotherapy in 
these fields. Therefore, it is necessary that new treatment modalities are developed to complete surgical 
and chemotherapeutical treatments. Radionuclide therapy is one of them, but for radionuclide therapy to be 
an interesting complement or alternative, it is necessary that disseminated tumor cells and small 
metastases are targeted and eradicated. Peptides and peptidomimetics are excellent candidates for the 
targeting of specific cell types. Indeed, most of their properties have revealed interesting applications in the 
drug discovery field91. 
 
- They usually are or mimic native ligands that target the cells in a mostly receptor-mediated 
way, thus allowing to apply whole or partial sequences found out by the nature and 
therefore to simplify the process. 
- They offer the availability of infinite combinations of amino acids, thus providing a great 
amount of possible variations in their sequence. This property is especially interesting, as it 
relies on simple synthesis (thanks to the solid-phase synthesis approach) and the use of 
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amino acid sequence variations in high-throughput screening (HTS) systems, now widely 
established in pharmaceutical companies. 
- They offer the possibility to replace only one amino acid, leading to interesting and 
systematic structure-activity relationship studies. 
- One or more amino acids can be replaced by non-natural amino acids providing peptidase 
resistance, rigidity and general in vivo stability, or even derivation possibilities by displaying 
functional groups on side chains. 
- These derivations can offer a direct linking opportunity for toxic components, or a coupling 
position for further carriers (e.g. metal chelator complexes such as DOTA, allowing the 
labeling of the molecule with radiometals). 
- Peptides usually have excellent tumor penetration, a low bone marrow accumulation and 
quite fast blood clearance. 
- The chemistry used to produce peptides is generally mild, as most reactions proceed at 
room temperature in relatively common solvents and reagents that are not extremely toxic. 
- By contrast to monoclonal antibodies used in similar applications, production of peptides 
with a molecular weight <1500 Da is cheaper. 
 
Further modifications of these peptides enable the complexation of radioactive metals to build diagnostic 
tools for the imaging technology, or even therapeutic tools. Oncology is a particularly demanding domain 
for such tools, as tumors and above all metastases are difficult to detect sometimes. Most cancers tend to 
overexpress surface receptors, and this property offers new perspectives to the now old concept of “magic 
bullet”. It raises the possibility to target the therapeutic agent specifically to the site of action, and gives an 
opportunity to expose the cancer cells to in situ generated radiation, ionizing radiation being one of the 
major strategies to kill tumor cells in patients. The elegance of the method comes naturally from its 
selectivity, as a whole-body exposition to radiations leads to severe side-effects and complications, thus 
lowering patient condition and treatment compliance. Additionally, some short-lived isotopes are of great 
interest, as the total exposition remains limited in time. 
 
The general principle of tumor targeting was well described in a review by Eberle et al.91. The illustration 
(Figure 21), modified from that review, gives an overview of the basic strategy of receptor-mediated tumor 
targeting using radiopeptides. “The radiopharmaceutical is applied systemically, in most cases 
intravenously, leading to accumulation in the target organ, and also in nontarget tissues, mainly the 
kidneys, spleen, and liver. Binding of the radiopeptide to its receptor induces receptor down-regulation and 
internalization of the receptor-ligand complex. The internalized receptor-ligand complexes are first found in 
endosomes, and later part of the radioactivity may be seen in the nucleus and also in the mitochondria (…). 
The selection of the radioisotopes depends on the purpose of the targeting: for diagnostic applications, 
isotopes emitting #-radiation are necessary, such as 99mTc, 111In, or positron-emitters (e.g. 68Ga), which also 
lead to #-radiation. For therapeutic application, short-range !-emitters (rare) or "-emitters (more frequent) 
are selected or, alternatively, isotopes that emit Auger electrons.” (cited from Eberle et al.91). 
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Figure 21: General principles of receptor-mediated targeting of tumor cells by radiopeptides labeled 
with diagnostic and therapeutic radioisotopes (modified from A.N. Eberle et al.
91
). 
 
 
The interest in radiopeptides was growing only after radiopeptides became available that offered structural 
stability and high biological activity. These new analogues were also able to carry chemical groups 
intended for the incorporation of various radioisotopes. Although most in vitro assays worked quite well, the 
first peptides tested in vivo suffered from two major drawbacks. The advances in the structural stability of 
the peptides did not meet the requirements of in vivo transport and resistance to peptidases, and the first 
radiopeptides to be tested were labeled with tritium, whose radiotoxicity was much lower than required. 
Nevertheless, uptake and accumulation of the peptides in the tumor cells could be observed. 
 
Great advances in the field of radiopeptides were achieved with somatostatin derivatives. Indeed, its 
receptor subtypes can be found on various types of tumors, and this contributed to the interest for this 
research field. Somatostatin research even led to the first radiopharmaceutical to be registered, octreotide 
(OctreoScan®), which was labeled with 111In, for tumor scintigraphy; further development even led to the 
first therapeutic radiopharmaceutical, OctreoTher®, which was labeled with 90Y. 
 
As mentioned earlier (see 1.4.4), MC1R usually are expressed at the surface of melanocytes, and even 
overexpressed at the surface of melanoma cells285,286. Therefore, the perspective of developing a 
diagnostic, staging or even a therapeutic tool against malignant melanoma by targeting the MC1R became 
very promising. First, radiolabeled monoclonal antibodies and antibody fragments against specific 
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melanoma cell epitopes have been investigated197,265. Unfortunately, it was discovered that individual tumor 
variants occurred, and their clinical application was thus limited. Additionally, monoclonal antibodies have 
quite poor tissue penetration abilities, they tend to accumulate in the bone marrow, and their cost of 
production is high. A new class of peptidic derivatives was then developed, based on the sequence of !-
MSH, MC1R!s native ligand. Their shorter sequence provides stability in the serum, especially against 
carboxypeptidases and other serum proteases. Their main advantage over antibodies or antibody 
fragments resides in their low immunogenic potential, faster blood clearance and better tumor penetration, 
and it has been proven with the development of the commercially available OctreoScan® that they are 
suitable tools for diagnostic purposes22. Indeed, the coupling of a chelating complex to the selective 
peptides enables the incorporation of radioactive metal isotopes such as 111In, 67Ga, 99mTc for diagnostic 
purposes, or 67Cu, 188Re and 90Y for therapy91. Nevertheless, the major drawback of these new chelated 
targeting peptides is their in vivo pharmacokinetical behavior. While the tumor uptake of these new 
peptides has increased, their kidney uptake has dramatically increased as well, making the new !-MSH 
analogs relatively unsuitable for diagnostic or therapeutic applications. 
 
Again, after solving existing issues, new difficulties appeared that had to be overcome. The main strategies 
and sensitive parameters able to influence the pharmacokinetical profile of !-MSH analogs will be detailed 
in the next main chapter (chapter 2). For this thesis, three major concepts were adopted in order to improve 
the ratio between the tumor uptake and the kidney uptake of radiolabeled !-MSH analogs. These new 
strategies are described in the following chapter. 
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1.8 Aims of the thesis 
 
Improving the tumor uptake of 111In-labeled !-MSH analogs instead of reducing their kidney uptake may be 
an efficient strategy to obtain improved tumor-to-kidney ratios. As dimeric ACTH or derivatives of !-MSH 
had been shown to display markedly increased receptor affinity compared to monomeric analogs, it was 
tempting to analyze this approach more closely. A synergistic effect was suspected to lead to a higher 
tumor uptake of the dimeric radiopeptides. Indeed, dimers present two core sequences available for 
binding in the vicinity of the receptor, thus providing two binding motifs on one ligand. To this end, three 
dimeric derivatives of !-MSH were synthesized and tested in vitro and in vivo, in order to assess their 
binding affinities as well as their pharmacokinetical profiles, with the aim of improving their general tumor-
to-non-target-tissue ratio by increasing their tumor uptake when used as radiopharmaceuticals. 
 
Glycosylation represents a very efficient way to influence the pharmacokinetical profile of a whole range of 
drugs. Changes in the hydrophilicity, either local or molecule-wide, modification of the specific interactions 
with the targeted receptors, improved penetration of membranes (particularly the blood-brain barrier93) and 
interaction with uptake, re-uptake or non-specific receptors of non-target tissues throughout the body 
represent some of the main goals through which glycosylation can display significant effects in affinity and 
biodistribution profiles. Previous studies with glycopeptides have shown switches from the hepato-biliary 
towards the renal excretion way after carbohydration as well. In order to improve the pharmacokinetical 
profile of radioactive !-MSH analogs through reduction of the kidney uptake, six glycopeptidic derivatives of 
!-MSH were synthesized and tested both in vitro and in vivo. The aim of this strategy was to determine the 
influence of glycation on the receptor binding affinity and on the pharmacokinetical profile of radioactive !-
MSH analogs. The peptides were glycated at various positions along the peptide sequence and with 
different carbohydrate moieties, in order to help to draw conclusions about structure-activity relationships in 
this class of glycopeptides. 
 
It has been shown that amount and repartition of charges on peptides or other molecules had an impact on 
their pharmacokinetical profile. As the surface of the cells building the proximal tubules is negatively 
charged, molecules carrying negative charges as well may undergo a lower reuptake in the kidney through 
electrostatic repulsion. The urinary excretion of these molecules would thus presumably be increased, and 
therefore their therapeutic index improved. Localization of the negative charge seems to be a fundamental 
parameter to take into account. To investigate this approach, a new radiolabeled !-MSH derivative with an 
overall negative charge was synthesized and tested. 
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2 Radioactive !-MSH analogs for melanoma targeting: State 
of the art 
 
 
Having to face new setbacks with optimized derivatives required investigations about the underlying 
mechanism of kidney retention. These findings allowed to improve non-specific uptake issues, and led to 
ameliorations at different levels, including a better understanding of structure-activity relationships. 
 
2.1 Proposed mechanism of radiopeptide retention in the kidney 
 
The kidney is a major site of catabolism of low-molecular-
weight proteins. Proteins and peptides are first filtrated by the 
glomerulus in a molecular-weight-dependent manner, then 
reabsorbed by tubular cells along the nephron, and finally 
degraded in the lysosomes. In addition to the size-exclusion 
filtration, the basement membrane of the glomerulus is 
negatively charged, thus helping cationic peptides and 
proteins to attach and to pass into the primary urine. Anionic 
peptides and proteins appear to be less efficiently filtrated, 
due to repulsing electrostatic forces33. In the case of 
radiopeptides, the mechanism of reabsorption is quite similar 
to the one just described. The peptides are then delivered to 
lysosomes where they are hydrolyzed to a final radioactive 
metabolite that cannot leave the lysosomes, leading to long-
term sequestration of the radioisotope in the proximal tubular 
cells. Indeed, whereas the resulting catabolic products of 
radioiodinated proteins and peptides are rapidly excreted, 
radiometal chelates remain partially trapped within 
lysosomes. The effect of injection of pharmacological 
amounts of cationic amino acids and their derivatives can be 
a tubular proteinuria by neutralization of negative charges on 
the luminal cell surface of tubular cells, which are thought to 
be essential for the binding of proteins and peptides to their 
respective receptors33. 
Figure 22: Schematic representation of the 
physiology of protein reabsorption and 
metabolism in the renal proximal tubule 
cells (from Behr et al, Eur J Nucl Med 25 
(1998), 201-212). 
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2.2 Choice of radionuclides 
 
Several types of radionuclides are adapted to tumor diagnosis or therapy. Depending on the desired 
application, various types of radiations are desirable in a tracer, and thus often different radionuclides. For 
instance, to allow detection by external scanners, long-range radiation is needed. This type of radiation 
travels through almost all kinds of tissues until it reaches detectors processing the signal and building an 
image of the targeted area. Medium- and short-range radiations are more therapy-oriented, as they allow, if 
an adequate radionuclide emitting sufficient energy is chosen, to destroy the targeted cells, or the targeted 
cells and additionally their surrounding cells. The range of emission is not the only criteria. The type of 
emission is also fundamental for the choice of an adequate radionuclide. There are 4 major types of 
radiation emission157: 
 
- In #-decay, a nucleus changes from a higher energy state (obtained, e.g., by preceding "--decay 
of a higher-order nuclide) to a lower energy state through the emission of electromagnetic 
radiation (photons). The number of protons (and neutrons) in the nucleus does not change in this 
process, so the parent and daughter atoms are the same chemical element. 
- In "#-decay, the weak interaction converts a neutron (n0) into a proton (p+) while emitting an 
electron (e#) and an antineutrino (%e). In "
+-decay, energy is used to convert a proton into a 
neutron, a positron (e+) and a neutrino (%e). 
- !-decay is a type of radioactive decay in which an atomic nucleus emits an alpha particle (two 
protons and two neutrons bound together into a particle identical to a helium nucleus) and decays 
into an atom with a mass number 4 less and atomic number 2 less. !-decay is a form of nuclear 
fission where the parent atom splits into two daughter products. 
- The Auger effect is a phenomenon in which the emission of an electron from an atom causes the 
emission of a second electron. When an electron is removed from a core level of an atom, leaving 
a vacancy, an electron from a higher energy level may fall into the vacancy, resulting in a release 
of energy. Although sometimes this energy is released in the form of an emitted photon, the 
energy can also be transferred to another electron, which is ejected from the atom. This second 
ejected electron is called an Auger electron. 
 
 
2.2.1 Tumor diagnosis 
 
Diagnosis requires a radiation type that is mostly detectable from outside the body or tissue. Thus, long-
range radiation is needed, such as #-radiation or "+-radiation, required for scintigraphic applications. #-
radiation can be detected by #-counters, for example, to measure the amount of radioactivity emitted by 
organs collected after dissection of laboratory animals in biodistribution experiments, or to allow patient 
imaging by a #-camera or a single photon emission computed tomography, also called SPECT (similar 
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principle as a #-camera, but allowing 3D-imaging by views taken from various angles and computer 
processing). The detection process for "+-radiation, on the other hand, is not a direct detection of the 
emitted particles. As the isotope undergoes positron emission decay, it emits a positron, which is the 
antimatter counterpart of an electron. This positron travels up to a few millimeters to encounter and 
annihilate with an electron, producing a pair of annihilation #-photons, moving in opposite directions. These 
are detected by a scintillating material in the PET-scanner, which creates an emission of light detected by 
photomultipliers, then able to rebuild an image. 
 
The first !-MSH analogs were labeled with 14C, but its specific radioactivity definitely remained too low for 
biological studies146. !-MSH analogs were then labeled with tritium (3H, 2 to 12 tritium atoms), and the 
obtained compounds were suitable for tissue distribution and stability studies in vivo. They showed a good 
uptake in melanoma cells in vitro and in melanoma tumors in vivo, but because of its too low-energy "- 
emission, tritium did not affect tumor growth, and thus was abandoned87,90. Then 125I, a #-emitter, became 
available and increased the specific activity by a factor 10. It allowed determination of the number of 
functional receptors expressed by various melanoma cell lines, the development of competitive binding 
assays as well as determination of ligand and receptor distribution in vitro and in vivo. Unfortunately, 
although the derivatives remained biologically active and had an interesting specific activity, a 
dehalogenation reaction was observed in vivo with radioiodinated !-MSH analogs, which reduced their 
potential as therapeutic tools90. 
 
New analogs bearing chelating complexes such as DTPA or DOTA (described in the next chapter) were 
then synthesized. The chelates allowed the complexation of charged radiometals, such as 99mTc, 67/68Ga, 
64Cu, 86Y or 111In. The major advantage of such radionuclides is their high specific activity, thus dramatically 
reducing the amount of peptide to inject, and by reducing the peptide load a lower non-specific 
accumulation can be reached91,249. This high specific activity, coupled to the #-radiation emitted, allows a 
low detection threshold and represents one of the main interests of 111In for biodistribution experiments in 
animals. The #-radiation emitted also allows local or whole-body imaging without being harmful to patients 
or animals at adequate doses. Additionally, 111In does not emit any "-radiation, which makes it safer to 
handle in experiments preceding therapeutic experiments involving much stronger radionuclides such as 
e.g. 90Y. Finally, its half-life of 67.9 h is very suitable for observations and measurements over several 
days. Unfortunately, its major drawbacks are its price and availability, as 111In can only be produced in a 
cyclotron. From another point of view, the relatively short half-life of 68Ga (68 min) is overcome by its 
availability. Indeed, it is generator-produced by decay of the parent 68Ge, displaying a half-life of 280 days, 
thus giving the generator a long half-life and allows PET imaging at institutions without an on-site cyclotron. 
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Table 4: Radioisotopes used for tumor diagnosis
91
. 
 
 
99mTc is the most important radionuclide for diagnostic nuclear applications used in the clinic. 
Radiopharmaceuticals labeled with 99mTc represent about 80% of all radioisotopes used clinically. It is a 
very convenient isotope, as it is easy to handle, it can be produced at a quite low cost, has an almost 
exclusively #-radiation (no " and no !) of 141 keV and excellent imaging properties. The supply problem is 
overcome by obtaining the parent 99Mo, which has a longer half-life (67 h) and continually produces 99mTc. 
The parent is delivered in a radionuclide generator allowing the easy separation of the daughter. The only 
disadvantage of 99mTc is a relatively short half-life of 6 h, making longer or delayed observations 
impossible91. Three methods are available for the labeling with 99mTc: 
 
- Direct labeling, which is a direct chelation of the metal by available sulfide groups in the peptide. 
A reducing agent converts cystein disulfide bridges into free thiols that bind with 99mTc. Of course, 
one limitation is the availability of cysteines along the peptide sequence. Additionally, the 
obtained complexes usually have a poor in vivo stability. Chen et al.58 used this technique to label 
early cyclic !-MSH analogs. 
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- Labeling can be performed with a preformed chelate approach. The radionuclide binds to a 
bifunctional chelating agent in a step preceding the attachment to a peptide. Its drawback is the 
multiple step approach, inapplicable to routine applications. 
- The best method is probably the indirect method, consisting of the attachment of a bifunctional 
chelating agent to the peptide during its synthesis, and of its subsequent labeling with 99mTc. This 
procedure is usually the standard procedure for the complexation of radiometals other than 99mTc 
to peptides91 as well. It is routinely used by several groups for labeling applications e.g. in the 
fields of somatostatin60 and !-MSH110. 
 
99mTc is used in more than 20 million diagnostic nuclear medical procedures worldwide every year. 
Depending on the transporter (drug, vector) it labels, it allows imaging of a lot of pathologies. For example, 
when exametazime is labeled with 99mTc, it is possible to image the cerebral perfusion, as exametazime is 
able to cross the blood brain barrier95,173. [99mTc]-sestamibi (methoxyisobutylisonitrile) can be used for 
myocardial perfusion imaging275 or parathyroid imaging312. Assessment of renal function performance and 
its imaging uses [99mTc]-mercapto acetyl triglycine, also known as a MAG3 scan8. 
 
#-Emitting radionuclides are used for #-camera or SPECT imaging. Practical applications are readily 
available, particularly with 99mTc and 111In. In the field of somatostatin, the synthesis and clinical application 
of OctreoScan® brought new perspectives for the imaging of neuroendocrine tumors expressing 
somatostatin receptors37,49. It is now routinely used for the diagnosis of such tumors. It is also used for 
diagnostic purposes in clinical studies investigating new treatments, e.g. recruitment and follow-up 
diagnostic imaging of a treatment of the ileal carcinoid with 90Y-DOTATOC (somatostatin derivative) were 
realized with OctreoScan®(Figure 23)37. 
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Figure 23: Bone and lymph node metastases from ileal carcinoid before and after 
90
Y-
DOTATOC therapy
37
. 
A OctreoScan at recruitment. Black arrows indicate bony lesions. The open arrow indicates lymph 
nodes. B OctreoScan 9 months after the second cycle: there is no more evidence of pathological 
uptake. 
 
 
As mentioned above, "+-emitting radionuclides are needed for PET imaging. 64Cu, 68Ga and 86Y are 
suitable for PET imaging, thanks to the appropriate specific activities displayed. 68Ga exhibits a very short 
half-life of 1.13 h. The technical timely difficulty can though be overcome, as it was shown in an experiment 
on mice bearing a subcutaneous malignant melanoma114. Nevertheless, peptides labeled with 68Ga do not 
allow longer-term observations in patients, due to the short-lived nature of the radionuclide. The other 
radionuclides display more interesting half-lives with 12.9 h for 64Cu and 14.7 h for 86Y. 64Cu, though, has 
suboptimal properties for PET-imaging, as only 19% of its decay mode consists of "+ radiation. 86Y has 
very similar properties to 68Ga, and its much longer half-life makes its preparation and application easier. A 
further diagnostic radioisotope to shortly mention is 18F. 18F is a "+-emitter mostly used in 
fluorodeoxyglucose (FDG), which is an analog of glucose commonly used in PET imaging. FDG is taken up 
by high-glucose-using cells such as brain, heart, kidney, and cancer cells, where phosphorylation prevents 
glucose from being released intact. The oxygen attached to C-2 in glucose is needed in further steps of the 
glycolysis, so that (as for 2-deoxy-D-glucose) FDG, whose hydroxyl group at position 2 is substituted by 18F, 
cannot be further metabolized in cells, and therefore the FDG-6-phosphate formed does not undergo 
glycolysis before radioactive decay. As a result, the distribution of 18F-FDG is a good reflection of the 
distribution of glucose uptake and phosphorylation by cells in the body. After FDG decays radioactively, 18F 
is converted into 18O and after catching a proton from the environment, FDG becomes glucose-6-
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phosphate labeled with a “heavy” oxygen at position 2, and thus will be normally metabolized during 
glycolysis246. 
 
Table 5: Characteristics of different radionuclides used for radiolabeling of peptides
222
. 
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2.2.2 Tumor therapy 
 
Whilst #-emission is needed for diagnostic purposes, radionuclide therapy requires other types of radiation 
in order to cause cell death. "--particles are generally preferred, thanks to their longer range (higher 
energy), to !-radiation or Auger electrons. The latter two usually require cell internalization (for Auger 
electrons even intranuclear localization) for the delivery of lethal doses. Achieving a high level of selectivity 
(targeting) is crucial for therapeutical applications, as normal tissues could otherwise be strongly affected or 
destroyed by the radiation of such radionuclides. It can be an advantage if the chosen radionuclide also 
emits #-radiation for simultaneous imaging or for dosimetry. 
 
"
-
-Emitters 
Thanks to the high-energy "--particles (2.3 MeV) emitted by 90Y, it has been very popular for the labeling of 
antibodies and peptides. Its longer-range radiation (1.1x10-2 m), though, is not ideal for the treatment of 
small cell clusters. Additionally, it does not emit any #-radiation, making imaging and dosimetry impossible. 
Its favorable half-life (2.5 days) and high-energy are very suitable for the treatment of large tumor cell 
clusters, as is 188Re (2.12 MeV, 80%), which also emits sufficient #-radiation for dosimetry and imaging293. 
Nevertheless, 90Y remains an interesting radionuclide for some applications. In studies involving the 
previously mentioned diagnostic OctreoScan, which is labeled with 111In, therapeutic experiments were 
carried out with high doses and showed tumor regression in some patients. The Auger electrons may have 
had this therapeutic effect, but their energy and range are very limited (2.6 keV, 3.7x10-7 m). Therefore, 
new experiments were realized by replacing 111In with 90Y for the high energy and greater range of its 
radiation, and showed promising results (see Figure 23 above). 186Re (1.07 MeV, 73%), displaying a 
medium-energy "--radiation, is more suitable for intermediate-sized cell clusters. 177Lu (0.498 MeV, 90%), 
has received attention, since its energy (and thus the range of its "--particles) is considerably lower than 
e.g. 90Y, thus allowing to spare the neighboring, potentially healthy tissue. Additionally, 177Lu is a #-emitter. 
Its half-life (6.7 days) may be too long, depending on the type of peptide used. 67Cu and 131I fall in the same 
class of radionuclides, with emissions comparable to those of 177Lu91,293,319. 
 
Radioiodinated peptides are routinely used in in vitro studies (125I). Single photon imaging studies have 
been realized with 123I (the #-radiation emitted by 125I has a too low energy), and 131I is a potentially 
therapeutic radionuclide. 131I can be produced in a nuclear reactor by fission at a relatively low cost. 
Labeling with iodine is usually a direct labeling, involving in situ generation of electrophilic species of 
radioiodine (with oxidants such as chloramine-T or Iodogen®), which react with tyrosine residues. It is 
difficult to obtain mono-iodinated products, as Tyr bears 2 sites for insertion of radioidide. Additionally, 
dehalogenation of Tyr occurs in vivo that makes iodine unsuitable for in vivo diagnosis and limits its 
application for therapy23. 
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!-Emitters 
The short range in tissue (< 0.1mm) and the high linear energy transfer associated with !-particle emitters 
results in a more concentrated deposition of energy at the site of radionuclide decay. Literally, a single 
atom emitting an !-particle can kill a target cell. Thus, if !-radiolabeled antibodies or peptides can be 
bound to malignant cells specifically, a high differential cell killing can be achieved between malignant and 
normal cells151. Their short-ranged radiation and high relative biological efficiency (5-20-fold that of "--
particles) are highly advantageous for the treatment of small tumors and micrometastases219. They are 
even suitable for the destruction of individual cells as for example for the treatment of leukemias334. !-
Emitting radionuclides have been applied mostly to immunoconjugates for radioimmunotherapy. Miao et 
al.205 studied the effect of a cyclic !-MSH analog labeled with 212Pb on melanoma-bearing mice and 
reported a longer survival time and even total remissions. Unfortunately, as observed earlier for the same 
derivatives labeled with 111In, kidney uptake remained a major issue. 211At and 213Bi have also been tested, 
but because of their usually short half-lives (7 h and 47 min, respectively) and the time required to achieve 
a useful tumor-to-normal tissue ratio after administration, !-emitters may be of limited value in the 
treatment of tumor masses when conjugated to intact antibodies319. 
 
Table 6: Beta- and alpha-emitting radioisotopes used for tumor therapy
91
. 
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Auger electron cascade 
The very short range of radiation of Auger electrons makes them a suitable alternative for therapy. As most 
radionuclides used in diagnostic applications emit Auger electrons (like 111In, discussed above), these may 
also be used as therapeutic tools if sufficient doses are able to reach tumor cells and, above all, if 
strategies are found that allow Auger emitters to reach the nucleus. Very high doses of the therapeutic 
agent have to be injected for these means, which usually results in a relative decrease in its uptake by the 
tumor. The uptake by non-target organs, on the other side, is normally not proportionally reduced, or may 
even increase. Therefore, the tumor-to-non-target tissue ratios may find themselves reduced, resulting in 
limited therapeutic indexes. Another limitation of very short-ranged emitters is their short tissue penetration 
(0.02-10 µm), which is unsuitable if not all cells constituting the tumor express the target receptor91. 
 
 
2.3 Chelates for peptide labeling 
 
 
As mentioned for 99mTc in the previous chapter, one of the best labeling techniques is to use chelating 
complexes. These metal-chelating agents allow control over the behavior and localization of metal ions. 
Several types of chelating agents are available: simple chelators like ethylenediaminetetraacetic acid 
(EDTA), as well as bifunctional chelating agents bearing a chelating group on one end, and a chemically 
reactive functional group on the other, allowing further coupling to targeting molecules201. The first chelate 
to be introduced was the hexadendate EDTA. It was coupled to bleomycin to complex 57Co for diagnostic 
tumor targeting186. It was then tried as chelate for magnetic resonance imaging with Gd(III), but a higher 
toxicity was reported in vivo than with diethylenetriamine-pentaacetic acid (DTPA) as chelate. In 
experiments with a bleomycin analog carrying EDTA and labeled with 111In, background radioactivity in 
various tissues made detection difficult129. Further studies involving 111In-labeling of proteins such as 
albumin and fibrinogen coupled to an EDTA-derivative revealed interesting properties but also a higher 
non-specific uptake298. Unfortunately, an EDTA-type complex of an In(III) ion is less stable than other 
In(III)-complexes formed in the blood stream. This instability is probably due to the very low concentration 
of the synthetic complex and the relatively high concentration of transferrin in the serum. However, some 
EDTA-derivatives were designed to have a slower rate of dissociation, and In(III) remained complexed in 
vivo for a longer time201. 
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Figure 24: Structures of EDTA and DTPA coupled to peptides
91
. 
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DTPA, an octadendate chelate, is an efficient chelate. It consists of a diethylenetriamine backbone 
modified with five carboxymethyl groups. The molecule can be viewed as an elongated version of EDTA. At 
first, it has been used to form stable complexes with Gd(III) for magnetic resonance imaging, and a further 
derivative was later approved for clinical applications91. Since then, DTPA and its derivatives have been 
important chelators in many domains, including somatostatin derivatives112,178,179,320 and !-MSH 
analogs19,20. OctreoScan®, which was already mentioned above, is a commercially available somatostatin 
analog (octreotide) bearing the DTPA chelate for the complexation of 111In for the diagnosis of 
neuroendocrine tumors. Nevertheless, attempts to label antibodies or small molecules with 90Y for 
radiotherapeutic applications using DTPA or DTPA derivatives as chelates were hampered by 
myelotoxicity, due to the in vivo instability of the 90Y-DTPA complex and the subsequent radioactivity 
uptake by the bone109. Additionally, DTPA-!-MSH analogues were also shown to nonspecifically 
accumulate in sites of distant melanoma metastases such as the liver. This side-effect prevented further 
developments of this class of !-MSH derivatives, as nonspecific accumulation in non-target tissues might 
have damaged the distant organ, or have prevented detection of metastases located in the same region20. 
The major problem of EDTA and DTPA seems to be the in vivo instability of the complex they form with 
metals. The anionic complexes of EDTA or DTPA with e.g. copper, indium and yttrium are either readily 
protonated or attract other competing metal ions (Ca2+, Mg2+ and Zn2+ are present in great amounts in 
human blood) to form mixed complexes with a reduced kinetic stability. Additionally, the following 
dissociation of the metal ion in vivo is essentially irreversible, as serum proteins such as transferrin or 
albumin will rapidly sequester the metal ion while the chelate will simultaneously be occupied by serum 
cations. Their relative instability at low pH (for example in the liver) also is a cause for the dissociation of 
the complex and thus involved metabolic issues231. 
 
The interest then switched to macrocyclic complexes which tend to undergo slower acid dissociation and 
cation exchange reactions. Peptides and antibodies carrying the macrocyclic DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) metal chelator, for example, were synthesized and tested. 
This chelator complex is able to incorporate a broader range of 2+ or 3+-charged radiometals than DTPA. 
Indeed, DOTA is almost a universal chelator, capable of strongly complexing metals such as 111In and 67Ga 
for single photon emission tomography, 68Ga, 86Y and 64Cu for PET, as well as 90Y for therapy144 and even 
lanthanides. Their stability was tested and, for example, less than 0.5% of Y dissociated from a DOTA-type 
ligand over 18 days in serum (pH 7.4, 37°C). In a similar manner, the 90Y-DOTA complex displayed no 
change during 72 h at pH 5.5, even in presence of a 500-fold excess of DTPA158. The complexes exhibit 
remarkable rigidity and are nonlabile, properties mostly not displayed by acyclic analogs such as EDTA and 
DTPA. The tetraaza macrocycle of DOTA acts as a frame to constrain its eight donor atoms (four tertiary 
nitrogen atoms and four carboxylic groups) into a nearly spherical arrangement. DOTA is usually attached 
to peptides or proteins through one of the carboxymethyl groups or a derivative thereof, thus leaving three 
free carboxylate groups for the complexation, in addition to the four nitrogen atoms158. Tumor-targeting 
studies have shown that DOTA-peptides have favorable properties in both animal models and humans, 
particularly regarding receptor binding, tumor uptake and tumor-to-non-target-tissue ratios, in both the 
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somatostatin and the melanocortin fields74. The development of various DOTA-peptides delivered 
molecules with better pharmacokinetic properties and thus a better therapeutic interest. 
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Figure 25: Structure of DOTA coupled to a peptide. 
 
Rigidified DOTA analogs with methylated arms have been synthesized as well. They are supposed to 
increase the stability of the complex, but have not been tested in vivo yet244. Other new bifunctional DOTA 
derivatives have been developed, bearing modifications on the macrocycle. 2-(p-nitrobenzyl)-DOTA, for 
example, was synthesized partly as precursor to other DOTA-derivatives. It was shown to bind a variety of 
metals better than other chelators, probably thanks to an additional free carboxylate, as in this case the 
chelate is bound to the peptide or protein through the p-nitrobenzyl extension or a derivative thereof, as it 
was shown by the same group for EDTA-derivatives. The additional carboxylate adds stability and strength 
to the complex, and it was shown to hold yttrium, for example, remarkably well under physiological 
conditions in human serum201,247. 
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Figure 26: Structures of 2-(p-nitrobenzyl)-DOTA, DOTAtrans and DOTASA. 
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Other derivatives of the same kind, such as DOTASA and DOTAtrans, have been synthesized and tested 
as well, but unfortunately, it appears that the in vitro and in vivo data of octreotide labeled with such 
chelates hardly revealed an advantage compared to standard DOTA. Adding methylene groups to increase 
the size of the macrocycle (one methylene group yielding TRITA or two TETA) and thus providing a more 
rapid complexation with the radiometal did not solve issues, as the stability constant for many metal ions91 
was reduced. 
 
An additional potential problem of DOTA or DOTA-like compounds is their relative slow complexation rate. 
It may interfere with the quite short half-life of some of the complexed radionuclides. In order to accelerate 
this reaction, heating at 80-100°C during 20-30min is required, depending on the metal, to incorporate the 
metal ion46. This may bring up stability issues with thermolabile proteins or peptides, as the reaction 
remains incomplete at lower temperatures. Additionally, as radiolabeled DTPA-peptides tended to 
accumulate in the liver and other organs, the first DOTA-peptides unfortunately tended to accumulate in the 
kidney almost as well as in the primary tumor. Some derivatives even accumulate much better in the kidney 
than in the tumor. Their therapeutic efficacy is thus strongly reduced, nephrotoxicity being the dose-limiting 
factor70,177. Additionally, the strong uptake of these derivatives by the kidney implies the same detection 
issue as the nonspecific uptake of the DTPA-peptides: indeed, any other tumor or distant metastasis 
located in the kidneys or the renal surroundings would be masked by the radioactive tracer taken up by the 
kidneys. This issue is not specific to somatostatin or melanocortin analogs, as it was observed with other 
peptides or antibody fragments as well32. 
 
Further developments yielded a whole variety of chelates. 1,4,7-triazacyclononane-1,4,7-triacetic acid 
(NOTA), for example, is a macrocycle with a smaller ring structure, bearing only three nitrogen atoms and 
three carboxylates. One derivative, NOTAGA, has one of its “arms” branched with a spacer bearing one 
more carboxylate group for peptide or protein binding. It was coupled to octreotide for experimentation, and 
yielded very stable complexes. It produced interesting results in cell binding assays as well as in in vivo 
assays with a high uptake in target tissues and a fast excretion, particularly at short times after injection. 
The authors suggest that the spacer separating the chelate from the pharmacophore is mainly responsible 
for the improved biological behavior94. 
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Figure 27: Structures of NOTA and NOTAGA. 
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This chelate could be an interesting alternative to DOTA and may have a positive effect on the biological 
properties of !-MSH analogs as well, although no apparent dramatic kidney uptake reduction was 
observed. 
 
For copper labeling, peptides, proteins or mAb have to be coupled to another type of chelate: 4-(1,4,8,11-
tetraazacyclotetradec-1-yl)-methyl benzoic acid tetrahydrochloride (CPTA) has already been extensively 
used, and appears to deliver an interesting kinetic stability290. It was also reported that mAb bearing CPTA 
and labeled with 67Cu displayed improved pharmacokinetical properties, thanks to the cellular retention of 
the 67Cu-CTPA complex leading to an increased accumulation of radioactivity in the target cells, compared 
to its radioiodinated equivalent220. 
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Figure 28: Structures of TETA and CPTA. 
 
64Cu-labeled octreotide analogs, with either CPTA or TETA as chelate, have been synthesized and 
compared. Both derivatives have shown higher affinity for the somatostatin receptor in mouse cell 
membranes, and displayed a specific uptake in target tissues as great or greater than their 111In-DTPA-
labeled counterpart. Their biological clearances, though, were different. The TETA-derivative exhibited a 
renal clearance similar to the 111In-DTPA reference peptide, while the CPTA-derivative, being more 
lipophilic, had a hepato-biliary clearance way. The TETA-derivative was shown to be pharmacokinetically 
superior to the CPTA-derivative13. In another group, an antineuroblastoma antibody was labeled with 67Cu 
using either CPTA or 1-(p-aminobenzyl)-1,4,7,10-tetraazacyclodecane-4,7,10-triacetate (DO3A), and 
investigated in biodistribution assays. It was shown that the use of DO3A improved the biodistribution of the 
mAb with an increase in tumor uptake and a reduction of kidney uptake at 48 h220. Nevertheless, CPTA 
definitively remains an interesting chelate for copper labeling. It exhibits a particularly high stability towards 
acid-promoted dissociation of copper in environments such as lysosomes or the liver. Another advantage of 
this chelate is the low temperature needed for the complexation of copper (room temperature), compared to 
other chelates such as TETA and DO3A (75°C), which can very destructive with thermolabile proteins or 
mAb221. CPTA is currently still successfully used in many investigations for the labeling of peptides or, 
mostly, mAb131,166. 
 
In conclusion, the DOTA chelate remains the method of choice for the labeling of !-MSH analogs, thanks 
to the positive effect it brings to the pharmacokinetic properties of the peptides it is coupled to. The stability 
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of the complex it forms with radionuclides and its ability to complex various 2+ and 3+-charged radiometals 
are certain advantages over other chelates. Additionally, most !-MSH analogs are relatively heat-resistant, 
and the heating needed for the labeling reaction certainly does not constitute a drawback to their use. 
These are the reasons why DOTA was chosen as chelate for the design of the !-MSH analogs developed 
in this work. 
 
 
2.4 Peptide design 
 
Naturally occurring peptides are great tools for receptor targeting. They are small enough to show adequate 
in vivo distribution profiles, and usually big enough to stand modifications such as attachment of carriers or 
chelates without these affecting their biological properties. Their limited stability in the circulation, though, 
represents their major drawback, as they can be rapidly degraded by proteases. The stability issue can be 
overcome with an adequate peptide design, the challenge remaining the synthesis of a protease-resistant 
peptide conserving its biological properties (binding affinity, pharmacokinetical profile, etc.). Some 
important aspects have to be kept in mind: 
 
- The affinity for the receptor should be high. 
- The molecular weight should be kept below 1,500 gmol-1. 
- The ratio hydrophilicity/hydrophobicity should be balanced. 
- The stability in the serum should be sufficient. 
- Plasma and kidney clearances should be adequate. 
- The selectivity should be kept high. 
- The labeling conditions should match the peptide stability. 
 
Peptides can be stabilized in different ways. The introduction of D-amino acids is certainly an efficient 
method, as proteases are not able to cleave the peptide anymore and the side chain of the amino acid 
remains the same. "-peptides may also be of interest, as their stability is dramatically increased in vivo. 
50% of a radiolabeled "-peptide were found intact in blood seven days after injection. This result is 
promising, but such a long presence in the body could also be problematic as it may lead to side-effects, 
particularly with radioactive tracers91. Other methods involve N-methylation, substitution of peptide bonds, 
N-terminal acetylation and C-terminal amidation, introduction of unnatural amino acids, cyclization, etc. N-
methylation of the backbone amine brings resistance to proteolysis234 at the expense of a somewhat more 
difficult coupling step in the synthesis of the peptide. N-terminal acetylation and C-terminal amidation have 
many advantages: enhanced cell permeability, stability toward aminopeptidases, peptide ends are blocked 
against synthetase activity and the amidation often enhances the activity of peptide hormones. The 
enhanced rigidity brought by cyclization limits its conformational possibilities, and allows to find key 
pharmacophore elements in three-dimensional space. It also avoids degradation and digestion by 
stabilizing the peptide structure26. All these methods are commonly used in syntheses of peptidic 
RADIOACTIVE !-MSH ANALOGS FOR MELANOMA TARGETING: STATE OF THE ART 
80
derivatives. Several modifications can be adopted simultaneously, with regard to the needs and constraints 
of peptide synthesis, bioavailability, pharmacological behavior, metabolism and excretion. 
 
A further advantage of peptides as drugs is the possibility to modify their side chains almost at will, in order 
to influence their pharmacological or pharmacokinetical properties. For example, introduction of positive or 
negative charges by modifying amino acid side chains or by replacing amino acids with others may have a 
dramatic influence on their binding affinity and on their pharmacokinetical profile. Functional groups, 
carbohydrates or any other chemical entity can be grafted to peptides at various positions, provided the 
free functional groups of the peptide allow it, and lead to the same kind of steering of their physicochemical 
properties and desired effects26. 
 
The list of modifications mentioned above is not comprehensive, and various other chemical alterations can 
be applied, but these will not be covered in this work. Indeed, the focus of this thesis will remain on 
modifications of !-MSH analogs, part of which will be reviewed in the following chapter. Some of the 
possibilities mentioned earlier were used in this work and by others, and have proven their usefulness by 
influencing various biological parameters to various extents. 
 
 
2.5 Improvement of the tumor-to-kidney ratio of !-MSH analogs: 
various strategies 
 
In order to obtain suitable derivatives for tumor diagnosis and treatment, the effort has concentrated on 
reducing the uptake of DOTA-radiopeptides by the kidney. Various methods have been developed to 
address this issue: 
 
• Co-injection of basic amino acids or basic amino acids cocktails. Thanks to this method, the kidney 
uptake of Fab! fragments could be reduced 5 to 6-fold in a dose-dependent manner30, and the 
kidney uptake of octreotide (labeled with either 111In or 90Y) could be reduced by more than 50% for 
DTPA-octreotide derivatives, and by 65% for a DOTA-octreotide derivative (90Y-DOTATOC)34. 
The kidney uptake of !-MSH analogs (e.g. 67Ga-DOTA-NAPamide) could also be dramatically 
reduced by co-injection of high-dosed L-Lysine58,114. On a molecular basis, the effect seems to rely 
essentially on the presence of a positively charged amino group33. L- and D-lysine were equally 
effective, whether given i.p. or orally. D-Glucosamine also showed efficiency, but its N-acetylated 
derivative, lacking the positive charge, did not. Basic polypeptides (e.g. poly-L-lysine) were also 
effective, their potency increasing together with their molecular weight (and thus the number of 
positive charges). 
 
• Use of different metal isotopes. In the case of !-MSH analogs, the best peptide (DOTA-NAPamide) 
labeled with 67Ga even showed a lower kidney uptake and a simultaneously higher tumor uptake 
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than 111In-DOTA-NAPamide114. The extent of this reduction does not improve the tumor-to-kidney 
ratio sufficiently, and further ameliorations with the use of other radiometals are improbable. 
 
Although these methods significantly improved the tumor-to-kidney ratios of the peptides, the results did 
not yet match the requirements for internal radiotherapy. Thus, new approaches had to be envisaged that 
would lower the kidney uptake of the !-MSH derivatives. 
Indeed, the key to the kidney uptake issue may reside more in the basic structure of the derivatives than in 
the type of isotope used (although ameliorations were observed with some) or the co-injection strategy. 
Therefore, existing analogs were modified in order to influence their bioavailability, their pharmacokinetical 
properties, or their possible direct interaction with surface receptors located in the kidney. Efforts are 
focusing on the elucidation of the mechanism leading to kidney retention of the radiopeptides. 
 
The two main goals to achieve to improve the tumor-to-kidney ratio of the !-MSH analogs are either an 
enhancement of the tumor uptake or a diminution of the kidney uptake. 
 
 
2.5.1 The superpotent [Nle4, D-Phe7]-!-MSH (NDP-MSH) 
 
 
By searching a way to prolong the biological activity of !-MSH, Sawyer et al. found (in 1980) that a 
synthetic analog carrying a norleucine at position 4 (replacing native Met) and a D-phenylalanine at position 
7 (replacing native L-Phe) exhibited a better resistance to enzymatic degradation in the serum than native 
!-MSH. Indeed, following a statement by Lande and Lerner (as early as 1967) saying that “it is important 
that !-MSH be made with D-amino acids in one or two places. If the site of racemization can be pinpointed, 
it may be possible to produce well-characterized peptides more active than the natural hormone”180, 
Sawyer et al. introduced the two unnatural amino acids mentioned above and were successful at 
prolonging the biological activity of !-MSH. Additionally, the peptide exhibited a dramatically increased 
biological activity (26-fold that of !-MSH) in adenylate cyclase assays. The racemization process happened 
under heat-alkali treatment267. 
These amino acid substitutions constitute the most striking effect achieved by modifying !-MSH. 
Unfortunately, in vivo dehalogenation reactions were observed with peptides labeled with iodine isotopes. 
These peptides are therefore less suitable for in vivo imaging and therapy. In tissues, iodine isotopes are 
most likely released from the Tyr they are attached to and the free radioiodide is cleared via the kidneys. 
Indeed, despite considerable biliary excretion, nearly all excreted radioactivity was found in the urine, and 
only a very small amount in the feces23. 
Radioiodinated NDP-MSH is still routinely used in in vitro assays as a competitive antagonist of other !-
MSH analogs. 
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
RADIOACTIVE !-MSH ANALOGS FOR MELANOMA TARGETING: STATE OF THE ART 
82
2.5.2 Shorter sequence: [DOTA-"-Ala3,Nle4,Asp5,D-Phe7,Lys10]-!-MSH3-10 
(DOTA-MSHoct) 
 
 
In order to favor blood clearance of the radiopeptide, Froidevaux et al.110 synthesized a shorter !-MSH 
analog carrying a DOTA chelator complex at its N-terminal end. It was then labeled with 111In and 
compared to the previously mentioned NDP-MSH, to which DOTA was also attached. The shorter 
sequence displayed favorable properties regarding tumor-to-non-target-tissue ratios and blood clearance, 
indicating possible future applications for tumor diagnosis and therapy. Like for most radiopeptides, the 
quite high kidney uptake remained its main issue, but the strategy of using a shorter peptide appeared to 
be promising. Additionally, autoradiographies of various organs (including distant metastases) were 
realized and revealed several interesting points110: 
 
- Melanotic melanoma metastases could be detected precisely on organs (liver and lungs). 
- Amelanotic melanoma metastases could be detected as well (lung). 
- Radioactivity in the kidneys appeared to be localized only in the cortical region, suggesting 
that 111In-DOTA-MSHoct is retained in the proximal tubules, probably after tubular reuptake. 
 
A new approach was being suggested with these findings, and further developments favored the use of 
shorter peptides. 
 
 
2.5.3 Position of DOTA: [Nle4, Asp5, D-Phe7, Lys11(DOTA)]-!-MSH4-11 (DOTA-
NAPamide) 
 
 
The basic structure of DOTA-NAPamide is quite similar to DOTA-MSHoct, but it still displays some critical 
differences: 
 
- The position of DOTA in the peptide is different: in DOTA-NAPamide, the DOTA moiety is 
coupled to the side chain of Lys11 (&-amino group), on the C-terminal end of the peptide. 
Thereby, it neutralizes the positive charge of the Lys11 side-chain. In DOTA-MSHoct it was 
coupled to the N-terminal end of the peptide. 
DOTA-"-Ala-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2 
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 
                                                      | 
                                                      DOTA 
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- Gly10 was restored in the sequence of the peptide in DOTA-NAPamide, as it was shown to 
play a role in MC1R affinity263. 
- The net charge of the peptide was changed: +1 for DOTA-NAPamide vs. +2 for DOTA-MSHoct. 
 
Upon synthesizing this peptide, Froidevaux et al. expected it to have a more favorable biodistribution profile 
than DOTA-MSHoct. Indeed, with Gly reinforcing the core structure of the peptide sequence and thus 
increasing the affinity for the receptor, and with a reduction of the net charge of the peptide (known to be 
associated with a reduction in both glomerular filtration and tubular reabsorption; as mentioned previously, 
Lawrence et al.181 showed that luminal cells carry negative charges on their surfaces), a better tumor-to-
kidney ratio could reasonably be expected. Additionally, Akisawa et al. had shown that renal uptake of 
111In-[DTPA-D-Phe1]-octreotide was enhanced upon replacement of D-Phe1 by Lys, but reduced when D-
Phe1 was substituted with Asp. This statement demonstrates the influence of charge on kidney retention of 
chelator-peptide conjugates7,114. 
 
The potency of DOTA-NAPamide in competitive binding assays was much higher compared to DOTA-
MSHoct. Apparently, allocation of the &-amino group of Lys
11 to DOTA does not affect the binding affinity. 
This result is in agreement with the biodistribution data: 111In-DOTA-NAPamide displayed a higher tumor 
uptake and a lower kidney accumulation than DOTA-MSHoct, and the observed kidney uptake was the 
lowest observed until then. The tumor-to-kidney ratio could even be increased by incorporating, as 
mentioned in 1.7.5, 67Ga instead of 111In, probably due to a different coordination geometry of the metal 
isotope in the chelator complex113. As mentioned earlier as well, further reduction of the renal accumulation 
could be obtained by co-administration of L-lysine, however to a larger extent than with other radiopeptides 
(64% vs. 40-52%)114. Further experiments confirmed the suitability of gallium-labeled DOTA-NAPamide for 
imaging of metastases, e.g. with 67Ga in autoradiographies of both distant melanotic and amelanotic 
melanoma lesions, and with 68Ga for PET-imaging114. 
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2.5.4 Structure-activity relationships study of NAPamide derivatives 
 
 
 
After the good results shown by DOTA-NAPamide, further attempts were made to try to increase the tumor-
to-kidney ratio. Moving the DOTA moiety back to the N-terminus of the peptide dramatically increased the 
kidney uptake (3x). But by acetylating the free &-amino group of Lys11 (and thus leaving its side chain 
neutral instead of carrying a positive charge), the kidney uptake was reduced to “normal”, supporting the 
statement that kidney uptake was relying more on charge than on the position of DOTA. 
Following these findings, new experiments were made with DOTA-NAPamide derivatives carrying negative 
charges on Lys11. It was envisaged that negative charges, found on both the proximal tubular cells and on 
the peptide, could have a repulsive effect on each other, and thus favor renal excretion of the peptide 
instead of reabsorption. To this end, DOTA-NAPamide was succinylated on the side chain of Lys11, and 
thus the whole peptide charge was neutral. On a second derivative, to accentuate the potential effect of 
negative charges, Lys11 was succinylated and the C-terminal amide was removed to make way for a 
carboxylate group, and thus the peptide carried a net charge of -1. Unfortunately, these modifications did 
not alter kidney accumulation. The peptide carrying the negative net charge showed only a very slight 
reduction in kidney uptake115. About this reduction, it was hypothesized that charge location within the 
peptide would have an influence rather than its net charge. 
 
It was also observed that the structure of the peptide does apparently not have a large influence on the 
release of radioactivity from tumors and the kidneys. Generally, it was observed that the release from the 
melanomas was much faster than from the kidneys. A proposed hypothesis mentions the documented 
upregulation of lysosomal enzymes in melanomas170, leading to a higher rate of radiopeptide hydrolysis 
and thus to a faster production of small radioactive metabolites with higher release potential115. 
DOTA-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 
                                                            | 
                                                             NH2 
 
 
 
DOTA-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 
                                                            | 
                                                           Ac 
 
 
 
 
 
 
DOTA-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-COOH 
                                                        | 
                                                        Succ 
 
 
 
DOTA-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 
                                                           | 
                                                           Succ 
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2.5.5 Cyclic peptides: CCMSH and derivatives 
 
 
 
Figure 29: The cyclic peptide ReCCMSH(Arg
11
), cyclized via rhenium-complexation
321
. 
 
 
As it had been reported that !-MSH peptides cyclized either via a disulfide bond between two cysteines 
([Cys(4, 10), D-Phe7]!-MSH)69 or via a lactam bond between the aspartate and the lysine 
([Nle4,Asp5,D-Phe7,Lys10]!-MSH)9 displayed increased receptor binding affinities and resistance to 
proteolysis, a research team around T.P. Quinn and S.S. Jurisson studied this class of derivatives for use 
as radiopeptides. They reported a whole series of cyclic derivatives that had not been cyclized via the two 
methods mentioned above, but via metal coordination, using three Cys3,4,10 sulfhydryls and one Cys4 amide 
nitrogen positioned in the sequence of the peptide124 for metal coordination. The peptides were mostly 
cyclized by complexing 99mTc or 188Re and displayed good tumor-targeting properties, but the kidney uptake 
issue was still present. Further derivatives were then synthesized with non-radioactive cores using ReO 
and TcO and coupled to a chelate (mostly DOTA) complexing various metal isotopes (86Y, 64Cu, 111In). ReO 
and TcO are commonly used as cores because of their ability to form stable complexes with amide 
nitrogens and thiolate sulfurs, both found in peptides. 
Most of the peptides did not show any amelioration of the tumor-to-kidney ratio compared to DOTA-
NAPamide (our reference)59,203,209, but some of them showed very good in vivo biodistribution, keeping up 
with DOTA-NAPamide. Indeed, particularly 111In-DOTA-Re(Arg11)CCMSH achieved a tumor-to-kidney ratio 
at 4h of 2.36 (111In-DOTA-NAPamide: 1.63115, 67Ga-DOTA-NAPamide: 2.37114), which is quite interesting 
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for an indium-labeled peptide60. It would be interesting to compare their tumor-to-kidney ratio of the AUC (4-
48h), but unfortunately most of the published results consider data in the time interval from 4 h to 24 h. 
 
 
2.5.6 Summary of the major modifications of !-MSH analogs 
 
 
As mentioned above, a number of derivatives of !-MSH have been synthesized, some of them delivering 
some major breakthroughs. Not all existing modifications that had been examined could be described here 
and the following table only lists some of the main strategies developed to improve the pharmacokinetic 
properties of !-MSH analogs for melanoma targeting and the observed effects. Nevertheless, it attempts to 
deliver an overview of the main existing strategies. 
 
Table 7: Summary of the major modifications of !-MSH analogs, and observed effects on pharmacokinetics thereof. 
Peptide 
Config-
uration 
Radio-
nuclide 
4h tumor-
to-kidney 
ratio 
Reference 
DOTA-CCMSH L 111In 0.12 Chen et al. (2001)59 
DOTA-ReCCMSH C 111In 1.02 Chen et al. (2001)59 
DOTA-NDP-MSH L 111In 0.78 Froidevaux et al. (2002)110 
DOTA-MSHoct L 
111In 0.32 Froidevaux et al. (2002)110 
DOTA-Re(Arg11)CCMSH C 111In 2.36 Cheng et al. (2002)60 
188Re-CCMSH C 188Re 0.17 Miao et al. (2003) 
188Re-(Arg11)CCMSH C 188Re 0.32 Miao et al. (2003) 
DOTA-NAPamide L 67Ga 2.37 Froidevaux et al. (2004)114 
DOTA-NAPamide L 111In 1.63 Froidevaux et al. (2005)115 
[DOTA-Nle4,Asp5,D-Phe7,Ac-Lys11-NH2]-!-MSH4-11 L 
111In 1.06 Froidevaux et al. (2005)115 
[DOTA-Nle4,Asp5,D-Phe7,Suc-Lys11-NH2]-!-MSH4-11 L 
111In 0.58 Froidevaux et al. (2005)115 
DOTA-Re(Arg11)CCMSH C 90Y 0.57 Miao et al. (2006)207 
DOTA-Re(Glu2,Arg11)CCMSH C 90Y 1.30 Miao et al. (2006)207 
DOTA-Re(Glu2,Arg11)CCMSH C 177Lu 1.57 Miao et al. (2006)207 
DOTA-Cyc-MSH (lactam cyclized) C 111In 0.35 Miao et al. (2008)209 
DOTA-GlyGlu-Cyc-MSH (lactam cyclized) C 111In 0.61 Miao et al. (2008)209 
(L stands for linear, C for cyclic) 
 
Table 7 indicates that most modifications adopted did not improve the tumor-to-kidney ratio of !-MSH 
analogs. For example, different cyclized peptides appear to have similar or inferior properties than the 
latest linear peptides. One cyclic peptide (DOTA-Re(Arg11)CCMSH) labeled with 111In seems to have 
excellent properties in vivo, but the same peptide labeled with 90Y exhibits much inferior properties.  
On the other side, not all modifications of linear peptides were successful at improving the tumor-to-kidney 
ratio, but investigations led to a very promising peptide, DOTA-NAPamide, that has since its development 
also been used by other groups62,63. Indeed, investigations showed that the properties of DOTA-NAPamide 
observed when labeled with 111In were even improved when labeled with 67Ga. Isotopes of Ga have many 
advantages. 68Ga can be produced from an on-site generator, and its half-life is quite short (68 min). 67Ga 
is suited for tumor diagnosis and potentially for internal radiotherapy (Auger electrons). Therefore, Ga-
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labeled analogs would provide polyvalent tools for the clinical management of melanoma, including PET-
diagnosis or -staging114. 
 
Linear peptides certainly remain a very promising tool, as they are easier to synthesize than cyclic peptides 
and their potential has apparently not been fully exploited yet. Some critical parameters improving their 
pharmacokinetical profile, though, still have to be discovered or improved. It appears that the choice of 111In 
as labeling radionuclide is adequate, as it constitutes an excellent “precursor” to studies with gallium 
isotopes. DOTA as chelate represents the method of choice as well, for its ability to bind various 
radiometals and for the stability of its complexes, as already mentioned in chapter 2.3. 
 
To improve the pharmacokinetical properties of !-MSH analogs, several of these modifications and 
ameliorations were considered and combined to new features in this work. As mentioned in the “aims of the 
thesis” (see chapter 1.8), new types of derivatives were synthesized. First, peptide dimers, then 
glycopeptides, and finally negatively-charged peptides. The results obtained will be described and analyzed 
in the next three chapters (chapters 3,4 and 5), that represent or contain manuscripts of three papers which 
already appeared (chapter 3) or will be submitted for publication (chapters 4 and 5). 
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ABSTRACT 
 
Dimeric analogs of !-melanocyte stimulating hormone (!-MSH) labeled with radiometals are potential 
candidates for diagnosis and therapy of melanoma by receptor-mediated tumor targeting. Both melanotic 
and amelanotic melanoma (over-)express the melanocortin-1 receptor (MC1-R), the target for !-MSH. In 
the past, dimerized MSH analogs have been shown to display increased receptor affinity as compared to 
monomeric MSH, offering the possibility of improving the ratio between specific uptake of radiolabeled !-
MSH by melanoma and non-specific uptake by the kidneys.  We have designed three linear dimeric 
analogs containing a slightly modified MSH hexapeptide core sequence (Nle-Asp-His- D-Phe-Arg-Trp) in 
parallel or antiparallel orientation, a short spacer and the DOTA chelator for incorporation of the radiometal. 
In vitro, all three peptides were more potent ligands of the mouse B16-F1 melanoma cell melanocortin-1 
receptor (MC1-R) than DOTA-NAPamide which served as standard. The binding activity of DOTA-
diHexa(NC-NC)-amide was 1.75-fold higher, that of diHexa(NC-NC)-Gly-Lys(DOTA)-amide 3.37-fold 
higher, and that of DOTA-diHexa(CN-NC)-amide 2.34-fold higher. Using human HBL melanoma cells, the 
binding activity of diHexa(NC-NC)-Gly-Lys(DOTA)-amide was 6-fold higher than that of DOTA-NAPamide. 
Uptake by cultured B16-F1 cells was rapid and almost quantitative. In vivo, however, the data were less 
promising: tumor-to-kidney ratios 4 h post-injection were 0.11 for [111In]DOTA-diHexa(NC-NC)-amide, 0.26 
for diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide, and 0.36 for [111In]DOTA-diHexa(CN-NC)-amide, as 
compared to 1.67 for [111In]DOTA-NAPamide. It appears that despite the higher affinity to the MC1-R of the 
peptide dimers and their excellent internalization in vitro, the uptake by melanoma tumors in vivo was 
lower, possibly because of reduced tissue penetration. More striking however was the marked increase of 
kidney uptake of the dimers, explaining the unfavorable ratios. In conclusion, although radiolabeled !-MSH 
dimer peptides display excellent receptor affinity and internalization, they are no alternative to the 
monomeric DOTA-NAPamide for in vivo application. 
 
DIMERIC PEPTIDES 
91
INTRODUCTION 
 
A variety of human tumors express or overexpress receptors for one or more of the many known regulatory 
neuropeptides or peptide hormones, thereby offering attractive targeting systems for tumor diagnosis and 
imaging248. Radiolabeled antibodies and peptides are the tools of choice for this kind of cancer 
management91,137. Because of their much lower molecular weight, and hence their very low immunogenicity 
and excellent tumor penetration, radiopeptides have attracted steadily increasing interest in receptor-
mediated tumor targeting during the past fifteen years. The list of the different regulatory peptides for tumor 
targeting in preclinical development has now exceeded the number of thirty48,91,198, but routine application 
as diagnostics in the clinic is confined to a much smaller number250, and internal radiotherapy is currently 
carried out with only a few selected radiopeptides251. The best example illustrating the rational of the 
strategy of receptor-mediated tumor targeting are radiolabeled analogs of somatostatin which are routinely 
used to image tumors expressing somatostatin receptors, thus demonstrating promise for internal 
radiotherapy in patients112. Yet, retention of considerable amounts of the injected dose by the kidneys limits 
the therapeutic efficacy of radiopeptides, as renal toxicity is the dose-limiting factor70,177,227. For the same 
reason diagnosis of tumors localized in the kidney region is strongly compromised. Renal accumulation of 
radiopeptides is however not specific to somatostatin analogs containing metal chelators such as 
macrocyclic DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or linear DTPA 
(diethylenetriaminepentaacetic acid)109; it is also observed with other peptides or antibody fragments31. 
Methods have therefore been developed to reduce uptake by the kidneys, such as infusion of basic amino 
acid cocktails31,34. Although much experience with the dosing of 90Y- or 177Lu-labeled somatostatin analogs 
has been acquired in the meantime38,92,96,176, the success of the therapeutic strategy with any other 
radiopeptide will rely on the possibility to lower their renal uptake39. Efforts are therefore focusing on the 
elucidation of the mechanism of retention of radiopeptides in the kidneys: It is now relatively well 
established that radiopeptides are reabsorbed by proximal tubules via luminal endocytosis after glomerular 
filtration. The peptides are then delivered to lysosomes where they are hydrolyzed to a final radioactive 
metabolite that cannot leave the lysosomes, leading to long-term sequestration of the radioisotope in the 
proximal tubular cells33,39. Radiopeptides exhibiting lower renal uptake per se would clearly represent a 
major step forward. However, as this is difficult to achieve, an alternative strategy is the development of 
radiopeptides with markedly enhanced tumor uptake so that the dose of injected radiopeptide can be 
reduced, leading to lower kidney uptake.  
 
The tridecapeptide hormone !-melanocyte stimulating hormone (!-MSH, MSH) has been studied 
extensively in the context of its melanogenic activity in melanocytes and melanoma cells (reviewed in 87-
89,98). MSH and its target, the type-1 melanocortin receptor (MC1-R), have turned out to be important 
regulators of pigment formation in mammalian skin87, including man2, and it was even proposed that MSH 
may be a useful pharmacological regulator of human skin tanning in the absence of or synergistically with 
sun light82,132. Whereas human melanocytes generally express low numbers of MC1-R76 and none of the 
other four MC receptor subtypes (i.e. MC2-R to MC5-R), melanoma cells frequently overexpress MC1-R 
which is therefore regarded as useful malignant melanoma marker21,122,159,264,284,287. This was the basis for 
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our original studies on the in vivo targeting of melanoma with 111In-labeled !-MSH containing DTPA as 
chelator for insertion of a radiometal19,20. In the past few years, we have developed short linear !-MSH 
analogs containing the macrocyclic DOTA chelator, e.g. DOTA-["Ala3, Nle4, Asp5, D-Phe7, Lys10]-!-MSH3-
10, (DOTA-MSHoct)
110 or [Nle4, Asp5, D-Phe7, Lys11(DOTA)]-!-MSH4-11 (DOTA-NAPamide)
114, in which DOTA 
was conjugated to the N-terminal or, respectively, the C-terminal end of the peptide. After labeling with 111In 
or 67Ga/68Ga, high and specific melanoma uptake and relatively moderate or low kidney uptake was 
observed in mice. The amount of radioactivity accumulation in the kidneys observed with [67Ga]DOTA-
NAPamide was the lowest reported to date compared with other synthetic DOTA-!-MSH analogs59-
61,90,202,204,207. For example, [111In]DOTA-MSHoct, which shares 6/8 amino acids with DOTA-NAPamide, 
exhibited a kidney uptake of 13.5% ID/g 4 h post-injection110 whereas renal uptake of [111In]DOTA-
NAPamide was only 3.98% ID/g114, making this analog a promising radiopeptide for diagnosis and bringing 
internal radiotherapy of metastatic melanoma further within reach. Therefore, DOTA-NAPamide has in the 
meantime been employed as melanoma-targeting agent also by other researchers62,63. Nevertheless, 
reducing the kidney uptake further is of great importance, and as introduction of negative charges into the 
DOTA-NAPamide molecule did not alter kidney uptake115, we thought to investigate possibilities of 
increasing the MC1-R receptor-affinity of the radiolabeled !-MSH ligand, thereby achieving the goal of 
higher tumor-to-kidney ratios by lowering the doses of the radiopharmaceutical for in vivo application, while 
maintaining excellent tumor uptake.  
 
Various strategies have been employed to increase the potency of the !-MSH molecule (reviewed in 87). 
The most striking effect was the introduction of a D-Phe residue in the place of Phe7 of !-MSH, either in 
combination with simultaneous replacement of Met4 by Nle(267) or maintaining the original Met at position 
4(87). This led to an elevation of receptor binding and activation by an average factor of 10 (depending on 
the biological system studied) and also to an increased duration of the response (owing to high resistance 
against proteolysis). Reduction of the !-MSH sequence with simultaneous modification of certain 
residues10,87,215 or cyclization of the peptide sequences123,124,133,267 also positively affected the stability, 
potency and selectivity to MC receptor subtypes, but all these structural changes were much less striking 
than the insertion of the D-Phe residue at position 7. Another striking effect on the potency of !-MSH 
peptides has already been reported in 1977, when several MSH molecules were covalently attached to 
albumin or thyroglobulin84,85, or to the tobacco mosaic virus (TMV)171, leading to a marked increase of 
potency of the complexes as compared to the free ligand. This synergistic effect was particularly evident 
with the TMV complex which contained approximately 300 !-MSH molecules per virus particle and 
displayed a 1,500-fold higher potency than !-MSH171. During these studies we noticed86,87 that also 
dimerized !-MSH, which was prepared by introducing a maleimido group in the N-terminus of the molecule, 
followed by crosslinking two molecules with dithioethane, displayed a 2.2- to 4.5-fold higher activity than !-
MSH in the Cloudman S91 tyrosinase assay and the Rana pipiens pigment migration assay, respectively. 
Vaudry and colleagues100 investigated dimerized ACTH(1-24), ACTH(7-24) and ACTH(11-24) on frog 
adrenal gland slices (expressing MC2-R) and found that dimeric ACTH(1-24) had reduced steroidogenic 
activity as compared to monomeric ACTH(1-24) but dimerized ACTH(7-24) and (11-24) displayed marked 
antagonist activity which was more prominent than that of the monomer compounds. Finally, Hruby and 
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colleagues314 later prepared a series of short MSH tetra- and hexapeptide dimers, linked with different 
types of spacer; the general findings were that dimerization led to enhanced potency for several of these 
peptides314. A dimerized MSH analog for tumor imaging had already been reported by Bagutti et al.21 who 
attached two MSH moieties to one DTPA chelator molecule; this compound displayed high in vitro activity. 
The current study followed a different approach: three homodimer hexapeptide MSH fragments with 
different orientation and containing only one chelator molecule at different positions were designed (Figure 
30) synthesized and studied in vitro and in vivo. We demonstrate that high in vitro potency at the melanoma 
MC1-R will not necessarily lead to elevated melanoma-to-kidney ratios in vivo. 
 
 
Figure 30: General orientation of the hexapeptide Nle-Asp-His-D-Phe-Arg-Trp sequence in the dimer peptides: DOTA-
diHexa(NC-NC)-amide and diHexa(NC-NC)-Gly-Lys(DOTA)-amide contained the two hexapeptides in linear parallel 
and consecutive N-to-C–spacer–N-to-C orientation; the spacer was "-Ala-Gly-"-Ala. In DOTA-diHexa(NC-NC)-amide, 
the DOTA moiety was attached at the N-terminus. In diHexa(NC-NC)-Gly-Lys(DOTA)-amide, the sequence was 
extended at the C-terminus by a –Gly-Lys-amide containing the DOTA in the e-amino position of Lys. The DOTA-
diHexa(CN-NC)-amide contained the two hexapeptides in antiparallel C-to-N–linker–N-to-C orientation. The linker 
consisted of a Cys-"-Ala attached to the N-terminus of one hexapeptide and, respectively, a "-Ala (containing a 
iodoacetyl group at its amino group) attached to the N-terminus of the other hexapeptide. The hexapeptide dimer was 
obtained by reacting the SH group of Cys with iodoacetyl of "-Ala, leaving the amino group of Cys free for attachment 
of DOTA. 
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MATERIALS AND METHODS 
 
Reagents 
 
!-MSH was a gift from Novartis (Basel, Switzerland). [Nle4, D-Phe7]-!-MSH (NDP-MSH) was purchased 
from Bachem (Bubendorf, Switzerland). 9-Fluorenylmethoxycarbonyl-(Fmoc-)amino acids were from 
Novabiochem (Läufelfingen, Switzerland), Fmoc-PAL-PEG-PS polystyrene resin from Applied Biosystems 
(Rotkreuz, Switzerland), and 1,4,7,10-tetraazacyclododecane-1,4,7-tris-tert-butyl acetate-10-acetic acid 
(DOTA-tris(t-butyl ester)) from Macrocyclics (Dallas TX, USA). N-Succinimidyl iodoacetate and Iodogen 
tubes were obtained from Pierce Biotechnology Inc. (Rockford IL, USA), Na125I (3.7 GBq/mL) from 
Amersham Bioscience (Otelfingen, Switzerland), 111InCl3 (370 MBq/mL) from Mallinckrodt (Petten, The 
Netherlands). 1,10-Phenanthroline was bought from Merck (Darmstadt, Germany) and all other organic 
reagents were obtained from Fluka or Sigma (Buchs, Switzerland) and were of highest purity available. Cell 
culture media were from Biochrom AG (Berlin, Germany) and Sigma (Buchs, Switzerland). Penicillin, 
streptomycin, vitamins and nonessential amino acids were all from Gibco/Invitrogen (Carlsbad CA, USA).  
 
 
Instrumentation 
 
Peptide synthesis was carried out on a Pioneer peptide synthesizer from PerSeptive Biosystems Inc. 
(Framingham MA, USA). Analytical reversed-phase-(RP)-HPLC was performed on a PU-980 system from 
Jasco Inc. (Easton MD, USA) with either Vydac 218TP54 C18 analytical columns (5 µm, 4.6'250 mm) or 
Waters Symmetry C18 analytical columns (5 µm, 3.9'150 mm). Preparative RP-HPLC of peptides used the 
same system but either with Vydac 218TP510 C18 semi-preparative columns (5 µm, 10'250 mm) or 
Waters SymmetryPrep C18 preparative columns (7 µm, 19'150 mm). Peptides were chromatographed 
with a gradient between solvent A (0.1% TFA in H2O) and solvent B (0.1% TFA in 70:30 acetonitrile/H2O). 
The 32-min gradient cycle consisted of the following parts: 95-10% A (0-27 min), 10-95% A (27-30 min), 
95% A (30-32 min); the flow rate was 1 mL/min for the analytical columns, 3 mL/min for the semi-
preparative column and 5 mL/min for the preparative column. UV absorption was recorded at 280 nm using 
a Jasco UV-1570 detector. Mass spectra were recorded on a Finnigan LCQ Deca electrospray ion trap MS 
system. 
 
Purity of radioligands was assessed by RP-HPLC using a dedicated Jasco PU-980 chromatography 
system connected to a Radiomatic 500TR LB506C1 #-detector (Packard, Meriden CT, USA) and equipped 
with a Spherisorb ODS2/5-µm column. Solvent A was 0.1% TFA in water; solvent B was 0.1% TFA in 
acetonitrile; the gradient cycle consisted of 96% A (0-2 min), 96-45% A (2-22 min), 45-25% A (22-30 min), 
25% A (30-32 min), 25-96% A (32-34 min); the flow rate was 1.0 mL/min. 
 
Cell-bound radioactivity from binding assays was collected on filters using a cell harvester (Packard) and 
measured on a TopCount microplate scintillation counter (Packard). Radioactivity in internalization and 
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biodistribution assays was measured on a Cobra II Auto-Gamma #-counter (Packard). Melanin content in 
cell culture media was quantified at 310 nm with a Spectra Max 190 microplate reader (Molecular Devices, 
Menlo Park CA, USA). 
 
 
Peptide synthesis 
 
General 
The peptides were synthesized in our laboratory on an automated Pioneer instrument using standard 
continuous-flow technology and Fmoc strategy18. As solid-phase support, flow-compatible Fmoc-PAL-PEG-
PS polystyrene resin containing the acid-labile amide linker PAL (5-[(4-Fmoc-aminomethyl-3, 5-
dimethoxyphenoxy]-pentanoic acid-polyethyleneglycol/polystyrene; substitution 0.21 mmol/g) was employed. 
Each synthesis cycle consisted of an Fmoc deprotection step (20% piperidine in DMF; 5 min), a coupling 
step (4 eq of Fmoc-amino acid; DIPEA and TBTU/HOBt in DMF; 60 min), and two washing steps after 
deprotection and coupling, respectively, using DMF (3 min). The following protecting groups were used for o-
protection: Trt for Cys, Boc for Lys and Trp, tBu for Asp, Pbf for Arg, and Trt for His. Manual Fmoc 
deprotection was also carried out with 20% piperidine in DMF (20 min), followed by a short wash with 20% 
piperidine/DMF and 5 washes of DMF; the deprotection was controlled by Kaiser test. Cleavage of the 
peptides from the resin was performed by addition of a solution containing 90% trifluoroacetic acid (TFA), 5% 
thioanisole, 4.5% H2O and 0.5% 1,2-ethanedithiol. After 2 h the solution was filtrated and the peptide 
precipitated. 
 
Conjugation of DOTA-tris(t-butyl ester) to the peptide derivatives was performed by addition of a solution 
containing the deprotected peptide (1 eq) and DIPEA (N,N!-diisopropylethylamine; 1.5 eq) in DMF (0.5 ml) 
to a solution containing DOTA-tris(t-butyl ester) (1 eq) which had been preincubated for 10 min with HATU 
(0-[7-azabenzotriazole-1-yl]-1,1,3,3-tetramethyluronium hexafluorophosphate; 1.2 eq) in DMF (0.5 ml). 
After 1 h of incubation at room temperature, another portion of preactivated DOTA-tris(t-butyl ester) was 
added in two portions. After a total reaction time of 2 h and subsequent precipitation of the peptides in ice-
cold t-butylmethyl ether, deprotection of DOTA was performed by the addition of a solution of 90% TFA, 5% 
thioanisole, 4.5% H2O and 0.5% 1,2-ethanedithiol (4 ml/5 mg of peptide). The mixture was stirred for 4 h, 
deprotected DOTA-peptide precipitated with ice-cold t-butylmethyl ether, resuspended in 10% acetic acid 
and purified by RP-HPLC. The major peaks were collected and analyzed by electrospray ionization ion trap 
mass spectrometry. All reactions and manipulations with DOTA were done in acid-treated (1 M HCl, >1 h) 
glassware.  
 
 
DOTA-NAPamide 
NAPamide was synthesized according to the general methods described above. The peptide was N-
terminally acetylated before cleavage from the resin: p-nitrophenyl acetate (2 eq) pre-activated with HOBt 
(1 eq) in DMF for 10 min was added to resin-bound NAPamide (1 eq) and incubated for 24 h, keeping the 
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volume of DMF as low as possible. The resin was filtrated and washed 5' with DMF and 4' with 
isopropanol. Cleavage from the resin and purification was done according to standard methods. The DOTA 
moiety was coupled to the &-amino group of C-terminal Lys and the peptide conjugate deprotected and 
purified as described above. RP-HPLC on a Waters Symmetry analytical column: tR = 9.53 min. Calculated 
monoisotopic mass: 1485.64 gmol-1; found: 1485.65 gmol-1. 
 
 
DOTA-diHexa(NC-NC)-amide 
DiHexa(NC-NC)-amide (Figure 31) was synthesized according to the general methods and DOTA was 
coupled to the N-terminus of the peptide when still attached to the resin. The conjugate was cleaved, 
precipitated, purified by HPLC and lyophilized. Calculated monoisotopic mass: 2312.55 gmol-1; found: 
2313.2 gmol-1. 
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Figure 31: Chemical structure of DOTA-diHexa(NC-NC)-amide. 
 
 
DiHexa(NC-NC)-Gly-Lys(DOTA)-amide 
DiHexa(NC-NC)-Gly-Lys-amide (Figure 32) was synthesized according to the general methods. A small 
amount of resin-bound tetradecapeptide was cleaved using the standard cleavage mixture, precipitated, 
purified by RP-HPLC and analyzed by mass spectrometry. RP-HPLC on a Waters Symmetry analytical 
column: tR = 10.85 min. Calculated monoisotopic mass: 2110.08 gmol-1; found: 2110.21 gmol-1. 
 
N-terminal acetylation of resin-bound diHexa-(NC-NC)-Gly-Lys was carried out as described above for 
NAPamide. After cleavage from the resin and precipitation, the purification by RP-HPLC on a Waters 
Symmetry analytical column yielded a product peak at tR = 12.8 min. Calculated monoisotopic mass: 
2153.41 gmol-1; found: 2153.2 gmol-1. 
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Figure 32: Chemical structure of diHexa(NC-NC)-Gly-Lys(DOTA)-amide. 
 
 
DOTA-tris(t-butyl ester) was coupled to the &-amino group of C-terminal Lys using standard procedures. 
After removal of the DMF, the product was dried in high vacuum for several hours. DOTA was deprotected 
in standard 90% TFA-mixture for 4 h, the peptide conjugate precipitated with t-butylmethyl ether, dried, 
purified by RP-HPLC, and lyophilized. RP-HPLC on a Waters Symmetry analytical column: tR = 13.12 min. 
Calculated monoisotopic mass: 2539.81 gmol-1; found: 2539.80 gmol-1. 
 
 
DOTA-diHexa(CN-NC)-amide 
DiHexa(CN-NC)-amide (Figure 33) was assembled by first synthesizing the two fragments A and B 
separately on the automated synthesizer, followed by fragment coupling. Fragment A, H-"Ala-Nle-His-D-
Phe-Arg-Trp-amide, was prepared, purified and analyzed by mass spectrometry according to the general 
methods. Calculated monoisotopic mass: 943.08 gmol-1; found: 943.5 gmol-1. Fragment B, H-Cys-"Ala-Nle-
His-D-Phe-Arg-Trp-amide, was synthesized in the same way. Calculated monoisotopic mass: 1046.225 
gmol-1; found: 1046.5 gmol-1. 
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Figure 33: Chemical structure of DOTA-diHexa(CN-NC)-amide. 
 
 
The two fragments were coupled by first dissolving fragment A (1 eq) in DMF, adding N-succinimidyl 
iodoacetate (1.7 eq) dissolved in DMF, and then adding 2.5 volumes of a borate/EDTA buffer (0.16 M Na-
borate, 50 mM EDTA, pH 8). The mixture was incubated under argon at room temperature for 30 min. 
Fragment B (1 eq) was dissolved in DMF, added to iodoacetylated fragment A and incubated under argon 
at room temperature for 60 min. The conjugate was purified by RP-HPLC and lyophilized. The DOTA 
moiety was then coupled to the peptide using the usual procedures. After deprotection of DOTA in standard 
90% TFA-mixture for 4 h and precipitation, DOTA-diHexa(CN-NC)-amide was purified by RP-HPLC and 
lyophilized. Calculated monoisotopic mass: 2415.69 gmol-1; found: 2415.7 gmol-1. 
 
 
Radiolabeling of peptides 
 
Labeling with 
111
In 
Incorporation of 111In into dimer DOTA-peptides was performed by the addition of 55.5 MBq of 111InCl3 to 
the DOTA-peptides (10 nmol) dissolved in 54 µl acetate buffer (0.4 M, pH 5) containing 2 mg of gentisic 
acid. After 10 min of incubation at 95°C, the radiolabeled DOTA-peptides were purified on a small 
reversed-phase cartridge (Sep-Pak C18, Waters) by first washing the column with 0.4 M sodium acetate 
buffer (pH 7) and then eluting it with ethanol. The purity of the radioligands was assessed by RP-HPLC/#-
detection (see above). The specific activity of the radioligand was always >7.4 GBq/µmol. 
 
Radioiodination 
Radioiodination of NDP-MSH was performed with the Iodogen® (Pierce) method. To this end, NDP-MSH 
(12.14 nmol) was mixed with Na125I (37 MBq; Amersham) in 60 µl phosphate buffer (0.3 M, pH 7.4) in a 
Iodogen®-precoated tubes. After a 15-min incubation at room temperature under shaking, the iodination 
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mixture was loaded onto a small reversed-phase cartridge (Sep-Pak C18, Waters) which was washed 
consecutively with water and acetic acid (0.5 M), and finally the peptide was eluted with methanol and 
collected. The fractions containing [125I]NDP-MSH were supplemented with dithiothreitol (1.5 mg/mL) and 
stored at –20°C. Preceding each binding experiment, an additional purification was performed by RP-
HPLC, and the radiotracer was lyophilized from lactose/bovine serum albumin (BSA) (20 mg of each per ml 
H2O). 
 
 
Cell culture 
The mouse B16-F1 melanoma cell line101 was cultured in modified Eagle!s medium (MEM) supplemented 
with 10% heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 1% nonessential amino acids, 1% vitamin 
solution, 50 IU/mL penicillin and 50 µg/mL streptomycin, in an atmosphere of 95% air/5% CO2 and at a 
temperature of 37°C. For cell expansion or experiments with isolated cells, the B16-F1 cells were detached 
with 0.02% EDTA in PBS (phosphate-buffered saline; 150 mM, pH 7.2-7.4). The human HBL melanoma 
cell line was cultured in modified RPMI medium supplemented with 10% heat-inactivated fetal calf serum, 2 
mM L-glutamine, 50 IU/mL penicillin and 50 µg/mL streptomycin in the same conditions as for B16-F1 cells. 
 
 
In vitro binding assay  
Competition binding experiments were performed in 96-well U-bottom microplates (Falcon 3077), each well 
containing 100 µL of B16-F1 or HBL cell suspensions adjusted to 4'106 cells/mL. The binding medium 
consisted of MEM with Earle!s salts, 0.2% BSA and 0.3 mM 1,10-phenanthroline. Triplicates of competitor 
peptide solution (50 µL), yielding a final concentration ranging from 1'10-6 to 1'10-12 M, were added, 
followed by the addition of 50,000 cpm [125I]NDP-MSH in 50 µL to each well111. The incubation conditions 
were 15°C for 3 h for B16-F1 cells and 37°C for 2 h for HBL cells. The reaction was stopped by placing the 
plates on ice for 10 min. The cell-bound radioactivity was collected on filters (Packard Unifilter-96 GF/B) by 
use of a cell harvester, and the radioactivity was counted on a TopCount scintillation counter (Packard). 
The IC50 values were calculated with Prism software (GraphPad Software Inc., San Diego CA, USA).  
 
 
In vitro melanin assay 
The biological activity of the !-MSH derivatives was assessed with an in situ melanin assay283. Briefly, B16-
F1 cells (2,500 cells per well in 100 µl) were distributed into 96-well flat-bottom cell culture plates, using 
MEM without phenol red and supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 
1% nonessential amino acids, 1% vitamin solution, 50 IU/mL penicillin and 50 µg/mL streptomycin. After 
incubation for approximately 16 h (overnight) at normal cell-culture conditions, serial concentrations of !-
MSH derivatives ranging from 1x10-8 to 1x 0-12 in 100-µL volumes were added and the incubation was 
continued for an additional 72 h. Melanin production was quantified by determining the absorbance at 310 
nm in a microplate reader. 
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In vitro internalization assay 
B16-F1 cells were seeded in 6-well plates and incubated overnight in MEM at 37°C. For the internalization 
experiments, the MEM was replaced by 1 mL mouse binding medium (MBM) internalization buffer, 
consisting of MEM with Earle!s salts, 0.2% BSA and 0.3 mM 1,10-phenanthroline. After a 1-h incubation at 
37°C, 74 kBq of radioligand were added and the plates incubated for different times. Nonspecific 
internalization was determined by addition of 50 µL of a 1 µM !-MSH solution to the incubation mixture. At 
the various time points indicated, the cells were extensively washed with MBM kept at 37°C to remove 
excess radioligand. The cells were then incubated in 2 ml ice-cold acid buffer (acetate-buffered Hank!s 
balanced salt solution, pH 5) for 10 min to allow dissociation of surface-bound ligand. After collection of the 
acid buffer fraction, the cells were rinsed once with cold MBM and the washings were pooled with the acid 
buffer fraction. The cells were then washed once more with MBM kept at 37°C, lysed in 1% Triton X-100 
and finally transferred to tubes for quantification. The radioactivity of all collected fractions was measured in 
a #-counter. Results are expressed as percent of the added dose per million cells. 
 
 
Biodistribution and stability of radioligands in B16-F1 tumor-bearing 
All animal experiments were performed in compliance with the Swiss regulations for animal welfare. 
Female B6D2F1 mice (C57BL/6'DBA/2F1 hybrids; breeding pairs obtained from IFFA-CREDO, France) 
were implanted subcutaneously with 500,000 B16-F1 cells in phosphate buffered saline (PBS), pH 7.4, to 
generate a primary skin melanoma. One week later, 185 kBq of [111In]DOTA-peptide in 200 µL PBS 
containing 0.1% BSA were injected i.v. into the lateral tail vein of each mouse. To allow determination of 
non-specific uptake of radioligand, 50 µg !-MSH were coinjected with the radioligand in control animals. 
The animals were killed at the indicated time points; organs and tissues of interest were dissected and 
rinsed of their excess blood, weighed, and their radioactivity was measured in a #-counter. The percentage 
of the injected dose per gram tissue (%ID/g) was calculated for each tissue. The total counts injected per 
animal were calculated by extrapolation from counts of a standard taken from the injected solution for each 
animal. 
 
As part of the biodistribution experiments, samples of urine were collected from melanoma-bearing mice at 
10, 15, 20 min and 4 h after injection of 185 kBq [111In]DOTA-peptide and kept frozen at -80°C until use. 
Urine (1 vol) was mixed with methanol (2 vol) to precipitate the proteins and the supernatant was analyzed 
by RP-HPLC/#-detection, as described above. 
 
 
Analysis of data 
Unless otherwise stated, results are expressed as means ± SEM. Statistical evaluation of the binding 
assays was performed using the Student!s t test. For analysis of biodistribution experiments, each mean 
value obtained for each organ was compared individually using the Student!s t test and the results were 
corrected using the Bonferroni correction. A P value of <0.05 was considered statistically significant. The 
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area under the curve (AUC) was calculated for a particular time period (4-48 h) using the Prism software; 
mean tissue uptake values at each time point were taken for this calculation. 
 
 
RESULTS 
 
 
Design, synthesis and labeling of dimer DOTA-MSH hexapeptide analogs 
Three dimer MSH peptides were designed which contained a slightly modified hexapeptide core sequence 
of the !-MSH molecule, Nle-Asp-His-D-Phe-Arg-Trp, in either parallel N-to-C–spacer–N-to-C orientation or 
in antiparallel C-to-N–linker–N-to-C orientation. DOTA-diHexa(NC-NC)-amide and diHexa(NC-NC)-Gly-
Lys(DOTA)-amide contained the two hexapeptides in the former orientation; the two hexapeptides and the 
tripeptide spacer "Ala-Gly-"Ala as well as the dipeptide –Gly-Lys extension at the C-terminus of the 
second peptide were assembled as linear 15-residue and, respectively, 17-residue peptides (Fig. 1). In 
DOTA-diHexa(NC-NC)-amide, the DOTA moiety was attached at the N-terminus, in analogy to DOTA-
MSHoct
(110). In diHexa(NC-NC)-Gly-Lys(DOTA)-amide, the DOTA was incorporated in the sequence 
extension at the C-terminus (–Gly-Lys(DOTA)-amide) to allow for easier fragmentation and excretion in the 
kidneys, similar to DOTA-NAPamide114. The third dimer peptide, DOTA-diHexa(CN-NC)-amide, contained 
the two hexapeptides in antiparallel C-to-N–linker–N-to-C orientation. The dimer was obtained by first 
extending one of the hexapeptides by a "Ala at its N-terminus, followed by coupling iodoacetyl to its free 
terminal amino group. The other hexapeptide was extended at its N-terminus by a Cys-"Ala moiety. The 
resulting hepta- and octapeptides were then linked through a thioether bond by reaction of the SH group of 
Cys with the iodoacetyl of "Ala, leaving the amino group of Cys free for attachment of DOTA. 
 
The synthesis, cleavage from the resin and purification of the linear hepta-, octa-, pentadeca- and 
heptadecapeptides were as straightforward as for NAPamide. Small amounts of the unprotected peptides 
were kept for biological assays. The larger part was used for attachment of DOTA (for the diHexa(CN-NC)-
amide preceded by thioether bond formation), yielding highly pure final products after RP-HPLC purification 
(for analytical details see Materials and Methods). It is important to note that during purification we noticed 
a marked stickiness to surfaces of all dimer DOTA-peptides. 
 
The radiolabeling of the dimer DOTA-peptides with 111In was much less straightforward and the first 
experiments yielded low incorporation of the radiometal. It appeared that prolonged heating during the 
labeling reaction was detrimental for these peptides. Therefore, the labeling reaction was minimized to a 
10-min incubation at 95°C and in addition, the labeling vial was precoated with 2% BSA to reduce non-
specific adsorption of the dimer peptides. Although good incorporation could now be obtained, the 
stickiness of the dimer [111In]DOTA-peptides was markedly higher than for monomeric DOTA-NAPamide. 
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Receptor binding and melanogenic activity 
The newly designed dimeric MSH analogs were first tested in a competition binding assay using B16-F1 
cells and [125I]NDP-MSH as radioligand. Figure 34 shows an exemplary experiment comparing diHexa(NC-
NC)-Gly-Lys(DOTA)-amide with !-MSH as reference compound. The dimer peptide was about 4-fold more 
potent than the standard. The binding activity of diHexa(NC-NC)-Gly-Lys-amide without DOTA was about 
3-fold higher than that of the DOTA-containing analog, i.e. the dimeric diHexa(NC-NC)-Gly-Lys-amide 
peptide was about 12-fold more potent than !-MSH and hence the most potent of the three different dimers 
(Table 8) to DOTA-NAPamide, diHexa(NC-NC)-Gly-Lys(DOTA)-amide displayed a 3.4-fold higher affinity in 
mouse B16-F1 cells, a 2.5-fold higher biological activity in the melanin assay, and a 6-fold higher affinity in 
human HBL cells, making it a promising candidate for in vivo targeting. 
 
 
Figure 34: Exemplary competition binding experiment with diHexa(NC-NC)-Gly-Lys(DOTA)-amide 
(triangles) and $-MSH (squares) using B16-F1 mouse melanoma cells and [125I]-NPD-MSH as 
radioligand. Each value represents the mean ± SEM (n = 9: triplicate values of three 
 
 
In the B16-F1 binding assay, DOTA-diHexa(NC-NC)-amide, which contained the DOTA at the N-terminus, 
was almost 2-fold less potent than diHexa(NC-NC)-Gly-Lys(DOTA)-amide. The difference between the two 
peptides was less prominent when the corresponding analogs without DOTA were compared (Table 8). 
The binding activity of DOTA-diHexa(CN-NC)-amide lay between the two other dimeric DOTA-peptides, 
differing from each by about a factor of 1.4. Interestingly, diHexa(CN-NC)-amide without DOTA was 1.5-fold 
less potent than the DOTA-containing analog. Summarizing these findings, the dimeric MSH peptides 
displayed enhanced biological activity in B16-F1 cells (and partly verified with HBL cells); the values were 
ranging between a 3- to 5-fold higher activity than that observed for the corresponding monomeric 
derivatives. 
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Table 8: MC1-R affinity and biological activity of !-MSH analogs with mouse B16-F1 and human HBL melanoma cells. 
Peptide B16-F1 Binding 
IC50 (nmol/L)
*
 
HBL Binding 
IC50 (nmol/L) 
Melanogenesis 
rEC50 (!-MSH = 1)
†
 
!-MSH 1.74 ± 0.12  1.91 ± 0.26‡ 1 
DOTA-NAPamide 1.38 ± 0.35 3.09 ± 1.11 0.66 ± 0.35 
diHexa(NC-NC)-amide  0.22 ± 0.01‡ ND ND 
DOTA-diHexa(NC-NC)-amide 0.79 ± 0.15 ND ND 
diHexa(NC-NC)-Gly-Lys-amide  0.14 ± 0.02‡ ND ND 
diHexa(NC-NC)-Gly-Lys(DOTA)-amide 0.41 ± 0.03  0.51 ± 0.04‡ 0.27 ± 0.05 
diHexa(CN-NC)-amide 0.87 ± 0.15 ND ND 
DOTA-diHexa(CN-NC)-amide 0.59 ± 0.02 ND ND 
*MC1R affinity of !-MSH analogs was assessed by competition binding experiments with B16F1 cells and 125I-NDP-MSH as 
radioligand (n=3-26) 
†Biological activity of !-MSH analogs was determined in melanin assay with B16-F1 cells, and the results are expressed as 
relative concentration (!-MSH = 1) inducing half-maximal response (rEC50; n = 3-10). 
‡
P < 0.05 vs. DOTA-NAPamide 
 
 
Internalization of diHexa(NC-NC)-Gly-Lys([
111
In]DOTA)-amide 
Internalization experiments were confined to one of the three dimer MSH radioligands. Figure 35 shows 
data on the rate of internalization of the diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide tracer into B16-F1 
cells: after 30 min, 71% of total cell-bound radioligand was internalized, after 2 h internalization was 84%, 
and after 3.5 h 92%. This demonstrates that down-regulation/internalization of MC1-R in mouse melanoma 
cells was not retarded by dimer MSH radioligands. 
 
 
 
Figure 35: Determination of internalization of diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide by cultured B16-F1 cells 
exposed to the peptide at 37°C for 0.5 h, 2 h and 3.5 h. Surface bound radioligand was released by an acid buffer 
wash and internalized radioligand was determined by lysing cells with detergent. Results are expressed in percent of 
the added dose per million cells. 
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Biodistribution in melanoma-bearing mice 
Table 9 presents the in vivo biodistribution of 111In-labeled DOTA-containing dimer !-MSH analogs and 
NAPamide in B16-F1 melanoma-bearing mice 4 h, 24 h and 48 h post-injection, when tissues including 
melanoma tumors were collected. The three dimeric DOTA-MSH analogs accumulated in melanoma to 
different degrees. After 4 h, [111In]DOTA-diHexa(CN-NC)-amide displayed a 1.17-fold higher accumulation 
in the tumor than [111In]DOTA-NAPamide. By contrast, with [111In]DOTA-diHexa(NC-NC)-amide only about 
50% of the radioactivity and with diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide about 65% were found in the 
tumor as compared to that of [111In]DOTA-NAPamide (set as 100%). The radioactivity in the tumor 
delivered by dimer peptides also appeared to be lost at a slightly higher rate than after delivery with DOTA-
NAPamide. 
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Table 9: Tissue distribution, including melanoma tumor, of 111In-labeled DOTA-containing dimer a-MSH analogs and 
NAPamide 4, 24 and 48h after injection. 
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Whereas incorporation of the radioactivity into the tumor was only marginally affected by dimerization of the 
MSH core sequence, the non-specific uptake by other tissues, most notably by the kidneys but also by the 
stomach, liver, spleen, and pancreas, were elevated by a factor of 3-10 (Table 9). Of the three dimeric 
analogs, the highest kidney values were observed with [111In]DOTA-diHexa(NC-NC)-amide, the lowest with 
diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide, and it was also noted that the clearance of 111In from the 
kidneys was much retarded when compared with [111In]DOTA-NAPamide. Whether uptake by the kidneys 
could have been modulated, e.g. by infusion of basic amino acids (see above) was not studied. When the 
biodistribution pattern of diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide was compared with [111In]DOTA-
NAPamide (Figure 36), it was obvious that the dimeric MSH radioligands were much inferior as compared 
to DOTA-NAPamide. Hence, the in vitro data were not predictive for the in vivo biodistribution 
characteristics. 
 
 
Figure 36: Comparison of organ distribution of diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide with [111In]DOTA-
NAPamide at 4 h, 24 h and 48 h post-injection. The radiopeptides were injected into B16-F1 melanoma-bearing mice, 
and tissues were collected at the time points indicated. Results are expressed % of injected dose per g of tissue 
(%ID/g; mean ± SEM, n = 4-12). †P < 0.05 vs. 111In-DOTA-NAPamide. ‡P < 0.001 vs. 111In-DOTA-NAPamide. §P < 
0.0001 vs. 111In-DOTA-NAPamide. 
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Effect of the position of DOTA on kidney uptake 
As demonstrated, kidney uptake of all three dimer MSH radioligands was much increased. The highest 
accumulation was observed for [111In]DOTA-diHexa(NC-NC)-amide which may indicate that N-terminal 
incorporation of DOTA is the least favorable. C-terminal DOTA in diHexa(NC-NC)-Gly-Lys([111In]DOTA)-
amide and insertion of DOTA into Cys of [111In]DOTA-diHexa(CN-NC)-amide both displayed a 1.4-fold 
lower kidney uptake. Comparison of tumor-to-kidney ratios at 4 h showed that the latter two peptides 
yielded values of 0.26 and 0.36, respectively, whereas the former peptide gave a value of only 0.11 (Figure 
37). These low values are in sharp contrast to the corresponding value for [111In]DOTA-NAPamide which 
was 1.67. It should be noted in this context that in the DOTA-NAPamide molecule, the position of DOTA in 
the peptide chain did not affect kidney uptake apart from a charge neutralization effect of the Lys side-
chain115. As there was no extra charge in the dimer MSH peptides which could have affected kidney 
uptake, it may therefore be concluded that an N-terminal position of DOTA in this type of dimer MSH 
conjugates should be avoided. 
 
 
Figure 37: Tumor versus kidney uptake of [111In]DOTA-NAPamide, [111In]DOTA-diHexa(NC-NC)-amide, diHexa(NC-
NC)-Gly-Lys([111In]DOTA)-amide, and [111In]DOTA-diHexa(CN-NC)-amide. The radiopeptides were injected into B16-
F1 melanoma-bearing mice and the radioactivity that accumulated in tumor and kidney was measured 4 h post-
injection. Results are expressed as tumor-to-kidney ratios of the means. 
 
 
 
DISCUSSION 
 
In previous reports, we presented promising data on receptor-mediated tumor targeting using short linear 
DOTA-!-MSH analogs, DOTA-MSHoct
110 and DOTA-NAPamide114, as melanoma vectors.  In tumor-bearing 
mouse models, 111In- and 67/68Ga-labeled DOTA-NAPamide exhibited high melanoma and low kidney 
uptake, leading to tumor-to-kidney ratios of the 4-h to 48-h AUC of 1.11 and 1.82, respectively114.  
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However, DOTA-MSHoct demonstrated much inferior biological performance with a tumor-to-kidney ratio of 
AUC calculated for the same time period as low as 0.24, suggesting that a small alteration in the chemical 
structure within the DOTA-NAPamide molecule was responsible for its superior melanoma targeting ability. 
As a high value for the tumor-to-kidney ratio is important for diagnostic application and imperative for 
therapeutic purpose (to reduce nephrotoxicity which is currently the dose-limiting factor), we thought to 
investigate MSH analogs that displayed increased receptor affinity so that lower doses could eventually be 
applied, concomitantly reducing kidney uptake. The previous finding in our84-87,171 and other 
laboratories100,314 that dimer and multimer !-MSH conjugates displayed markedly enhanced receptor 
activity prompted us to investigate dimerized DOTA-MSH analogs in vitro and in vivo. 
 
In this report, we described the design, synthesis and biological characteristics of three dimer MSH 
peptides containing a modified hexapeptide core sequence of !-MSH, Nle-Asp-His-D-Phe-Arg-Trp, in either 
parallel or antiparallel orientation, separated by a short spacer or linker. The spacer length was kept short 
as there was no intention to hit simultaneously two receptors with one and the same dimer conjugate. 
Instead, the concentration of binding species in the vicinity of the receptor should be elevated by the 
dimerization so that with one ligand molecule two binding motifs are offered to the receptor, hence 
increasing the apparent affinity of the ligand. Introduction of any unnecessary positive charge should be 
avoided because the investigations by Froidevaux et al.115 on the effect of different charges on the DOTA-
NAPamide molecule with respect to non-specific kidney uptake revealed that a positive charge on, e.g., a 
C-terminal Lys side-chain increased kidney retention considerably. Therefore, positive charges on the 
dimer peptides should be confined to the two core sequences where they are important for receptor 
binding87,88. In all three dimer peptides, the terminal charges were blocked by introducing a C-terminal 
amide group and an N-terminal acetyl group (or DOTA), respectively. 
 
The first type of peptide, diHexa(NC-NC)-amide, contained the two hexapeptides in the same orientation, 
separated by a tripeptide spacer; it had two negative charges and four positive charges originating from the 
side-chains of Asp, His, and Arg. The chelating analog, DOTA-diHexa(NC-NC)-amide, displayed additional 
charges on the DOTA moiety. The solubility of this pentadecapeptide was good but its stickiness to 
surfaces may have resided in either a possible tendency to form aggregates or in the hydrophobic central 
part around the spacer sequence. The second type of dimer peptide, the heptadecapeptide diHexa(NC-
NC)-Gly-Lys(DOTA)-amide, was almost identical with the first, except for its –Gly-Lys-NH2 extension at the 
C-terminus for attachment of DOTA, and the chemical characterstics were also very similar. The reason for 
the introduction of the –Gly-Lys(DOTA)-NH2 as C-terminal extension was the expectation, based on 
previous observations, that the Lys(DOTA)-NH2 would be readily cleaved from the molecule and excreted 
by the kidneys. The third peptide, DOTA-diHexa(CN-NC)-amide, was the least stable, possibly because of 
potential S-oxidation of the thio-ether group at elevated temperature (e.g. during the 111In-labeling reaction). 
 
In vitro, the biological characteristics of the three dimeric DOTA-MSH conjugates were excellent as they 
retained higher MC1-R receptor affinity than any other DOTA-MSH analog reported to date, in both mouse 
B16-F1 and human HBL melanoma cells (the latter was only studied with diHexa(NC-NC)-Gly-Lys(DOTA)-
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amide); hence the three dimer peptides exceeded the remarkable activity profile of DOTA-NAPamide. The 
diHexa(NC-NC)-Gly-Lys([111In]DOTA)-amide also showed rapid internalization into cultured B16-F1 
melanoma cells. However, the decreased tumor uptake in vivo and the disappointingly high kidney uptake 
precluded their further use as radiopharmaceuticals for direct receptor targeting. The difference between 
tumor uptake of dimer peptides and DOTA-NAPamide may reside in a lower tissue penetration of the 
dimers, owing to their stickiness to surfaces. Interestingly, there was no difference between diHexa(NC-
NC)-Gly-Lys([111In]DOTA)-amide and [111In]DOTA-NAPamide with respect to release of radioactivity from 
melanoma and kidneys following biodistribution. Both types of DOTA-!-MSH analogs were found to be 
much more rapidly released from melanoma than kidney leading to a decreasing tumor-to-kidney ratio over 
time. The reason for this differential excretion rate is not clear since DOTA-!-MSH analogs are assumed to 
undergo a similar process in kidney and melanoma after cellular uptake115. Indeed, [111In]DOTA-!-MSH 
analogs were shown to accumulate in the endosomal/lysosomal compartment of B16F1 cells after in vitro 
exposure (Froidevaux et al., unpublished observation). It appears that for both monomeric and dimeric 
DOTA-!-MSH radioligands, the rate of peptide hydrolysis was equally elevated in melanoma lysosomes 
(compared to kidneys), resulting in faster production of small radioactive metabolites. The significant 
difference in kidney retention between monomeric and dimeric DOTA-peptides is not well understood at 
present as both peptides contain the DOTA moiety in the e-amino group of C-terminal Lys-NH2. Our 
assumption of an efficient cleavage of –Gly-Lys(DOTA)-NH2 or –Lys(DOTA)-NH2 from diHexa(NC-NC)-Gly-
Lys(DOTA)-amide by the kidneys did not come true. Interestingly, dimer peptide uptake by the liver – 
although elevated – was far lower than that of the first DTPA-dimer !-MSH conjugate reported by Bagutti et 
al.20. Taken together, a first conclusion about the biological data is that no correlation can be made 
between the receptor affinity determined in the in vitro binding assay and the pharmacokinetic 
characteristics observed in vivo and that kidney retention of radiopeptides is unpredictable. Indeed, it 
appears that high receptor affinity in vitro of a radiopeptide does not implicitly result in high in vivo tumor 
accumulation. 
 
MC1 receptor-mediated melanoma targeting with different types of !-MSH-based 67/68Ga-, 111In-, 64Cu-, 
90Y-, or 177Lu-labeled peptide radiopharmaceuticals studied in different laboratories19,20,59-
63,90,110,114,115,200,202,204,321 has brought together a wealth of information and ideas for melanoma diagnosis 
and therapy in the past 13 years. More recently, 90mTc-labeled MSH has been added to the list208, and 
therapy experiments using an animal model and b-radiation (188Re) or a-radiation have been carried 
out205,206. Although the experimental data obtained with the !-MSH/MC1-R system are of comparable 
quality to those using somatostatin receptor targeting, clinical studies have been scarce so far because 
melanoma can nowadays be diagnosed well with 18F-fluorodesoxyglucsose/positron emission tomography 
(FDG-PET). By contrast, receptor-mediated targeting for therapy of melanoma metastases, which is the 
main goal of the studies with MSH/MC1-R, requires novel strategies to further increase the tumor-to-kidney 
ratio in order to minimize nephrotoxicity of these radiopharmaceuticals. The dimer peptide approach is 
obviously not the solution for therapy but dimeric or multimeric peptide conjugates could nevertheless 
become important if the strategy will not be based on direct labeling of the dimeric compounds. Instead 
such dimers or multimers may serve as one of the components of a pretargeting system in which the 
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labeled component is pharmacokinetically less problematic and of smaller size. This may be the strength of 
peptide multimers or dendrimers which are currently receiving much attention135,262,304,330. 
 
In conclusion, the biological evaluation of three dimeric MSH peptides containing the DOTA chelator for 
incorporation of radiometals has demonstrated that these compounds have very high in vitro affinity to the 
MC1-R which however was not mirrored by their in vivo melanoma tumor uptake. In addition, the uptake by 
the kidneys of all three dimeric peptides was about 5 times higher than that of monomeric DOTA-
NAPamide, precluding their direct use as radiopharmaceuticals. The high receptor affinity of dimeric or 
multimeric !-MSH conjugates may perhaps be of use in a pretargeting strategy, whereby receptor-bound 
dimer or multimer containing a specific affinity group may serve to fish a radioactive counterpart. 
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4 Glycopeptides 
4.1 Background 
 
At first, glycopeptides were introduced to improve drug delivery to target tissues, either by taking advantage 
of specific uptake mechanisms or by enhancing the peptide bioavailability. Peptides were shown to exhibit 
prolonged effects (glycosylated enkephalin peptides93) due to better delivery to the target tissue, enhanced 
renal peptide uptake from blood (glycosylated Arg8-vasopressin), an improved stability toward enzymatic 
degradation in vivo, or a better intestinal absorption, thus enhancing the bioavailability of the peptides324. 
 
Other effects of glycation on peptide properties emerged, including (depending on the attached sugar) 
higher or lower accumulation in the proximal tubules of the renal cortex. Suzuki et al. made systematic 
investigations in the field of modified Arg-vasopressin (AVP) by linking it to a variety of sugars281,302. They 
listed structural requirements to exploit or to avoid targeting of the kidney301, and they synthesized 
derivatives based on their “alkylglycoside”, a novel targeting vector for the kidney. SAR studies revealed 
the influence of the sugar type on the affinity for the kidney membrane cells. Various positions of the 
hydroxyl groups of the carbohydrates were found to be essential (in this case, equatorial OH at position 4 is 
mandatory, OH at position 2 could either be oriented or absent, etc.) for the targeting of the kidney. 
 
 
 
 
 
 
 
 
Figure 38: Structure of some compounds used 
by Suzuki et al. as "alkylglycosides".
302
 
A, AVP; B, Glc-O-C8-AVP; C, Glc-S-Cn-AVP (n = 5, 
Glc-S-C5-AVP; n = 8, Glc-S-C8-AVP; n = 11, Glc-S-
C11-AVP). 
 
 
Keeping in mind that these findings are specific to the alkylglycoside derivatives, it is clear nevertheless 
that carbohydrated derivatives can have a major influence on the pharmacokinetics of peptides, either 
positively or negatively. 
 
Wester et al. also mention in their review324 that after carbohydration of somatostatin derivatives, a switch 
in the way of excretion could be observed. It appeared that the glycopeptides tended to exhibit a lower 
hepatic clearance as well as a lower hepatic and intestinal uptake, exhibiting a switch towards renal 
GLYCOPEPTIDES 
112
excretion. The uptake of some octreotide derivatives in SST-expressing tissue remained mostly 
unchanged, except for [125I]Gluc-TOC, exhibiting a tumor uptake of 160% of the reference. 
 
 
Figure 39: Some of the derivatives synthesized by Schottelius et al.. Structures of [
125
I]Gluc-
TOC, [
125
I]Malt-TOC and [
125
I]Mtr-TOC
273
. 
 
Various other carbohydrated derivatives were investigated by the same group, and in the different 
approaches adopted, it appeared that glycopeptides could dramatically influence the pharmacokinetic 
behavior of somatostatin derivatives (blood and whole body clearance, clearance pathways, reduction of 
liver uptake, reduction of renal uptake, enhancement of urinary excretion, or even increased tumor 
uptake)273,274,323,324. 
 
These promising findings led to the development of carbohydrated !-MSH derivatives in our group. Indeed, 
as seen earlier in this thesis, the main issue of most radiolabeled !-MSH tracers remains their relatively 
high kidney uptake. Therefore, given the potential reduction of the kidney uptake or the increase of tumor 
uptake observed with other peptide derivatives, a similar approach with !-MSH analogs was tempting, and 
is described in the next subchapter. 
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4.2 Carbohydrated !-MSH analogs 
 
Carbohydration of peptides represent an interesting approach to improve the general pharmacokinetic 
properties of diagnostic and therapeutic peptides. A systematic approach was adopted regarding the 
screening of potential glycopeptidic derivatives of radiolabeled !-MSH analogs. Indeed, various 
carbohydrate moieties were attached at various positions along a chosen peptide backbone, in an attempt 
to optimize its pharmacokinetical profile. It was logical to use the most successful peptide of our laboratory 
as basis for the synthesis of glycated derivatives. 
 
 
Simple and commonly found sugars were used to determine the influence of glycation on the in vitro and in 
vivo profiles of the chosen radiopeptide. Carbohydrate moieties such as glucose (Gluc), galactose (Gal) 
and maltotriose (Mtr) were coupled to the NAPamide sequence using different synthetical approaches, 
ranging from synthesis with building blocks to the use of the naturally occurring Maillard reaction (see 
chapter 4.3.2). As mentioned, their affinity profiles were then assessed by use of competitive binding 
assays on murine (B16F1) or human (HBL) cell lines, their internalization profiles on the same murine cells 
using the radiolabeled (111In) peptide, as well as their biological activity (melanin production assay) with the 
unlabeled peptide. Finally, their pharmacokinetical profiles were determined in in vivo biodistribution assays 
on B6D2F1 melanoma-bearing mice. 
 
 
4.3 Syntheses of the carbohydrated derivatives 
4.3.1 The “building blocks” strategy 
 
First, it was planned to adopt a “building blocks” strategy in order to facilitate the synthesis of derivatives in 
a “high-throughput screening” combinatorial chemistry way for potential further developments. To this end, 
a carbohydrate derivative based on galactose and bearing a carboxylic group at its anomeric center was 
synthesized. This synthesis was originally described by Arya et al., and the supporting material of the 
publication mentions the synthesis of various carboxylic derivatives 16. The carbohydrate was incorporated 
as !-linked C-glycoside. 
 
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 
                                                      | 
                                                      DOTA 
DOTA-NAPamide 
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Figure 40: Synthesis strategy of DOTA-Gal-NAPamide. 
 
Commercially available penta-O-acetyl-protected "-D-galactose was allylated at position 1 to form the !-
allylated D-galactopyranoside. It was then oxidized through ozonolysis to form the aldehyde derivative. 
Finally, the aldehyde was oxidized by potassium permanganate to form the ethanoic acid. The compound 
was then coupled to the free N-terminus of NAPamide on solid phase through HATU-mediated coupling, 
and the peptide was cleaved from the resin (simultaneously, its side-chains were deprotected) using TFA. 
This step yielded 25% product. The 4 O-acetyl protecting groups from the carbohydrate were cleaved using 
hydrazine hydrate. The DOTA chelator complex was coupled, and its protecting groups were cleaved, 
yielding final DOTA-Gal-NAPamide. 
 
The HATU (O-(7-azabenzotriazol-1-yl)-N,N,N!,N!-tetramethyluronium hexafluorophosphate) approach was 
chosen for its improved properties compared to other HOBt-based or even to some HOAt-based 
phosphonium and uronium salts. In the presence of base, HATU cleanly converts carboxylic acids to the 
corresponding OAt esters. These esters are far more reactive than the corresponding OBt esters towards 
aminolysis, due to OAt being a better leaving group than OBt and the active participation of the pyridine 
nitrogen in the amide bond forming reaction. This greater reactivity leads to higher coupling yields with less 
enantiomerization53,185,212. 
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Figure 41: The proposed mechanism of the HATU-mediated glycation reaction in detail. 
 
 
In our case, the total reaction could be achieved, but it also involved unusual laboratory equipment 
(especially for the ozonolysis step) during the preparation of the carbohydrate moiety, i.e. equipment that 
was not always at our disposal. The purification of the allylic derivative was very difficult, as several by-
products present after the synthesis could not be well separated from the desired product. Then, the 
obtained yields for the glycation step were acceptable (25%), but the sugar moiety had later to undergo 2 
deprotection steps, as the first turned out to be incomplete. This caused additional product losses. Finally, 
due to the poor yields commonly obtained in the DOTA-coupling step, total yields were quite low (~7.4%). 
Therefore, and although two final glycopeptides (DOTA-Gal-NAPamide and DOTA-NAPamide-Gal) could 
be synthesized using this strategy, it was decided to adopt another, simpler and more quantitative strategy. 
DOTA-NAPamide-Gal was synthesized later than several of the derivatives produced with the Maillard 
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reaction, but due to the requirements of a C-terminal coupling strategy, the HATU-mediated glycation way 
was the method of choice. 1-Amino-1-deoxy-"-D-galactose was the commercially available carbohydrate 
moiety used for this synthesis. Again, quite poor yields were obtained (7.7% for the sole glycation step). 
 
 
4.3.2 The Maillard reaction 
 
The Maillard reaction is a very common chemical reaction (usually associated with heat) in the food 
industry, as it is responsible for a whole range of colors and flavors. It was investigated in the 1910s by 
Louis-Camille Maillard195. It is implicated in the roasting of coffee and the browning of bread or other bakery 
products. It is present in malted barley as in malt whiskey or beer and in roasted or seared meat, etc. In all 
these areas, it is responsible for the characteristic brown color and some very specific aromas and flavors. 
Less than 0.1 ng/l of some end products are needed to reach the human odor threshold. It is a form of non-
enzymatic browning (as is caramelization, though in a totally different way, caramelization involving simple 
pyrolysis of certain sugars) promoted by heating. The Maillard reaction is a reaction between an amino acid 
and a reducing sugar. The reactive carbonyl group of the sugar reacts with the nucleophilic amino group of 
the amino acid, and forms a variety of interesting but poorly characterized molecules responsible for a 
range of odors and flavors. The process is accelerated in an alkaline environment, as the amino groups are 
deprotonated and hence have an increased nucleophilicity. Hundreds of different flavor and color 
compounds may be formed by this reaction. The product pattern is subject to large variations, depending 
on parameters such as the reaction time, the temperature, the concentration of the reactants, the pH of the 
reaction, and of course the amino acids and sugars involved. This reaction is the basis of the flavoring 
industry, since the type of amino acid determines the resulting flavor. 
This reaction was already used by other groups for the glycation of various peptidic derivatives. Albert et al. 
used it successfully as one of the first in peptide synthesis11. More particularly, Schottelius et al. 
synthesized several somatostatin analogues derivatives using this technique273,274,323,324. 
 
Reaction 
 
Three main stages may be considered in the Maillard reaction. The early stage is the formation of a Schiff 
base which, through rearrangements, produces an “Amadori product” (ketoamine), if the reducing sugar is 
an aldose. This Amadori product is then degraded to a variety of carbonyl compounds. It is an important 
intermediate in the Maillard chemistry. The Amadori products are mainly degraded through dehydration of 
the sugar moiety, forming deoxyglucosones. A later stage leads these highly reactive carbonyl compounds 
to the formation of a group of substances known as advanced glycation end products, or AGEs. AGEs are 
often colored and prone to produce crosslinks in proteins, and this may be the cause of their potential 
implication in complications of various diseases (e.g. diabetes, ageing)150. 
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Steps: 
 
• Formation of a Schiff base: for example the aldehyde group of a glucose molecule will combine 
with the amino group of a lysine molecule (in a protein) to form an imine or Schiff base, which is a 
double bond between the carbon atom of the glucose and the nitrogen atom of the lysine. 
• Formation of an Amadori product: the Amadori product is a re-arrangement from the Schiff base 
wherein the hydrogen atom from the hydroxyl group adjacent to the carbon-nitrogen double bond 
moves to bond to the nitrogen, leaving a ketone. 
• Formation of an advanced glycation end product (AGE): the Amadori product is oxidized, most 
often by transition metal catalysis. 
 
The first two steps in this reaction are both reversible, but the last step is irreversible. The reaction 
mechanism is described in the following figure (Figure 42): 
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Figure 42: Detailed mechanism of the Maillard reaction until the Amadori compound (adapted from 
Horvat et al.
150,258). 
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This reaction happened to work quite well for all the peptides that were synthesized with this simpler 
approach, compared to the HATU-mediated coupling of a sugar acid. Yields between 16% and 31% were 
obtained for the Maillard reaction for “normal” N-terminal coupling, but a lysine &-amino-group-coupling 
yielded as little as 1.5% product. It is noteworthy that the DOTA chelator complex was already present on 
the peptide when the carbohydrate was coupled, which probably had an influence on glycation because of 
sterical hindrance, leading to such a low yield. 
The main interest of the Maillard reaction resides in the fact that carbohydrates as simple as "-D-glucose, 
"-D-galactose, or maltotriose, can be inserted into peptides bearing a free N-terminal end. The reaction 
(under slight heating, 60°C under reflux) is spontaneous, although quite a long reaction time is needed 
(72 h), but it does not require any specific reagent or any preparation of starting products. It is carried out in 
an acidic mixture of MeOH/AcOH (95/5). The simplicity of the reaction definitely represents its main 
advantage over other methods, which is the reason why it was the strategy chosen for the synthesis of 
peptide derivatives that allowed it. Peptides synthesized this way were DOTA-Glc-NAPamide, DOTA-Mtr-
NAPamide and N$-DOTA-[Lys(Gluc)8]-NAPamide. 
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4.4 Manuscript to be submitted 
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ABSTRACT 
 
!-Melanocyte-stimulating hormone (!-MSH) is known to bind to the melanocortin receptor 1 (MC1R), which 
is overexpressed at the surface of both melanotic and amelanotic melanoma cells. !-MSH analogs are 
potential candidates for specific targeting of metastatic melanoma. Several peptides were already designed 
and tested in the past, and showed high affinity for the MC1R in vitro, as well as a good incorporation in 
tumor xenografts in vivo. However, considerable kidney reabsorption of radiolabeled MSH analogs could 
not be avoided. In this study, we synthesized several carbohydrated derivatives with the aim to increase 
the tumor-to-kidney ratio. Methods: Six glycosylated derivatives of NAPamide, an !-MSH octapeptide 
analog with high tumor selectivity, were synthesized and coupled to the chelator DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid). The peptides were evaluated in vitro for MC1-R binding 
and agonist bioactivity and, after labeling with 111In, for in vitro cellular uptake and in vivo tissue distribution 
in the B16F1 melanoma mouse model. Results: The glycopeptides showed excellent binding affinities in 
the low nanomolar or sub-nanomolar range with both murine and human melanoma cell lines. However, 
five glycopeptides displayed lower selectivity in vivo than the parent DOTA-NAPamide, because of either a 
lower tumor uptake or a higher kidney uptake. In particular C-terminal extension of the amide group by a 
galactosyl moiety increased the kidney retention dramatically. By contrast, the N-terminally positioned 
galactose residue in DOTA-Gal-NAPamide improved the tumor-to-kidney ratio (4-48 h AUC of 1.34) by a 
factor of about 1.2 as compared to the parent DOTA-NAPamide (4-48 h AUC of 1.11). Conclusion: A new 
carbohydrated !-MSH analog, DOTA-Gal-NAPamide, displays promising pharmacokinetic properties with 
higher tumor-to-kidney ratio than previously investigated peptides. 
Key words: melanoma targeting; !-melanocyte-stimulating hormone; DOTA; glycopeptide; melanocortin-1 
receptor; internal radiotherapy 
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INTRODUCTION 
 
Overexpression of melanocortin type-1 receptors (MC1R) on the surface of melanoma cells is known as a 
potential target for the diagnosis or therapy of malignant melanoma21,122,284. Radiolabeled !-melanocyte-
stimulating hormone (!-MSH), the natural ligand of MC1R, and numerous types of synthetic analogs have 
been studied as potential candidates for diagnosis or therapy of melanoma metastases59,60,110,114,115,203,207. 
Radiopeptide targeting of primary tumors and metastases has been proven to be a highly sensitive and 
selective approach now routinely used in the clinic mainly for the diagnosis and therapy of tumors 
expressing somatostatin receptors113. 
 
Some !-MSH analogs show excellent binding properties to both murine and human tumor cells in vitro. 
However, major side effects of an unspecific retention in the kidneys in vivo refrain from a possible use in 
human clinical applications. As shown for radiolabeled somatostatin analogs, the general renal toxicity of 
radiopeptides remains their main dose-limiting factor70. Various approaches of modification of the chelator-
peptide structures have been applied to improve in vitro and in vivo characteristics of peptide hormone 
analogs, e.g. structural modifications of the peptide itself or its overall peptide length110, structural variation 
of the chelator for the radiometal22,108,328, the use of different radiometals such as 67/68Ga, 111In, 90Y, 177Lu, 
99mTc, 188Re114, the adjustment of the net charge of chelator-peptide complex7,115, the position of the 
chelator on the peptide115, cyclization of the peptides via a rhenium core60,207, and the synthesis of 
dimerized !-MSH analogs25. Another approach to reduce non-specific uptake by the kidneys is the co-
injection of cationic amino acids33, All these strategies, though, did not sufficiently lower the kidney uptake 
so that radiotherapy can ever become an option. 
 
Thus, alternative approaches need to be studied for the identification of new leads that may yield !-MSH 
compounds with improved pharmacokinetic properties, in particular high receptor affinity, low non-target 
tissue retention and almost exclusively urinary excretion route. The kidney reabsorption and retention, 
though, should be further reduced to minimize nephrotoxicity. Coupling of carbohydrate moieties to 
peptides can strongly influence the pharmacokinetics of peptides, owing to the more hydrophilic character 
which they provide to the molecule. Their excretion in the primary urine may be favored and re-uptake by 
the tubular system of the kidneys reduced, as shown for glycosylated peptides and proteins281,303. It has 
been shown that carbohydrates, if properly positioned, preserve structure-activity relationships (SAR) of the 
peptides with their target receptors. For example, glycosylated enkephalin derivatives have been shown to 
keep their binding properties and to exhibit prolonged bioavailability102,237. The in vivo stability of renin 
inhibitors could also be improved103, and it has been shown that carbohydration of somatostatin analogs 
improved their pharmacokinetical profile by reducing their liver uptake and biliary excretion273,323,324, 
switching their excretion route from hepato-biliary to renal. Suzuki et al. investigated numerous 
modifications of Arg-vasopressin by coupling of a whole variety of different sugar moieties in order to target 
the kidney. Their investigations revealed how the affinity of the peptides for kidney membrane cells could 
be influenced, depending on the type of sugar used281,301,303. 
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In this study, we synthesized and evaluated, both in vitro with mouse and human melanoma cells and in 
vivo with biodistribution experiments using tumor-bearing mice, several radiolabeled carbohydrated !-MSH 
analogues based, on the structure of the very efficient derivative [111In]DOTA-NAPamide previously 
synthesized in our laboratory114. The peptides varied in the nature and position of the carbohydrate 
moieties which were inserted into the C-terminal, N-terminal as well side-chains of the NAPamide peptide. 
The novel MSH peptides studied included DOTA-NAPamide-Gal, N!-DOTA-[Lys(Gluc)8]-NAPamide, 
DOTA-[Asp(Gal)2]-NAPamide, DOTA-Mtr-NAPamide, DOTA-Gluc-NAPamide, DOTA-Gal-NAPamide 
(Figure 43). 
 
 
MATERIALS AND METHODS 
 
 
Peptides and Analytical Procedures 
!-MSH was a gift from Novartis and (Nle4, D-Phe7)-!-MSH (NDP-MSH) was purchased from Bachem 
(Bubendorf, Switzerland). The reference compound DOTA-NAPamide114 and all other peptides were 
synthesized in our laboratory using a Pioneer peptide synthesizer (PerSeptive Biosystems Inc., 
Framingham, MA, USA) and the continuous-flow strategy with Fmoc (9-fluorenylmethoxycarbonyl) 
protection of N!-amino groups (for details see Bapst et al.25). Fmoc-amino acids were purchased from 
Novabiochem (Läufelfingen, Switzerland). Fmoc-PAL-PEG-PS polystyrene resin was from Applied 
Biosystems (Rotkreuz, Switzerland) and TentaGel S TRT-Lys(Boc)-Fmoc acid-labile resin from Fluka 
(Buchs, Switzerland). Fmoc-Asp(1,2:3,4-diisopropylidene-6-amino-!-D-galactosyl)-OH was a gift from 
SynphaBase AG (Muttenz, Switzerland). Other carbohydrates and organic reagents were purchased from 
Fluka or Sigma (Buchs, Switzerland). 
 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. Assignment of 1H and 
13C spectra was achieved using 2D methods (COSY, HSQC). Chemical shifts are expressed in ppm using 
residual CDCl3 and CHD2OD as references. Mass spectra (MS) were recorded on a Finnigan LCQ Deca 
electrospray ion trap small molecules and proteomics MS system. Analytical reversed-phase high-
performance liquid chromatography (RP-HPLC) of all peptides was performed on a Jasco PU-980 system 
(Jasco Inc., Easton, MD, USA) with usually a Waters Symmetry C18 analytical column (5 µm, 3.9 ' 150 
mm), or (mentioned if used) a Vydac 218TP54 C18 analytical column (5 µm, 4.6 ' 250 mm). Preparative 
RP-HPLC of peptides was performed on the same system but either with a Vydac 218TP510 C18 semi-
preparative column (5 µm, 10 ' 250 mm) or a Waters SymmetryPrep C18 preparative column (7 µm, 19 ' 
150 mm). Peptides were eluted by applying a gradient of 5-95% solvent B (solvent A: 0.1% trifluoroacetic 
acid (TFA) in H2O, solvent B: 0.1% TFA in 70:30 acetonitrile/H2O; gradient cycle: 0-27 min, 95%-10% A; 
27-30min, 10%-95% A; 30-32 min, 95% A) in 32 min at constant flows of 1 mL/min for the analytical 
columns, 3 mL/min for the semi-preparative column and 5 mL/min for the preparative column. UV-detection 
was performed at 280 nm on a Jasco UV-1570 UV-VIS detector. 
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Preparation of glycopeptides 
 
DOTA-Gal-NAPamide 
The peptide with an N-terminal Gal and DOTA on the Lys side-chain was synthesized by first preparing and 
attaching a Gal-octanoic acid residue to the N-terminus of partially protected NAPamide: 
 
Allyl-2,3,4,6-tetra-O-acetyl-!-D-galactopyranoside: 1,2,3,4,6-penta-O-acetyl-"-D-galactopyranose (10.24 
mmol, 1 eq) was dissolved in anhydrous acetonitrile (40 ml) and cooled down to 0°C. Allyl-trimethylsilane 
(30.76 mmol, 3 eq) and boron trifluoride diethyl etherate (58.4 mmol, 5.7 eq) were carefully added under an 
N2-atmosphere. The mixture was slowly warmed up to room temperature and stirred overnight under N2. It 
was then neutralized by pouring the solution into an erlenmeyer containing NaHCO3 (40 ml). Once the 
bubbling was over, the reaction mixture was transferred to a separation funnel, extracted with 
dichloromethane (2'40 ml) and dried over Na2SO4. The crude product was purified by column 
chromatography (petrol ether/ethyl acetate 3:1 to 2:1), resulting in a clear syrup. Yield: 6.96 mmol (68%). 
1H NMR (CDCl3, 500.1 MHz) !: 1.97 (s, 3H, CH3), 1.98 (s, 3H, CH3), 2.01 (s, 3H, CH3), 2.06 (s, 3H, CH3), 
2.21 (m, 1H, CH2CH=CH2), 2.40 (m, 1H, CH2CH=CH2), 4.00-4.04 (m, 2H, H-5, H-6a), 4.14 (m, 
3
J5,6b = 9.1 
Hz, 
2
J6a,6b =12.9 Hz, 1H, H-6b), 4.24 (m, 1H, H-1), 5.03-5.08 (m, 2H, CH2CH=CH2), 5.15 (dd, 
3
J3,4 =3.3 Hz, 
3
J2,3 = 9.3 Hz, 1H, H-3), 5.21 (dd, 
3
J1,2 = 5.0 Hz, 
3
J2,3 = 9.3 Hz, 1H, H-2), 5.35 (m, 1H, H-4), 5.69 (m, 1H, 
CH2CH=CH2). 
13C NMR (CDCl3, 125.8 MHz) !: 20.67, 20.73, 20.74, 20.79 (4C, 4 CH3), 30.92 (1C, 
CH2CH=CH2), 61.45 (C-6), 67.58 (C-4), 67.90 (C-3), 68.24 (2C, C-5, C-2), 71.43 (C-1), 117.67 (1C, 
CH2CH=CH2), 133.30 (1C, CH2CH=CH2), 169.81, 169.94, 170.09, 170.56 (4C=O). 
 
2,3,4,6-Tetra-O-acetyl-!-D-galactopyranosyl aldehyde: A solution of allyl-2,3,4,6-tetra-O-acetyl-!-D-
galactopyranoside (6.96 mmol) was dissolved in anhydrous CH2Cl2 (100 ml) and cooled to –70°C. Ozone 
(O3) was bubbled through the solution for approximately 1 h, until the solution turned blue. The mixture was 
de-ozonized by bubbling N2 through the solution until it was colorless. Acetic acid (10 ml) and zinc dust (7.5 
g) were added to the solution and the suspension was slowly warmed up to room temperature overnight 
under stirring. The suspension was filtrated through Celite and the filtrate was concentrated to dryness. The 
crude product was purified by column chromatography (petrol ether/ethyl acetate 1.5:1) and dried under 
high vacuum. Yield: 4.74 mmol (68%). 
1H NMR (CDCl3, 500.1 MHz) !: 2.05 (s, 6H, 2 CH3), 2.06 (s, 3H, CH3), 2.11 (s, 3H, CH3), 2.65-2.76 (m, 2H, 
CH2CHO), 4.05-4.11 (m, 2H, H-5, H-6a), 4.32 (m, 1H, H-6b), 4.86 (m, 1H, H-1), 5.17 (dd, 
3
J3,4 = 3.2 Hz, 
3
J2,3 = 8.5 Hz, 1H, H-3), 5.28 (dd, 
3
J1,2 =4.7 Hz, 
3
J2,3 = 8.4 Hz, 1H, H-2), 5.41 (m, 1H, H-4), 9.72 (m, 1H, 
CHO). 13C NMR (CDCl3, 125.8 MHz) !: 20.63, 20.67, 20.70 (4C, 4 CH3), 41.94 (CH2CHO), 60.82 (C-6), 
66.62 (C-1), 66.88 (C-4), 67.72 (C-3), 67.84 (C-2), 69.67 (C-5), 169.61, 169.72, 169.88, 170.63 (4 C=O), 
198.31 (CHO). 
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2,3,4,6-Tetra-O-acetyl-!-D-galactopyranosyl ethanoic acid: A solution of 2,3,4,6-tetra-O-acetyl-!-D-
Galactopyranosyl aldehyde (4.74 mmol) in tert-butanol (20 ml) and a solution of KH2PO4 (1.25 M, 8 ml) 
were added to a vigorously stirred solution of KMnO4 (1 M, 9 ml). The mixture was stirred for 20 min. A 
solution of saturated Na2SO3 was added dropwise until KmnO4 was neutralized, yielding out a brown 
precipitate of MnO2 which was filtrated on Celite and washed with ethanol (2 ' 25 ml). Ethanol was then 
removed from the filtrate under reduced pressure and the remaining solution was acidified to pH=3 using 
1n HCl, then extracted with dichloromethane (4 ' 30 ml). The combined extracts were concentrated and 
dried under high vacuum to yield a white foam (4.31 mmol, 91%). 
1H NMR (CDCl3, 500.1 MHz) !: 2.04 (s, 6H, 2 CH3), 2.07 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.63 (dd, 
3
J = 5.6 
Hz, 2J = 15.7 Hz, 1H, CH2CO2H), 2.72 (dd, 
3
J = 8.9 Hz, 2J = 15.6 Hz, 1H, CH2CO2H), 4.10-4.17 (m, 2H, H-
5, H-6a), 4.24 (dd, 3J5,6b = 6.9 Hz, 
2
J6a,6b = 10.7 Hz, 1H, H-6b), 4.70 (m, 1H, H-1), 5.17 (dd, 
3
J3,4 = 3.3 Hz, 
3
J2,3 = 8.9 Hz, 1H, H-3), 5.33 (dd, 
3
J1,2 = 5.0 Hz, 
3
J2,3 = 8.9 Hz, 1H, H-2), 5.43 (m, 1H, H-4). 
13C NMR 
(CDCl3, 125.8 MHz) !: 20.65, 20.65, 20.70 (4C, 4 CH3), 33.02 (CH2CO2H), 61.04 (C-6), 67.04 (C-4), 67.56 
(C-2), 67.77 (C-3), 68.73 (C-1), 69.45 (C-5), 169.57, 169.85, 169.98, 170.65 (4 C=O), 174.90 (CO2H). 
 
 
DOTA-Gal-NAPamide: 2,3,4,6-Tetra-O-acetyl-!-D-galactopyranosyl ethanoic acid (2 eq) in DMF was 
preactivated with HATU (2 eq) for 10 min and added to a suspension of solid-phase-bound, partially 
protected NAPamide (1 eq peptide) containing DIPEA (4 eq). After 40 h at room temperature the resin was 
washed (DMF, MeOH, DMF) and the coupling cycle repeated. After washing of the resin, the peptide was 
cleaved using a 90% TFA-mixture25, precipitated in t-butyl methyl ether and purified by RP-HPLC (tR = 
12.51 min). The DOTA moiety was then coupled to the &-amino group of Lys11 and deprotected in acid-
treated (2 N HCl, >1 h) glassware using the standard procedure25. Deprotection of the acetyl groups of the 
carbohydrate moiety was carried out in liquid phase using hydrazine hydrate (diluted 1:9 in DMF, 1 mL/20 
mg peptide) for 5 h, and purified by RP-HPLC (Vydac semi-preparative column, tR = 14.80 min). Calculated 
monoisotopic mass: 1647.79 gmol-1; measured: 1647.5 gmol-1. 
 
DOTA-Gluc-NAPamide 
The glucose moiety was coupled to solid-phase bound NAPamide using the Maillard reaction which is a 
slow non-enzymatic chemical reaction of reducing sugars modifying amino groups of peptides, proteins, 
lipids and nucleic acids12, thus leading to the formation of Amadori products11,116,150. The resin containing 
NAPamide (1 eq) was stirred in the presence of "-D-glucose (10 eq) under reflux in a mixture of 
MeOH/AcOH (95:5) at 60°C for 72 h. After washing with MeOH and isopropanol, completion of the reaction 
was checked by a Kaiser test. The peptide was then cleaved from the resin, precipitated with t-butyl methyl 
ether and purified by RP-HPLC (tR = 8.94 min). Coupling and deprotection of DOTA followed standard 
procedures (see above), followed by purification with RP-HPLC (tR = 9.10 min). Calculated monoisotopic 
mass: 1605.6 gmol-1; measured: 1605.5 gmol-1. 
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DOTA-Mtr-NAPamide 
The maltotriose moiety was coupled to solid-phase-bound NAPamide using the Maillard reaction, followed 
by the addition and deprotection of DOTA, as described above for DOTA-Gluc-NAPamide. RP-HPLC 
yielded the product peak at tR = 7.80 min. Calculated monoisotopic mass: 1930.03 gmol
-1; measured: 
1930.1 gmol-1. 
 
DOTA-[Asp(Gal)
2
]-NAPamide 
To the solid-phase-bound partial NAPamide sequence His-D-Phe-Arg-Trp-Gly-Lys-resin (with side-chain 
protection) Fmoc-Asp(1,2:3,4-diisopropylidene-6-amino-!-D-galactosyl)-OH and, subsequently, Fmoc-Nle-
OH were coupled manually using the HOBt-DIPC method. After cleavage of Fmoc, the N-terminal acetyl 
group was introduced to the peptide-resin (1 eq, suspended in a very small amount of DMF) by the addition 
of p-nitrophenyl acetate (2 eq) activated by HOBt (1 eq). After 24 h the resin was filtrated and washed 5' 
with DMF and 4' with isopropanol. The peptide was cleaved from the resin using a 90% TFA-mixture, 
precipitated and purified by RP-HPLC (Vydac analytical column, tR = 13.71 min). The DOTA moiety was 
then coupled to the &-amino group of Lys11 and deprotected as described above. RP-HPLC on the Waters 
Symmetry analytical column yielded the product peak at tR = 10.68 min. Calculated monoisotopic mass: 
1646.8 gmol-1; measured: 1646.8 gmol-1. 
 
N!-DOTA-[Lys(Gluc)
8
]-NAPamide 
Solid-phase bound NAPamide was first N-terminally extended by DOTA, cleaved from the resin and then 
Gluc was attached to the &-amino group of Lys11. Protected tri-t-Bu-DOTA (1.2 eq) was preincubated with 
HATU (1.4 eq) in DMF (~1ml) for 10 min and added in five portions (in 5-min intervals) to the peptide-resin 
suspension (1 eq) in DMF containing DIPEA (1.5 eq). After 1 h, 0.6 eq of tri-t-Bu-DOTA and 0.7 eq of 
HATU were added and the reaction was continued for another hour. The peptide was then cleaved from the 
resin and the chelator complex was simultaneously deprotected using the standard 90% TFA-mixture. After 
precipitation, the peptide was purified by RP-HPLC (tR = 9.50 min) and lyophilized. The carbohydrate 
moiety was coupled using a slightly modified Maillard reaction: N!-DOTA-NAPamide (1 eq) and "-D-glucose 
(10 eq) were stirred for only 45 h at 60°C under reflux and an N2-atmosphere using a mixture of 
MeOH/AcOH (95:5). Completion of the reaction was checked by a Kaiser test. The peptide was then 
directly purified by RP-HPLC (tR = 8.59 min) and lyophilized. Calculated monoisotopic mass: 1605.75 
gmol-1; measured: 1605.8 gmol-1. 
 
DOTA-NAPamide-Gal 
NAP (Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys) was assembled on TentaGel S TRT-Lys(Boc)-Fmoc resin 
containing an acid-labile linker producing a free C-terminal acid under very mild acid cleavage conditions, 
without deprotection of the side-chains. The free N! group of Nle was acetylated as described above and 
the peptide cleaved from the resin using dichloromethane DCM/TFE/AcOH 7:2:1 (1 ml/0.1 g of resin; 1 h). 
The solvent volume was reduced by careful evaporation and the peptide precipitated by the addition of 10 
volumes of ice-cold diethyl ether and purified by RP-HPLC (tR = 21.32 min). Calculated monoisotopic mass: 
1851.21 gmol-1; measured: 1850.69 gmol-1. The peptide (1 eq) was dissolved in DMF and the free C-
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terminal –COOH group preactivated  with HATU (2 eq) for 10 min. 1-Amino-1-deoxy-"-D-galactose (2 eq) 
and DIPEA (4 eq) were added, the mixture was agitated for 1 h and then left at room temperature 
overnight. Purification by RP-HPLC (tR = 20.95 min) and lyophilization. Calculated monoisotopic mass: 
1770.05 gmol-1; measured: 1770.10 gmol-1. Side-chain protecting groups were now cleaved using a 94% 
TFA-mixture (2 h) containing only 1% thioanisole which would keep the formation of side-products minimal. 
Solvents were removed by careful evaporation with the help of added diethyl ether as solvent carrier. The 
peptide was dissolved by consecutive addition of 20% AcOH, H2O and CH3CN and purified by RP-HPLC (tR 
= 9.90 min). Finally, the DOTA moiety was coupled to the &-amino group of Lys11 and deprotected using 
standard procedures as described above. Purification by RP-HPLC (tR = 10.12 min). Calculated 
monoisotopic mass: 1647.79 gmol-.1; measured: 1648.0 gmol-1. 
 
 
Radioligands 
 
111
In-Labeled peptides 
Incorporation of 111In into DOTA-peptides was performed by the addition of 55.5 MBq of 111In-Cl3 
(Mallinckrodt, Petten, The Netherlands; stock concentration: 370 MBq/ml) to the DOTA-peptides (10 nmol) 
dissolved in 54 µl of acetate buffer (0.4 mol/L, pH=5) containing 2 mg of gentisic acid. After 10 min of 
incubation at 95°C, the radiolabeled DOTA-peptides were purified on a small reversed-phase cartridge 
(Sep-Pak C18, Waters), with first sodium acetate buffer (pH=7), then ethanol, as solvents. The purity of the 
resulting radioligands was assessed by RP-HPLC on a Jasco PU-980 chromatography system, connected 
to a Radiomatic 500TR LB506C1 #-detector (Packard) and a Spherisorb ODS2/5-µm column under the 
following conditions: eluent A = 0.1% TFA in water; eluent B = 0.1% TFA in acetonitrile; gradient = 0-2 min, 
96% A; 2-22 min, 96%-45% A; 22-30 min, 45%-25% A; 30-32 min, 25% A; 32-34 min, 25%-96% A; flow 
rate, 1.0 mL/min. The specific activity of the radioligand was always >7.4 GBq/µmol. 
 
125
I-Labeled peptide 
NDP-MSH was iodinated using the IODO-GEN® method. NDP-MSH (12.14 nmol) was mixed with 37 MBq 
Na125I (Amersham Bioscience, Otelfingen, Switzerland; stock concentration: 3.7 GBq/mL) in 60 µl 
phosphate buffer (0.3 M, pH=7.4) in IODO-GEN®-precoated tubes (Pierce, Rockford, IL, USA). After 15 min 
incubation at room temperature under shaking, the mixture was loaded on a small reversed-phase 
cartridge (Sep-Pak C18, Waters), washed with water and acetic acid (0.5 M) and finally the peptide was 
eluted with methanol and collected. The fractions containing 125I-NDP-MSH were supplemented with 
dithiothreitol (1.5 mg/mL) and stored at –20°C. Before each binding experiment, an additional purification 
was performed by RP-HPLC/#-detection. 
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Cell culture 
 
The mouse B16F1 melanoma cell line101 was cultured in modified Eagle!s medium (MEM; Biochrom AG, 
Germany) supplemented with 10% heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 1% 
nonessential amino acids, 1% vitamin solution, 50 UI/mL penicillin and 50 µg/mL streptomycin (all from 
Gibco/Invitrogen, Carlsbad, CA, USA) at 37°C in an atmosphere of 95% air/5% CO2. For expansion or 
experiments, the cells were detached with 0.02% ethylenediaminetetraacetic acid (EDTA) in PBS (150 
mmol/L, pH=7.2-7.4). 
The human HBL melanoma cell line was cultured in modified RPMI medium (Biochrom AG) supplemented 
with 10% heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 50 UI/mL penicillin and 50 µg/mL 
streptomycin in the same culture and expansion conditions as B16F1 cells. 
 
 
In vitro binding assay with B16F1 or HBL cells 
 
Competitive binding experiments were performed by incubating MC1R-expressing B16F1 or HBL cells in 
microplates with the radioligand 125I-NDP-MSH and a series of dilutions of competitor peptides (from 1 ' 10-
6 to 1 ' 10-12 mol/L) as described previously111. Triplicates of 100 µL B16F1 or HBL cell suspensions 
adjusted to 4 ' 106/mL were incubated in 96-well U-bottom microplates (Falcon 3077) for 3 h at 15°C 
(B16F1) or for 2 h at 37°C (HBL) with 50 µL of 125I-NDP-MSH (50,000 cpm). The binding medium consisted 
of MEM with Earle!s salts (Biochrom AG), 0.2% bovine serum albumin and 1,10-phenanthroline (0.3 
mmol/L; Merck). The reaction was stopped by incubation on ice for 10 min, and the cell-bound radioactivity 
was collected on filters by use of a cell harvester (Packard, Meriden, CT, USA). The radioactivity was 
counted by use of a TopCount microplate scintillation counter (Packard) and the 50% inhibitory 
concentration (IC50) was calculated with the Prism software (GraphPad Software). 
 
 
In vitro melanin assay 
 
The biological activity of the !-MSH derivatives was assessed with an in situ melanin assay. B16F1 cells 
(2,500 per well, 100 µl) were distributed in cell culture flat bottom 96-well plates in medium consisting of 
MEM without phenol red and supplemented with 10% heat-inactivated fetal calf serum, 2 mmol/L L-
glutamine, 0.31 mmol/L L-tyrosine, 1% nonessential amino acids, 1% vitamin solution, 50 U/mL penicillin 
and 50 µg/mL streptomycin. After overnight incubation in a cell incubator at 37°C, serial concentrations of 
!-MSH derivatives, ranging from 1 x 10-8 to 1 x 10-12 in 100 µL volume, were added and incubation was 
prolonged for an additional 72 h. Melanin production was then monitored through measurement of the 
absorbance at 310 nm in a microplate reader (Spectra MAX 190, Molecular Devices, Menlo Park, CA). 
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In vitro internalization assay 
 
B16F1 cells were seeded in 6-well plates and incubated overnight at 37°C in B16F1 cell culture medium. 
For the experiments, B16F1 medium was removed and replaced by 1 mL Mouse Binding Medium (MBM) 
internalization buffer, consisting of MEM with Earle!s salts (Biochrom AG, Germany), 0.2% bovine serum 
albumin and 1,10-phenanthroline (0.3 mmol/L; Merck). After 1 h incubation at 37°C, 74 kBq of radioligand 
(111In-labeled peptides) were added and the plates were incubated for different times. Nonspecific 
internalization was assessed by addition of 50 µL of a 1 µM cold !-MSH solution. Samples were taken from 
the supernatant after 0.5, 2 and 3.5 h to determine the total dose added, immediately followed by extensive 
washings of the cells (6x) using pre-warmed (37°C) MBM to remove the excess of radioligand. The cells 
were then incubated in 2 ml ice-cold acid buffer (acetate-buffered HBSS, pH 5) for 10 min to dissociate 
surface-bound ligand. After collection of the acidic fraction, cells were rinsed once with MBM and the 
washing pooled with the acid buffer fraction. The cells were then washed once more with MBM (37°C), 
lysed in 1% Triton X-100 and finally transferred to tubes for quantification. The radioactivity of all collected 
fractions was determined in a Cobra II Auto-Gamma #-counter (Packard). One counting plate was 
submitted to the same treatment as the plate incubated for the longest time. Cells from this plate were not 
lysed, but detached (EDTA) and counted. Results of the experiments are expressed as percentile of the 
added dose per million cells. 
 
 
Biodistribution in B16F1 tumor-bearing mice and stability of radioligands after kidney excretion 
 
All animal experiments were performed in compliance with Swiss regulations for animal welfare. Female 
B6D2F1 mice (C57BL/6 ' DBA/2 F1 hybrids; breeding pairs obtained from IFFA-CREDO) were implanted 
subcutaneously with 0.5 million B16F1 cells in Phosphate Buffer Saline (PBS) to generate a primary skin 
melanoma. One week later, 200 µL containing 185 kBq of radioligand diluted in PBS/BSA (pH 7.4) were 
injected intravenously in the lateral tail vein of each mouse. To allow determination of non-specific uptake, 
50 µg !-MSH were co-injected with the radioligand in some mice. The animals were killed at the indicated 
time points; organs and tissues of interest were dissected and rinsed of their excess blood, weighed, and 
their radioactivity was measured in a #-counter. The percentage of the injected dose per gram tissue 
(%ID/g) was calculated for each tissue. The total counts injected per animal were calculated by 
extrapolation from counts of a standard taken from the injected solution for each animal. 
As part of the biodistribution experiments, samples of urine were collected from melanoma-bearing mice 
10, 15, 20 min and 4 h after injection of 185 kBq 111In-DOTA peptide and kept frozen at -80°C until use. 
Urine (1 vol) was mixed with methanol (2 vol) to precipitate the proteins and was analyzed by RP-HPLC/#-
detection under the conditions mentioned above. 
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Analysis of data 
 
Unless otherwise stated, results are expressed as mean ± standard error of the mean (SEM). Statistical 
evaluation of the binding assays was performed by using Student!s t-test. For the analysis of data collected 
during biodistribution experiments, the mean value obtained for each organ was compared individually to 
each DOTA-NAPamide organ values by using Student!s t-test, and the results were corrected with the 
Bonferroni correction. A P-value of <0.05 was considered statistically significant. The area under the curve 
(AUC) was calculated for a particular time period (4-48 h) using the GraphPad Prism software; mean tissue 
uptake values at each time point were used for this calculation. 
 
 
RESULTS 
 
Synthetic glycosylated DOTA-NAPamide analogs 
 
The preparation of glycosylated DOTA-NAPamide analogs followed four different strategies: (1) synthesis 
of a galactopyranosyl-ethanoic acid for straightforward attachment to the N!-terminal amino group of the 
peptide, as indicated for DOTA-Gal-NAPamide (Figure 43 and Figure 44), requiring a three-step synthesis 
of the glyco-derivative (allylation of its anomeric center, followed by ozonolysis and oxidation16); (2) Maillard 
reaction of "-D-glucose or maltotriose with the N!-terminal or the N&-side-chain amino group, as exemplified 
for DOTA-Gluc-NAPamide, DOTA-Mtr-NAPamide, or N!-DOTA-[Lys(Gluc)8]-NAPamide (Fig. 1); (3) use of 
the Fmoc-Asp(1,2:3,4-diisopropylidene-6-amino-!-D-galactosyl)-OH building block for a direct introduction 
of the carbohydrate during solid-phase assembly into the side-chain position of residue 2 of DOTA-
[Asp(Gal)2]-NAPamide; and (4) functionalization of the C-terminal amide as glyco-amide, by attachment of 
1-amino-1-deoxy-"-D-galactose to the free carboxy terminus of a side-chain protected peptide., followed by 
deprotection and attachment of the DOTA group at the N&-side-chain of Lys 8. The final product, DOTA-
NAPamide-Gal was obtained in high purity, however in low yield. The other syntheses also produced 
peptides of high purity and in higher yields. 
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!-MSH: 
  1              13 
             Ac—Ser—Tyr—Ser—Met—Glu—His—Phe—Arg—Trp—Gly—Lys—Pro—Val—NH2 
 
 
!-MSH derivatives: 
               1              8 
W—HN—Nle—Asp—His—D-Phe—Arg—Trp—Gly—Lys—CO—Z 
   |  | 
     CO   NH 
    |   | 
                                X   Y 
 
Peptide W X Y Z 
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Figure 43: Structures of the glycopeptides used in this study. Ac = acetyl group. 
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Figure 44: Structure of DOTA-Gal-NAPamide. 
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Receptor binding 
 
MC1R affinity of the glycated NAPamide analogs was assessed by competition binding assays against 125I-
NDP-MSH on both murine B16F1 and human HBL melanoma cell lines, using !-MSH and DOTA-
NAPamide as reference compounds.  All peptides showed very good binding affinities to mouse and 
human MC1R with IC50s ranging from 0.45 to 7.61 nmol/L (Table 10). DOTA-[Asp(Gal)
2]-NAPamide 
displayed the highest affinity for the MC1R on both B16F1 and HBL cells and exceeded that of DOTA-
NAPamide by a factor of 3 to 3.5. DOTA-NAPamide-Gal was also slightly more active than DOTA-
NAPamide. DOTA-Gal-NAPamide and DOTA-Gluc-NAPamide displayed slightly lower IC50s than DOTA-
NAPamide, while the affinity of DOTA-Mtr-NAPamide and N!-DOTA-[Lys(Gluc)8]-NAPamide was about 2- 
to 3.5-fold lower than that of DOTA-NAPamide. The glycopeptides without the DOTA chelator all showed 
markedly higher affinity (data not shown). 
 
Table 10: MC1R affinity and biological activity of glycopeptides, compared to !-MSH and DOTA-NAPamide. 
 
MC1R Affinity and Biological Activity of !-MSH Analogs on B16F1 and HBL cells 
!-MSH analogs B16F1 IC50 (nmol/L)
*
 HBL IC50 (nmol/L)
*
 rEC50 (!-MSH=1)
†
 
!-MSH 1.50 ± 0.14 1.91 ± 0.26 1 
DOTA-NAPamide 1.38 ± 0.35 3.09 ± 1.11 0.66 ± 0.35 
DOTA-Gal-NAPamide 1.62 ± 0.20 5.08 ± 0.25 0.63 ± 0.13 
DOTA-Gluc-NAPamide 1.90 ± 0.07 5.57 ± 0.58 0.34 ± 0.03 
DOTA-Mtr-NAPamide  2.95 ± 0.17‡  7.61 ± 0.66‡ 0.62 ± 0.37 
DOTA-[Asp(Gal)2]-NAPamide  0.45 ± 0.01‡ 0.88 ± 0.08 0.26 ± 0.03 
N$-DOTA-[Lys(Gluc)8]-NAPamide  4.58 ± 0.42‡ 5.61 ± 2.17 1.02 ± 0.21 
DOTA-NAPamide-Gal 1.24 ± 0.22 2.00 ± 0.13 0.48 ± 0.17 
_________ 
*MC1R affinity of !-MSH analogs was assessed by competition binding experiments with B16F1 or HBL cells and 125I-
NDP-MSH as radioligand (n=3-16) 
†Biological activity of !-MSH analogs was determined in melanin assay with B16F1 cells, and results are expressed as 
relative concentration inducing half-maximal response (rEC50, n=3-10) normalized on !-MSH=1. 
‡
P < 0.05 vs. DOTA-NAPamide 
 
 
Biological activity 
 
In the melanin assay using B16F1 cells, all DOTA-glycopeptides, except for N!-DOTA-[Lys(Gluc)8]-
NAPamide, displayed higher biological (agonist) activity than DOTA-NAPamide, all in the picomolar to 
range. In order to compare the EC50 of different experiments, these were normalized against the EC50 of 
the reference compound !-MSH whose rEC50 was defined as 1 (Table 10). DOTA-[Asp(Gal)
2]-NAPamide 
and DOTA-Gluc-NAPamide showed the lowest rEC50s with 0.26 and 0.34, respectively. The values of the 
other glycopeptides were comparable to that of DOTA-NAPamide. The induction of melanin synthesis by 
B16F1 cells started at doses matching their IC50s and lower. Only DOTA-Mtr-NAPamide showed a slightly 
worse rEC50, but still matching those of !-MSH. Again, DOTA-[Asp(Gal)
2]-NAPamide exhibited the best 
behavior in vitro. 
GLYCOPEPTIDES 
132
Internalization assay 
 
Internalization assays were carried out to determine if and how fast the glycopeptides were internalized by 
B16F1 cells. The results were excellent, all glycopeptides being almost totally internalized in 2 h or less. As 
an example, Figure 45 shows the internalization kinetic of DOTA-Gal-NAPamide, which reached a plateau 
after 2 h when internalization of the peptide was almost total. These data show that internalization of the 
peptide by tumor cells cannot be an issue regarding the in vivo tumor uptake. 
 
 
 
Figure 45: Exemplary internalization experiment with DOTA-Gal-NAPamide. 
 
 
Biodistribution in melanoma-bearing mice 
 
Table 2 shows the tissue distributions of the different 111In-labeled, glycated DOTA-NAPamide peptides in 
comparison with [111In]-DOTA-NAPamide at 4, 24 and 48 h after injection of the radioligand. Co-injection of 
an excess of !-MSH to block MC1R reduced the 4-h tumor uptake of DOTA-Gal-NAPamide by >90%, of 
DOTA-Mtr-NAPamide by 89%, of N!-DOTA-[Lys(Gluc)8]-NAPamide by 86%, of DOTA-Gluc-NAPamide by 
80%, of DOTA-NAPamide-Gal by 77%, and of DOTA-[Asp(Gal)2]-NAPamide by 75%, indicating that all 
these derivatives are taken up by melanoma cells through receptor-mediated internalization. DOTA-Gal-
NAPamide showed the highest tumor uptake among the glycopeptides, comparable to that of DOTA-
NAPamide (Figure 46), followed by DOTA-Mtr-NAPamide, DOTA-NAPamide-Gal, DOTA-[Asp(Gal)2]-
NAPamide, N!-DOTA-[Lys(Gluc)8]-NAPamide and DOTA-Gluc-NAPamide. The ranking of melanoma 
uptake of the different glyco-NAPamide peptides did not correspond with the in vitro MC1R binding affinity. 
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Table 11: Tissue distribution, including melanoma tumor, of glycated 
111
In-labeled !-MSH analogs and DOTA-
NAPamide 4, 24 and 48h after injection. 
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Clearance of 111In from the kidneys was found to be quite a slow process, as also reported for other 
peptides. Indeed, 46% of the radioactivity measured in the kidneys 4 h after injection of DOTA-Gal-
NAPamide was still present after 24 h, and 26% after 48 h. For DOTA-[Asp(Gal)2]-NAPamide the values 
were 49% and 33%, for DOTA-Mtr-NAPamide 34% and 27%, for DOTA-Gluc-NAPamide 65% and 43% 
and for N!-DOTA-[Lys(Gluc)8]-NAPamide 66% and 35%. The slowest clearance from the kidneys was 
observed for DOTA-NAPamide-Gal whose values were 99% and 34% and hence was opposed to the 
expectation of a marked reduction by glycating the C-terminal amide of Lys8. 
 
 
Figure 46: Biodistribution profile of [
111
In]-DOTA-Gal-NAPamide. 
 
Radioactivity released from the tumor was faster than from the kidneys, with 25% of the radioactivity 
measured after 4 h still present after 24 h and 11% after 48 h for DOTA-Gal-NAPamide, and slightly higher, 
but comparable values for DOTA-[Asp(Gal)2]-NAPamide, DOTA-Gluc-NAPamide, N!-DOTA-[Lys(Gluc)8]-
NAPamide and DOTA-NAPamide-Gal, in part due to their lower overall tumor uptake. Indeed, DOTA-Mtr-
NAPamide, which displayed an almost similar tumor uptake as DOTA-Gal-NAPamide after 4 h, exhibited 
values of 22% and 8% at 24 h and 48 h. 
 
The glycopeptides with the highest in vitro binding affinity displayed a lower in vivo accumulation in 
melanoma than would have been predicted from their in vitro potency. DOTA-Gal-NAPamide showing an 
average receptor binding affinity comparable to DOTA-NAPamide, delivered a more favorable 
biodistribution profile with higher tumor uptake after 4 h (8.30% ± 1.22%ID/g) and higher tumor-to-kidney 
ratio after 4 h (1.87 ± 0.15) than any other glycopeptide. Indeed, DOTA-Gal-NAPamide exhibited a 4-48 h 
AUC tumor-to-kidney ratio of 1.34 (Figure 47) which exceeds that of DOTA-NAPamide (1.11) by 17%, 
making it one of the best radiolabeled !-MSH analogs synthesized so far. 
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Figure 47: Tumor-to-kidney ratios of the glycopeptides compared to DOTA-NAPamide, calculated from the 
AUC (4-48h). 
 
 
DISCUSSION 
 
This study focused on the influence of introducing different types of carbohydrates at N-terminal, C-terminal 
and side-chain positions of the !-MSH derivative DOTA-NAPamide. In view of the reports that glycosylation 
of peptides or proteins would reduce re-uptake by the tubular system of the kidneys281,303, our first attempt 
was to study a DOTA-NAPamide derivative whose C-terminal amide was glycosylated. Previous 
observations in our lab (unpublished data) demonstrated that an important metabolite of [111In]DOTA-
NAPamide was H-Lys([111In]DOTA)-NH2 which was regularly observed in the urine collected from mice 
treated with this peptide. However, DOTA-NAPamide-Gal showed a higher and much longer kidney 
retention than all other glycopeptides which we investigated. Most likely, the C-terminal carbohydration led 
to increased re-uptake and trapping of the peptide or its metabolites in endosomes in tubular cells of the 
kidney. 
 
Glycation of the amino acid side-chains of Asp2 or Lys8 does not seem to be a good alternative option. 
DOTA-[Asp(Gal)2]-NAPamide and N!-DOTA-[Lys(Gluc)8]-NAPamide both displayed slightly lower tumor 
uptake and higher kidney uptake than the other glycopeptides. Again, the increased kidney uptake may be 
the result of higher rate of internalization and marked retention by tubular cells. A precise molecular 
explanation would require a detailed analysis, particularly in view of the very high in vitro potency of DOTA-
[Asp(Gal)2]-NAPamide which would rule out steric hindrance by the side-chain galactosyl moiety. 
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Finally, three different glycopeptides bearing a glucose, galactose or maltotriose moiety at their N-terminal 
end were then examined in order to assess the influence of the type of sugar on the pharmacokinetics. The 
derivative with a glucose residue displayed poor pharmacokinetic properties, displaying an in vivo tumor-to-
kidney ratio of its AUC (4-48 h) of only 0.60 (Figure 5), although it exhibited a similarly low kidney uptake 
after 4h (4.48 %ID/g) as [111In]DOTA-Gal-NAPamide. The analog with N-terminal maltotriose showed much 
better properties with a tumor-to-kidney ratio (4-48 h AUC) of 0.99. The tumor uptake was similar to that of 
[111In]DOTA-NAPamide, but the higher kidney uptake led to a lower the ratio as compared to DOTA-
NAPamide. The most encouraging data were obtained with [111In]DOTA-Gal-NAPamide which exhibited 
relatively highest melanoma uptake and lowest kidney uptake in vivo, leading to a tumor-to-kidney ratio 
which exceeded that of [111In]DOTA-NAPamide by a factor of about 1.2. This advance is very valuable, as 
AUC tumor-to-non-target-tissue ratios are fundamental for future therapeutic applications, nephrotoxicity 
remaining the main issue of radiolabeled !-MSH analogs. 
 
In conclusion, we demonstrated that introduction of different types of sugars at various positions along the 
sequence of 111In-labeled NAPamide analogs affected their in vitro binding affinities and their in vivo 
pharmacokinetic behavior. It is noteworthy that carbohydration generally did not reduce the binding affinity 
when compared to non-glycosylated reference peptide. Kidney re-uptake and retention, however, was 
increased with side-chain and C-terminal sugar groups, but decreased with an N-terminal galactosyl group. 
This compound, DOTA-Gal-NAPamide, exhibited favorable pharmacokinetical data. Its high melanoma 
uptake and low kidney retention, and above all its improved tumor uptake to kidney uptake ratio calculated 
from the AUC, opens the doors to a new class of derivatives for melanoma targeting.  
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5 Negatively charged peptides 
5.1 Manuscript to be submitted 
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ABSTRACT 
 
Both melanotic and amelanotic melanomas overexpress receptors (melanocortin type 1 receptors, MC1R) 
for !-melanocyte stimulating hormone (!-MSH) at their surface. Radiolabeled !-MSH analogs have a great 
potential as diagnostic or therapeutic tools for the treatment of malignant melanoma. They show high 
affinity for MC1R in vitro, high tumor uptake in vivo, but suffer from a high kidney uptake and retention in 
vivo. Several structural modifications were adopted in the past, either to enhance the tumor uptake or to 
reduce the kidney uptake of the radiolabeled analogs, but were unsuccessful at improving their 
pharmacokinetical behavior. Various studies showed that the introduction of negative charges into peptides 
had a strong impact on their general in vivo behavior, and particularly on their excretion way. More 
specifically, it was shown that their kidney uptake could be significantly reduced. For radiolabeled !-MSH 
analogs, we have shown earlier and confirmed in this study with a derivative carrying two negative charges 
towards its C-terminal end that the introduction of negative charges at the C-terminus did not deliver any 
improvement in kidney excretion. Indeed, the derivative used in this study lost its receptor affinity without 
reducing the kidney uptake. Suspicion that the localization of the negative charge could be a fundamental 
parameter led to the development of a new derivative carrying an additional negative charge towards the N-
terminal end of the peptide. DOTA-phospho-!-MSH2-9, bearing a phosphotyrosine in the second position, 
was evaluated in a comparative study using DOTA-NAPamide, one of the best linear !-MSH analogs, as 
reference. Although its MC1R affinity was slightly lower than that of DOTA-NAPamide, its biodistribution 
profile was markedly improved. A significant reduction of the kidney uptake was observed 4 h after injection 
of the tracer, yielding a 1.6-fold lower accumulation than DOTA-NAPamide. The tumor-to-kidney ratio 
calculated from the AUC (4-48 h) could consequently be improved, reaching 1.42 for the new derivative 
(1.11 for DOTA-NAPamide). Therefore, localization of negative charges appears to be crucial for 
pharmacokinetics, as DOTA-phospho-MSH2-9 delivered the best tumor-to-kidney ratio ever reached for 
linear 111In-labeled !-MSH analogs, and is therefore very promising. 
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INTRODUCTION 
 
Cutaneous malignant melanoma has become the most common malignancy among young adults79, and its 
prognosis is usually poor. As this type of tumor overexpresses melanocortin type-1 receptors (MC1R) at its 
surface122,284, it represents a good candidate for targeting using radiolabeled tracers. The hormone !-MSH 
is the native ligand of MC1R, and peptide analogs with better binding affinities were already synthesized in 
the past, such as [Nle4, D-Phe7]-!-MSH (NDP-MSH)267 or DOTA-NAPamide114. Such peptides, depending 
on the isotope used for their labeling, may be used either in diagnostic or therapeutic applications, as it was 
shown for somatostatin analogs37. However, !-MSH analogs suffer from the disadvantage that their 
benefits of excellent tumor selectivity is diminished by a high kidney uptake60,114,115. Several strategies were 
developed to overcome the kidney uptake, such as the use of different radioisotopes114, variations in the 
position of the chelate (DOTA), amidation of the C-terminal end115, co-injection of basic amino acids32,34, 
cyclization124 and dimerization25. Unfortunately, all these methods were unsuccessful in sufficiently 
improving the tumor-to-kidney ratio of the injected radiopeptides in order to allow their use as diagnostic or 
therapeutic tools. 
 
Various investigations in the past showed the crucial role of negatively charged peptides (or other 
molecules) on their pharmacokinetics, more specifically on their excretion way and clearance time. At the 
level of glomerular filtration, it appears that capillary cells, in addition to their size-exclusion function, seem 
to play a role in restricting transport of polyanions. As early as in 1980, Deen et al.78 discussed a 
“theoretical model for glomerular filtration of charged solutes”, which described electrostatic exclusion as 
the mechanism by which polyanions were less prone to pass through the capillary wall than neutral 
macromolecules, and the latter less than polycations. Depending on the drug, this could have a negative 
effect on pharmacokinetics by letting the drug recirculate several times before being finally excreted or 
metabolized by other organs. Thus, its toxicity might be enhanced. 
 
It has been shown that the surface of tubular cells is negatively charged, and that electrostatic interactions 
at this level contributed greatly to the reuptake of molecules in the kidney33. Christensen et al. revealed the 
influence of the total molecular charge and the distribution of the local charges on protein binding by the 
luminal membrane, and thus on their subsequent endocytosis by the proximal tubule67. They showed that 
cationic or neutral molecules or proteins were much more (up to 5 times more) reabsorbed by the proximal 
tubule than their anionic counterparts. Lawrence et al. also showed that the increased urinary clearance 
observed with negatively charged bovine albumin derivatives was due to a large reduction in the amount of 
protein absorbed by the proximal tubular epithelium. They also showed that this reduction in reuptake was 
able to swamp the effects of the lower glomerular ultrafiltration mentioned above181. Kok et al. also 
confirmed these results by investigating the effect of the presence of positive charges on pharmacokinetics 
of low molecular weight lysozyme. They compared two modified lysozyme derivatives, one carrying six free 
primary amino groups, and the other with these six amino groups “blocked” by succinylation. They 
observed a dramatic increase in excretion for the succinylated derivative, suggesting that reduction of the 
positive charge has a positive effect on urinary excretion168. 
NEGATIVELY CHARGED PEPTIDES 
140
In the field of somatostatin, Akizawa et al. confirmed the influence of negative charges on the excretion of 
radiolabeled peptides
7
. Introduction of differently charged amino acids close to the DTPA-chelate involved 
differences in kidney uptake and retention, and confirmed the findings of the studies mentioned earlier 
showing the positive impact of negative charges on pharmacokinetics, especially concerning kidney 
excretion. The derivative carrying L-Asp next to the chelate showed the lowest kidney radioactivity levels of 
the tested peptides, and conserved its target affinity. 
These promising findings led us to consider the introduction of negative charges into !-MSH analogs. 
Derivatives carrying one or two negative charges through succinimidyl groups at their C-terminal end were 
synthesized earlier in our group and did not show any amelioration of their pharmacokinetic properties. 
They carried, though, the DOTA moiety at their N-terminal end. A new derivative bearing two negative 
charges through introduction of two D-Asp at its C-terminus (DOTA-NAP-D-Asp-D-Asp) was synthesized 
and tested, with the expectation that the C-terminal Lys(DOTA)-NH2 moiety observed in the urine of treated 
mice in previous biodistribution experiments (unpublished data) would be more extensively excreted. 
Additionally, in order to assess the importance of the localization of the negative charges on 
pharmacokinetics, another novel derivative carrying an additional negative charge (compared to DOTA-
NAPamide) through a phosphate functional group positioned towards the N-terminal end of the peptide and 
delivering a global net charge of -1, was synthesized and tested. 
 
 
!-MSH: 
           1         13 
             Ac—Ser—Tyr—Ser—Met—Glu—His—Phe—Arg—Trp—Gly—Lys—Pro—Val—NH2 
 
 
 
  
DOTA-NAPamide 
                4      11 
Ac—Nle—Asp—His—D-Phe—Arg—Trp—Gly—Lys—NH2 
     | 
            DOTA 
 
 
DOTA-NAP-D-Asp-D-Asp 
               4      11 
Ac—Nle—Asp—His—D-Phe—Arg—Trp—Gly—Lys—D-Asp—D-Asp—NH2 
    | 
       DOTA 
 
 
DOTA-Phospho-MSH2-9 
    2          9 
DOTA—Gly—Tyr—Nle—Asp—His—D-Phe—Arg—Trp—NH2 
               | 
             OPO3H2 
 
Figure 48: Structures of !-MSH, DOTA-NAPamide, DOTA-NAP-D-Asp-D-Asp and DOTA-Phospho-MSH2-9. 
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Experimental procedures 
 
Reagents 
 
!-MSH was received as gift from Novartis (Basel, Switzerland). [Nle4, D-Phe7]-!-MSH (NDP-MSH) was 
obtained from Bachem (Bubendorf, Switzerland). Fmoc-PAL-PEG-PS polystyrene resin was purchased 
from Applied Biosystems (Rotkreuz, Switzerland), TentaGel S AC-D-Asp(tBu)Fmoc resin from Rapp-
Polymere (Tübingen, Germany), 9-fluorenylmethoxycarbonyl-(Fmoc-)amino acids from Novabiochem 
(Läufelfingen, Switzerland), and 1,4,7,10-tetraazacyclododecane-1,4,7-tris-tert-butyl acetate-10-acetic acid 
(DOTA-tris(t-butyl ester)) from Macrocyclics (Dallas TX, USA). N-Succinimidyl iodoacetate and Iodogen 
tubes were from Pierce Biotechnology Inc. (Rockford IL, USA), Na125I (3.7 GBq/mL) from Perkin Elmer 
(Waltham MA, USA), 111InCl3 (370 MBq/mL) from Mallinckrodt (Petten, The Netherlands). 1,10-
Phenanthroline was bought from Merck (Darmstadt, Germany) and all other organic reagents were 
obtained from Fluka or Sigma (Buchs, Switzerland). All reagents were of highest purity available. Cell 
culture media were from Biochrom AG (Berlin, Germany) and Sigma (Buchs, Switzerland). Penicillin, 
streptomycin, vitamins and nonessential amino acids were bought from Gibco/Invitrogen (Carlsbad CA, 
USA) or Sigma (Buchs, Switzerland).  
 
 
Instrumentation 
 
Continuous flow peptide synthesis was carried out on a Pioneer peptide synthesizer from PerSeptive 
Biosystems Inc. (Framingham MA, USA). Analytical reversed-phase-(RP)-HPLC was performed on a PU-
980 system from Jasco Inc. (Easton MD, USA) with a Vydac 218TP54 C18 (5 µm, 4.6%250 mm) or a 
Phenomenex Jupiter  C18 300 Å (5µm, 4.6%250 mm) analytical columns. DOTA-NAPamide-D-Asp-D-Asp 
was chromatographed with a gradient between solvent A (0.1% TFA in H2O) and solvent B (0.1% TFA in 
70:30 acetonitrile/H2O). The 40-min gradient cycle consisted of the following parts: 95% A (0-2 min), 95-
70% A (2-10 min), 70-30% A (10-30 min), 30-5% A (30-34 min), 5% A (34-36 min), 5-95% A (36-38 min), 
95% A (38-40 min); the flow rate was 1 mL/min with the Vydac 218TP54 analytical column. UV absorption 
was recorded at 280 nm using a Jasco UV-1570 detector. DOTA-Phospho-MSH2-9 was chromatographed 
with the same gradient, but by replacing solvent A with NH4OAc 0.02 M. The analytical column used was 
the Penomenex Jupiter, and the UV absorption was recorded under the same conditions. Mass spectra 
were determined on a Finnigan LCQ Deca electrospray ion trap MS system. 
Purity of the radioligand was assessed by RP-HPLC using a dedicated Jasco PU-980 chromatography 
system bearing a Radiomatic 500TR LB506C1 #-detector (Packard, Meriden CT, USA) and equipped with a 
Spherisorb ODS2/5-µm column. Solvent A was 0.1% TFA in water; solvent B was 0.1% TFA in acetonitrile; 
the gradient consisted of 96% A (0-2 min), 96-45% A (2-22 min), 45-25% A (22-30 min), 25% A (30-32 
min), 25-96% A (32-34 min); the flow rate was 1.0 mL/min. A cell harvester (Packard) was used to collect 
cell-bound radioactivity from binding assays on filters. Their radioactivity was measured on a TopCount 
microplate scintillation counter (Packard). Radioactivity in internalization and biodistribution assays was 
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measured on a Cobra II Auto-Gamma #-counter (Packard). In biological activity assays, melanin content in 
cell culture media of each well was quantified on a Spectra Max 190 microplate reader (Molecular Devices, 
Menlo Park CA, USA) reading at 310 nm. 
 
 
Peptide synthesis 
 
General 
The peptides were synthesized using standard continuous-flow technology and Fmoc strategy. As solid-
phase support, flow-compatible Fmoc-PAL-PEG-PS polystyrene resin containing the acid-labile amide 
linker PAL (5-[(4-Fmoc-aminomethyl-3, 5-dimethoxyphenoxy]-pentanoic acid-
polyethyleneglycol/polystyrene; substitution 0.21 mmol/g) was used. The following protecting groups were 
used for o-protection: Trt for Cys, Boc for Lys and Trp, tBu for Asp and D-Asp, Pbf for Arg, and Trt for His. 
Manual Fmoc deprotection was realized with 20% piperidine in DMF (20 min), followed by a short wash 
with 20% piperidine/DMF and 5 washes with DMF; deprotection completion was assessed by a Kaiser test. 
Cleavage of the peptide from the resin was performed with a solution of 90% trifluoroacetic acid (TFA), 5% 
thioanisole, 4.5% H2O and 0.5% 1,2-ethanedithiol. After 2 h the solution was filtrated and the peptide 
precipitated with a 10-fold volume of t-Bu-methyl ether or diethylether. All reactions and manipulations with 
DOTA were carried out in acid-treated (1 M HCl, >1 h) glassware.  
 
DOTA-NAPamide 
NAPamide was synthesized according to the general methods described above. The peptide was N-
terminally acetylated before cleavage from the resin: for these means, p-nitrophenyl acetate (2 eq) pre-
activated with HOBt (1 eq) in DMF for 10 min was added to a suspension of the resin carrying NAPamide 
(1 peptide eq) and incubated for 24 h. The resin was filtrated and washed 5x with DMF and 4x with 
isopropanol. Cleavage from the resin and purification was done according to the methods described above. 
The DOTA moiety was coupled to the &-amino group of C-terminal Lys and the peptide conjugate 
deprotected (90% TFA-mixture, 4 h) and purified as described above. RP-HPLC on a Vydac C18 analytical 
column: tR = 17.5 min. Calculated monoisotopic mass: 1485.64 gmol
-1; found: 1485.65 gmol-1. 
 
DOTA-NAP-D-Asp-D-Asp 
Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-D-Asp-D-Asp-OH was synthesized on the peptide synthesizer 
according to the general methods. Its N-terminus was then acetylated by pre-activation of N-
hydroxybenzotriazole (HOBt) (1 eq) and p-nitrophenyl acetate (2 eq) for 10 min, reacting with the Fmoc-
deprotected on-support peptide (1 eq) for 24 h in as few DMF as possible. The conjugate was then cleaved 
with the 90%-TFA mixture mentioned above, precipitated in diethylether, purified by HPLC and lyophilized.  
RP-HPLC: tR = 16.1 min. Calculated monoisotopic mass: 1330.40 gmol
-1; found: 1327.3 gmol-1. 
Conjugation of the partially protected DOTA-tris(t-butyl ester) to the peptide derivative was performed by 
addition of a solution containing the deprotected peptide (1 eq) and DIPEA (N,N!-diisopropylethylamine; 2 
eq) in DMF to a solution containing DOTA-tris(t-butyl ester) (1 eq) which had been preincubated for 10 min 
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with HATU (0-[7-azabenzotriazole-1-yl]-1,1,3,3-tetramethyluronium hexafluorophosphate; 1.2 eq) in DMF. 
After 1 h at room temperature, half the initial quantity of preactivated DOTA-tris(t-butyl ester) was added to 
the mixture, and after a total reaction time of 2 h, the peptide was precipitated in ice-cold diethylether. Its 
DOTA-moiety was then deprotected by addition of 90%-TFA mixture (4 ml/5 mg of peptide). The mixture 
was stirred for 4 h, and deprotected DOTA-peptide was then precipitated in ice-cold diethylether, 
resuspended in 10% acetic acid and purified by RP-HPLC. 
RP-HPLC: tR = 16.7 min. Calculated monoisotopic mass: 1716.80 gmol
-1; found: 1716.79 gmol-1. 
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Figure 49: Structure of DOTA-NAP-D-Asp-D-Asp 
 
DOTA-phospho-MSH2-9 
The first amino acid was coupled to the Fmoc-PAL-PEG-PS resin by hand. Fmoc-Trp(Boc)-OH (3 eq) was 
preactivated with HOBt (3 eq + 15%) for 10 min. Then the mixture was added to a suspension of the Fmoc-
deprotected resin, and DIPC (3 eq) was added, and let for reaction overnight. It was then washed 5x with 
DMF, and completion was checked by a Kaiser test. The sequence Nle-Asp-His-D-Phe-Arg-Trp-NH2 was 
then synthesized on the peptide synthesizer according to the methods mentioned above. After deprotection 
of the N-terminal Fmoc protecting group, Fmoc-Tyr(PO(OBzl)-OH)-OH (5 eq) was preactivitated with HOBt 
(1 eq), and then coupled to the peptide (1 eq peptide on resin) by adding TBTU (1 eq) and DIPEA (15 eq). 
After an overnight incubation, the reaction was repeated in the same conditions. After cleavage from the 
Fmoc protecting group, Fmoc-Gly-OH was coupled in the same conditions. Finally, after Fmoc 
deprotection, DOTA was coupled to the on-resin peptide by preactivating DOTA (3 eq) with HATU (3 eq) for 
10 min, then by adding DIPEA (9 eq) to the resin suspension (1 eq peptide) for an overnight reaction. The 
peptide was then simultaneously cleaved from the resin and deprotected, as was the DOTA moiety, by 
adding the 90% TFA-mixture for 4 h, and precipitated in ice-cold diethylether. The peptide was finally 
purified by RP-HPLC (tR = 16.5 min). Calculated monoisotopic mass: 1558.59 gmol
-1; found: 1558.30 
gmol-1. 
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Figure 50: Structure of DOTA-Phospho-MSH2-9. 
 
 
Radiolabeling of peptides 
 
Labeling with 
111
In 
Incorporation of 111In into DOTA-peptides was performed by the addition of 55.5 MBq of 111InCl3 to the 
DOTA-peptides (10 nmol) that had been dissolved in 54 µl acetate buffer (0.4 M, pH 5) containing 2 mg of 
gentisic acid. Incubation for 10 min at 95°C allowed completion of the reaction. The radiolabeled DOTA-
peptides were then purified on a small reversed-phase cartridge (Sep-Pak C18, Waters) by first washing 
the column with 0.4 M sodium acetate buffer (pH 7) and then eluting the peptides with ethanol. The purity of 
the radioligands was assessed by RP-HPLC/#-detection in the conditions mentioned above. The specific 
activity of the radioligand was always >7.4 GBq/µmol. 
 
 
Radioiodination 
The Iodogen® (Pierce) method was used for the radioiodination of NDP-MSH. To this end, NDP-MSH 
(12.14 nmol) was mixed with Na125I (37 MBq; Perkin Elmer) in 60 µl phosphate buffer (0.3 M, pH 7.4) in a 
Iodogen®-precoated tube. After 15 min incubation at room temperature under agitation, the iodination 
mixture was loaded onto a small reversed-phase cartridge (Sep-Pak C18, Waters), which was washed 
consecutively with water and acetic acid (0.5 M). Finally, the peptide was eluted with methanol. The 
collected fractions containing [125I]NDP-MSH were supplemented with dithiothreitol (1.5 mg/mL) and stored 
at –20°C. Each binding experiment was preceded by an additional purification of the radiotracer by RP-
HPLC and subsequent lyophilization from lactose/bovine serum albumin (BSA) (20 mg of each per ml of 
tracer solution). 
 
Cell culture 
The mouse B16-F1 melanoma cell line101 was cultured in modified Eagle!s medium (MEM) containing 10% 
heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 1% nonessential amino acids, 1% vitamin solution, 
50 IU/mL penicillin and 50 µg/mL streptomycin, in an atmosphere of 95% air/5% CO2 and at a temperature 
of 37°C. For cell expansion or experiments with isolated cells, the B16-F1 cells were detached with 0.02% 
EDTA in PBS (phosphate-buffered saline; 150 mM, pH 7.2-7.4). The human HBL melanoma cell line122 was 
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cultured in modified RPMI medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-
glutamine, 50 IU/mL penicillin and 50 µg/mL streptomycin in the same conditions as for B16-F1 cells. 
 
In vitro binding assay  
Triplicates of 100-µL B16-F1 or HBL cell suspensions adjusted to 4 x 106/mL were incubated in 96-well U-
bottom microplates (Falcon 3077). The binding medium consisted of MEM with Earle!s salts, 0.2% BSA 
and 0.3 mM 1,10-phenanthroline. This binding medium was called Mouse Binding Medium (MBM) 
Triplicates of competitor peptide solution (50 µL), yielding final concentrations ranging from 1x10-6 to 1x10-
12 M, were added. 50,000 cpm [125I]NDP-MSH in 50 µL were finally added to each well. The plates were 
incubated at 15°C for 3 h for B16-F1 cells and at 37°C for 2 h for HBL cells. The incubation was stopped by 
covering the plates with ice for 10 min. A cell harvester was used to collect cell-bound radioactivity on filters 
(Packard Unifilter-96 GF/B). The collected radioactivity was counted on a TopCount scintillation counter 
(Packard) after addition of 50 µl Microscint-20 scintillation cocktail (Perkin Elmer). The IC50 values were 
calculated with the Prism software (GraphPad Software Inc., San Diego CA, USA).  
 
In vitro melanin assay 
The biological activity of the !-MSH derivatives was assessed with an in situ melanin assay. Briefly, B16-
F1 cells (2,500 cells per well in 100 µl) were distributed into 96-well flat-bottom cell culture plates. MEM 
without phenol red, supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 0.31 
mmol/L L-tyrosine, 1% nonessential amino acids, 1% vitamin solution, 50 IU/mL penicillin and 50 µg/mL 
streptomycin, was used as culture medium. After overnight incubation at cell culture conditions mentioned 
above, concentrations of !-MSH derivatives ranging from 1x10-8 to 1x 10-12 in 100-µL volumes were added 
(in 3-fold dilution steps) and the incubation went on for additional 72 h. Melanin production was quantified 
by determining the absorbance at 310 nm in a microplate reader. 
 
In vitro internalization assay 
B16-F1 cells were seeded in 6-well plates and incubated overnight in MEM at 37°C. For the internalization 
experiments, MEM was replaced by 1 mL MBM internalization buffer, consisting of MEM with Earle!s salts, 
0.2% BSA and 0.3 mM 1,10-phenanthroline. After a 1-h incubation at 37°C, 74 kBq of radioligand (111In-
labeled peptides) were added and the plates were incubated for different time periods. Nonspecific 
internalization was determined by addition of 50 µL of a 1 µM !-MSH solution to the incubation mixture. 
After the desired incubation times, the cells were extensively washed with MBM kept at 37°C to remove 
excess radioligand. Incubation in 2 mL ice-cold acid buffer (acetate-buffered Hank!s balanced salt solution, 
pH 5) for 10 min allowed dissociation of surface-bound ligand. After collection of the acid buffer fraction, the 
cells were rinsed once with cold MBM and the washings were pooled with the acid buffer fraction. The cells 
were then washed again with MBM kept at 37°C, then lysed in a 1% Triton X-100 solution and finally 
transferred to tubes for quantification. The radioactivity of all collected fractions was measured in a #-
counter. A counting plate underwent the same treatment as the plate incubated for the longest time, but its 
cells were detached with 0.02% EDTA in PBS instead of being lysed with the Triton X-100 solution. Cells 
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from 3 wells were collected, counted, and thus allowed for normalization of the results obtained. Results 
could be expressed as percent of the added dose per million cells. 
 
Biodistribution and stability of radioligands in B16-F1 tumor-bearing mice 
All animal experiments were performed in compliance with Swiss animal welfare regulations. 0.5 million 
B16-F1 were implanted subcutaneously to female B6D2F1 mice (C57BL/6 % DBA/2F1 hybrids; breeding 
pairs obtained from IFFA-CREDO, France). 7 days later, 185 kBq of [111In]-labeled ligand in 200 µl 
PBS/0.1% BSA were injected intravenously into the lateral tail vein of each mouse. Control mice were 
injected with a mixture of the tracer and 50 µg !-MSH to determine the nonspecific uptake of radioligand. 
The animals were sacrificed 4, 24 and 48 h post-injection. They were dissected and the tissues of interest 
were collected, rinsed of excess blood and weighed. The radioactivity emitted by each organ was 
measured in a #-counter to determine the tissue uptake as percentage of the injected dose per gram of 
tissue (%ID/g). Total injected counts per animal were determined by extrapolation from counts of a 
standard collected from the injection solution for each animal. Urine samples were collected at 10, 15, 20 
min and 4 h after injection, and kept frozen at -80°C until use. Urine (1 vol) was mixed with methanol (2 vol) 
to precipitate proteins, and the supernatant was analyzed by RP-HPLC/#-detection, as described earlier. 
 
Analysis of data 
Results are expressed as means ± SEM, unless otherwise stated. Statistical evaluation of the binding 
assays was performed using the Student!s t test. For biodistribution data, each mean value obtained for 
each organ was compared individually using the Student!s t test and the results were corrected by the 
Bonferroni correction. A P value of <0.05 was considered statistically significant. The area under the curve 
(AUC) was calculated for the time period of interest (4-48 h) using the Prism software; mean tissue uptake 
values at each time point were used for this calculation. 
 
 
RESULTS 
 
Peptide synthesis 
The synthesis of DOTA-NAPamide, DOTA-NAP-D-Asp-D-Asp and DOTA-phospho-MSH2-9 were performed 
as described in the Experimental Procedures. DOTA-NAPamide was obtained in >99% purity and in 15% 
overall yield (after RP-HPLC purification). DOTA-NAP-D-Asp-D-Asp was obtained in >99% purity as well 
and in 8.3% overall yield. DOTA-phospho-MSH2-9 was obtained in >99% purity and in 5.3% overall yield. 
The expected molecular weights were confirmed by mass spectrometry and are indicated in the 
Experimental Procedures. The net charges of DOTA-NAP-D-Asp-D-Asp and DOTA-Phospho-MSH2-9 at 
physiological pH are -1, and were calculated on the basis of known pKa values for amino acid residues and 
functional groups. 
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In vitro receptor binding assay and biologic activity 
The binding affinity of the peptides was assessed by competition binding assays vs. [125I]-NDP-MSH in both 
the murine B16F1 and the human HBL cell lines. Table 12 summarizes the IC50-values obtained for the 
tested peptide compared to the values of the native ligand !-MSH and the reference peptide DOTA-
NAPamide. DOTA-phospho-MSH2-9 displayed affinities in the nanomolar range on both cell lines. Although 
the IC50 obtained for DOTA-phospho-MSH2-9 on the B16F1 cell line was slightly lower than that of DOTA-
NAPamide, its binding affinity for HBL cells was comparable. DOTA-phospho-MSH2-9 displayed a good !-
MSH agonist activity (see Table 12), as demonstrated by the induction of melanin synthesis by B16F1 cells 
at a dose matching its IC50. On the other side, DOTA-NAP-D-Asp-D-Asp seems to have lost affinity for the 
receptor through the adopted modifications. Indeed, affinities were between around 10-fold (B16F1) to 100-
fold (HBL) lower than those of DOTA-NAPamide. Its biological activity is also around 10-fold lower than the 
reference peptide. 
 
 
Table 12: MC1R affinity and biological activity of !-MSH analogs on B16F1 and HBL cells. 
!-MSH analogs 
B16F1 IC50 
(nmol/L)
*
 
HBL IC50  
(nmol/L)
*
 
rEC50 
(!-MSH=1)
†
 
!-MSH 1.50 ± 0.14 1.91 ± 0.26 1 
DOTA-NAPamide 1.38 ± 0.35 3.09 ± 1.11 0.66 ± 0.35 
DOTA-NAP-D-Asp-D-Asp  19.7 ± 4.48‡ 333.9 ± 59.78  7.66 ± 0.33‡ 
DOTA-phospho-MSH2-9 2.32 ± 0.80 3.03 ± 0.59 0.85 ± 0.11 
_________ 
*MC1R affinity of !-MSH analogs was assessed by competition binding experiments with B16F1 or HBL cells and 125I-
NDP-MSH as radioligand (n=3-16). Data for DOTA-NAPamide are from Bapst et al. (J Recept Signal Transduct Res 
(2007) 27, 383-409. 
†Biological activity of !-MSH analogs was determined in melanin assay with B16F1 cells, and results are expressed as 
relative concentration inducing half-maximal response (rEC50, n=3-10) normalized on !-MSH=1. 
‡
P < 0.05 vs. DOTA-NAPamide 
 
 
Internalization 
DOTA-NAP-D-Asp-D-Asp and DOTA-phospho-MSH2-9 exhibited excellent internalization profiles. Although 
the plateau phase was not quite reached for the former, probably because of its lower receptor affinity, the 
plateau phase was almost reached after 2 h already for DOTA-phospho-MSH2-9, indicating that nearly the 
totality of the peptide was internalized. For DOTA-NAP-D-Asp-D-Asp, this inability to reach the plateau 
phase may be seen as an issue regarding in vivo tumor uptake. For DOTA-phospho-MSH2-9, the results 
exclude internalization of the peptide by tumor cells as a potential issue regarding the in vivo tumor uptake, 
and show that MC1R-downregulation was not retarded by the negatively charged ligand. 
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Figure 51: Determination of internalization of DOTA-Phospho-MSH2-9 by cultured B16F1 cells. 
 
 
Biodistribution experiment in tumor-bearing mice 
Tissue distributions of the new radiolabeled !-MSH analog and of the reference peptide DOTA-NAPamide 
are listed in Table 13. Tissues, including melanoma tumors, were collected 4 h, 24 h and 48 h after 
injection of the 111In-labeled analog. Clearance from the blood was fast for both radiopeptides, as almost no 
radioactivity could be detected after 4 h. DOTA-NAP-D-Asp-D-Asp accumulated in the kidney in a higher 
extent (25% more) than the reference peptide DOTA-NAPamide, which does not confirm the expected 
effect of the negative charges. On the other side, the receptor affinity seemed to be lost, as only 1.93 
%ID/g accumulated in the tumor 4 h after injection, which is a reduction of 75 % compared to DOTA-
NAPamide. Other organs did not accumulate the radioactive tracer at all. 
The other peptide studied displayed much more promising data. After 4 h, DOTA-Phospho-MSH2-9 
accumulated in the tumor to a lesser extent than DOTA-NAPamide did (6.12 ± 0.44 %ID/g vs. 7.77 ± 0.35 
%ID/g). This 1.27-fold lower accumulation was compensated for by a much lower uptake of radioactivity by 
the kidney (2.98 ± 0.20 %ID/g vs. 4.77 ± 0.26 %ID/g), representing a 1.6-fold reduction, and producing the 
highest tumor-to-kidney ratio at 4 h (2.05) ever observed for a linear peptide. The non-specific uptake by 
other organs remained comparable to the data obtained for DOTA-NAPamide, thus excluding a switch in 
the excretion way. Coinjection of 50 µg of !-MSH confirmed that melanoma uptake was an MC1R-
mediated process for the !-MSH analog, as it was significantly reduced. An average retention was 
observed in the tumor, as only 40% of the radioactivity measured after 4 h was found after 24 h, and 17% 
after 48 h. On the other side, clearance from the kidney appeared to be a slower process. Indeed, 70% and 
39% of the radioactivity measured after 4 h were still measured after 24 h and 48 h, respectively. 
Nevertheless, the difference in uptake observed after 4 h, as can be seen in Figure 52, was sufficient to 
deliver a tumor-to-kidney ratio calculated from the AUC (4-48 h) of 1.42 (Figure 53), which is the best ratio 
observed for a linear radiolabeled !-MSH analog to date. Indeed, DOTA-NAPamide, which was considered 
as the best linear !-MSH analog, bears a tumor-to-kidney ratio of the AUC (4-48h) of 1.11. Thus, the ratio 
exhibited by DOTA-phospho-MSH2-9 is 28% better than the reference peptide. 
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Table 13: Tissue distribution, including melanoma tumor, of the negatively charged 
111
In-labeled !-MSH analogs 
and DOTA-NAPamide 4, 24 and 48h after injection, expressed in %ID/g of tissue. 
  %ID/g of tissue† 
Organ Time 
(h) 
DOTA-NAPamide DOTA-Phospho-MSH2-9 DOTA-NAP-DAsp-DAsp 
Blood 4 0.09 ± 0.02 0.02 ± 0.00  0.01 ± 0.00‡ 
 24 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
 48 0.00 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 
Tumor 4 7.77 ± 0.35 6.12 ± 0.44  1.93 ± 0.11‡ 
 24 2.32 ± 0.15 2.42 ± 0.10  0.63 ± 0.03‡ 
 48 1.41 ± 0.12 1.06 ± 0.13  0.23 ± 0.02‡ 
Stomach 4 0.09 ± 0.01 0.17 ± 0.08 0.11 ± 0.02 
 24 0.12 ± 0.02 0.16 ± 0.02  0.03 ± 0.00‡ 
 48 0.11 ± 0.05 0.07 ± 0.00 0.02 ± 0.00 
Kidney 4 4.77 ± 0.26  2.98 ± 0.20‡ 5.95 ± 0.85 
 24 2.41 ± 0.20 2.09 ± 0.13 4.09 ± 0.16 
 48 1.55 ± 0.07 1.16 ± 0.08 2.02 ± 0.08 
Liver 4 0.34 ± 0.05 0.20 ± 0.01  0.10 ± 0.00‡ 
 24 0.31 ± 0.02  0.16 ± 0.02‡  0.09 ± 0.00‡ 
 48 0.27 ± 0.02  0.12 ± 0.01‡  0.07 ± 0.00‡ 
Spleen 4 0.14 ± 0.01 0.11 ± 0.01  0.07 ± 0.00‡ 
 24 0.11 ± 0.01 0.10 ± 0.01  0.07 ± 0.00‡ 
 48 0.10 ± 0.01 0.09 ± 0.01 0.07 ± 0.00 
Lung 4 0.08 ± 0.01 0.07 ± 0.02 0.06 ± 0.00 
 24 0.05 ± 0.01 0.04 ± 0.00 0.04 ± 0.00 
 48 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
Small Intestine 4 0.07 ± 0.01 0.11 ± 0.03 0.05 ±0.01 
 24 0.08 ± 0.01 0.06 ± 0.00 0.04 ± 0.01 
 48 0.05 ± 0.01 0.06 ± 0.00 0.03 ± 0.00 
Pancreas 4 0.04 ± 0.00 0.05 ± 0.01 0.03 ± 0.00 
 24 0.03 ± 0.00 0.03 ± 0.00 0.02 ± 0.00 
 48 0.02 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
Heart 4 0.05 ±0.01 0.04 ± 0.00 0.03 ± 0.00 
 24 0.03 ± 0.00 0.03 ± 0.00 0.03 ± 0.00 
 48 0.01 ± 0.00  0.03 ± 0.00‡  0.03 ± 0.00‡ 
Bone 4 0.11 ± 0.02 0.08 ± 0.01 0.07 ± 0.01 
 24 0.14 ± 0.02 0.11 ± 0.02  0.06 ± 0.01‡ 
 48 0.05 ± 0.01 0.06 ± 0.01 0.07 ± 0.01 
Muscle 4 0.05 ± 0.01 0.02 ± 0.00 0.02 ± 0.00 
 24 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
 48 0.01 ± 0.00  0.02 ± 0.00‡  0.03 ± 0.00‡ 
Skin 4 - 0.12 ± 0.03 0.06 ± 0.01 
 24 - 0.07 ± 0.02 0.06 ± 0.00 
 48 - 0.08 ± 0.02  0.04 ± 0.00‡ 
____________ 
* Data for DOTA-NAPamide from Froidevaux et al., J Nucl Med (2005) 46, 887-895. 
† Tissue radioactivity is expressed as means ± SEM (n=4-12). 
‡ P < 0.05 vs. DOTA-NAPamide. 
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Figure 52: Tissue distrubution of 
111
In-labeled DOTA-phospho-MSH2-9 at 4h, 24h and 48h after injection. Results 
expressed in %ID/g of tissue (means ± SEM), 
†
P<0.05 vs. 
111
In-DOTA-NAPamide. 
 
 
 
Figure 53: Tumor-to-kidney ratios of 
111
In-labeled DOTA-phospho-MSH2-9 compared to 
111
In-labeled DOTA-NAPamide, calculated from the AUC (4-48h).  
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DISCUSSION 
 
The main goals in the development of new radiolabeled receptor-targeted peptides for applications in 
nuclear oncology are the maximization of tumor targeting and the minimization of nonreceptor-mediated 
accumulation. Radiolabeled !-MSH analogs suffer from a high uptake by the kidneys, the main organs 
responsible for its excretion. In the last years, several studies have shown that the attempts to increase the 
uptake of radiolabeled !-MSH analogs by the tumor may have reached its limits25,59,60,110,114,115,203,209. 
Therefore, reduction of their kidney uptake has become a crucial step in the further development of these 
potential tools for melanoma diagnosis and therapy. 
 
Physicochemical properties of the radioactive tracers are determinant for their uptake in excretory organs. 
Net charge, particularly, seems to have a dramatic impact on the in vivo behavior of targeting 
peptides7,67,168,181. Indeed, it has been shown that the surface of tubular cells is negatively charged, 
involving repulsing electrostatic effects with negatively charged molecules in the luminal part of the 
proximal tubules33,78. Additional observations that coinjection of solutions of basic amino acids such as Lys 
or Arg significantly reduced the uptake of radiopeptides by the kidney contributed to this theory114,256. 
Indeed, it has been assumed that positively charged amino acids compete with peptides for the charge-
dependent uptake by renal tubular cells. 
 
Earlier peptides with a global negative charge were studied in our group and delivered no satisfactory 
results regarding in vivo behavior115. One of these peptides carried a succinimidyl group at the C-terminal 
end of the sequence, and had a global net charge of -1 as well. It delivered a slightly lower kidney uptake 
than the reference peptide DOTA-NAPamide, but lost its affinity for the tumor in vivo. This result, which was 
in contradiction with the earlier findings mentioned above, suggested that charge localization might be an 
essential parameter in the quest of improved biodistribution profiles. 
 
The first derivative synthesized during this study bore a -D-Asp-D-Asp ending at its C-terminal end, in order 
to assess the effect of negative charges at the C-terminus with a peptide more robust than the previously 
mentioned succinimidyl derivative. The aim of this strategy was to enhance kidney excretion of the 
Lys(DOTA)-NH2 moiety, presumably a main radioactive metabolite (unpublished observations), by 
attaching two negative charges supposed to have a repulsive electrostatic interaction with the negatively-
charged tubular cells. Receptor affinity was quite poor on both human and murine cells, and these findings 
were confirmed by biodistribution data. The peptide apparently loses its receptor affinity both in vitro and in 
vivo through its modifications. In vitro, binding affinities were 10- to 100-fold lower than the reference 
peptide DOTA-NAP-amide on B16F1 or HBL cells, respectively. In vivo, the expected reduction of the 
kidney uptake could not be observed. Kidney uptake was even slightly higher than that of the reference 
peptide. Additionally, as expected from the in vitro data, tumor uptake was drastically reduced to reach only 
about one fourth of that of the reference. 
To determine the influence of the position of the negative charge, a phosphotyrosine residue was 
introduced in the sequence in second position, towards the N-terminal end, providing the peptide with a 
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global net charge of -1. This alteration involved a slight decrease in MC1R affinity (1.68-fold worse than 
DOTA-NAPamide) in B16F1 cells, but surprisingly did not affect affinity in HBL cells. The position of the 
additional negative charge was definitely crucial for the pharmacokinetic behavior of !-MSH analogs, as 
the newly synthesized DOTA-phospho-MSH2-9 delivered a significant reduction of the kidney uptake at 4 h 
(1.6-fold lower than DOTA-NAPamide), without extensively affecting its tumor uptake. This positive impact 
of the negative charge was reported on the tumor-to-kidney ratio of the AUC (4-48 h), exhibiting a ratio of 
1.42, which is 28% better than that of DOTA-NAPamide. 
In conclusion, the reduction and above all the adequate positioning of the net charge of peptides has a 
significant impact on their pharmacokinetics. The influence of this factor on accumulation in MC1R-
expressing cells and tissues, however, was not substantial. The in vitro affinity of the peptide corresponded 
to that of DOTA-NAPamide, although slightly lower. This was proven by the biodistribution data, which 
displayed an average uptake of the negatively charged peptide by the tumor. On the other side, the 
adequate position of the negative charge on DOTA-Phospho-MSH2-9 certainly contributed to the reduction 
of its renal accumulation. Therefore, it constitutes now the best linear radiolabeled !-MSH analog and the 
very promising properties it exhibited will certainly be a strong base for further developments in this 
direction. 
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6 General discussion and conclusion 
 
 
During the last two decades, different approaches have been used in an attempt to target melanoma tumor 
cells. Radiolabeled peptide !-MSH analogs represent one of these approaches and have shown attractive 
targeting properties. Indeed, on one hand in vitro binding affinities on both murine and human cell lines 
have generally been good and have reached excellence in the last years with IC50s in the (sub-)nanomolar 
range, which is, per se, striking in the world of pharmaceutical drugs. On the other hand, their targeting 
properties in vivo have also improved dramatically, especially in the last decade. Their usefulness has been 
proven for the targeting of melanoma tumors in pharmacokinetic studies on mice, with interesting tumor-to-
non-target-tissue ratios. However, they suffer from a major drawback: their kidney uptake and retention 
remain relatively high compared to their tumor uptake. Attempts have been made to either increase their 
uptake by the tumor, or to reduce their uptake by the kidney. Some major advances (replacement of Phe7 
by D-Phe7, replacement of Met4 by Nle4, positioning of DOTA on Lys11 side chain, etc.) have led to more 
favorable pharmacokinetical profiles. But if DOTA-NAPamide displays one of the best tumor-to-kidney 
ratios to date, its profile is still far from satisfying the criteria required for melanoma diagnosis or therapy in 
humans. Its kidney uptake remains too high, and thus could mask the diagnosis of distant metastases in 
the renal region, and could irremediably damage the kidney with the higher doses and more harmful 
radionuclides needed for therapy. Further modifications (localized net charge, cyclization, etc.) have not 
solved the kidney issue. 
 
The present work was undertaken to determine if new modifications might improve the pharmacokinetical 
profile of !-MSH analogs. The three major approaches mentioned earlier in this thesis were investigated in 
a systematical way. First, the derivatives were synthesized, purified and characterized. Then, they were 
tested in vitro against [125I]-NDP-MSH, the well-known high-potency agonist of !-MSH for the MC1R, in 
competitive binding assays on both murine B16F1 and human HBL cells. They were also tested in cell 
internalization assays as 111In-labeled peptides, and finally for their biological (melanogenic) activity in 
melanin assays. The pharmacokinetical profile of the !-MSH analogs was then assessed in in vivo 
biodistribution experiments using melanoma bearing mice. 
 
Firstly, dimeric derivatives were investigated. As mentioned, the idea behind this strategy was to increase 
the concentration of the binding motif in the vicinity of the receptor in order to ultimately improve the tumor 
uptake of the peptides in vivo. The expected effect could be observed in vitro in competitive binding 
assays, as the binding affinities (IC50) were between 1.75 and 3.37-fold better (murine cells, depending on 
the peptide) or even 6-fold better (human cells) than those of DOTA-NAPamide, the peptide used for 
comparison. The biological activity assays (EC50) revealed very similar profiles to DOTA-NAPamide, and 
internalization assays displayed similarly fast and almost complete uptake of the peptides by the cells. 
GENERAL DISCUSSION AND CONCLUSION 
154
On the other hand, their in vivo pharmacokinetic profiles did not match the encouraging results obtained in 
vitro. Indeed, their kidney uptake dramatically increased to reach values between 25 and 35%ID/g of tissue 
at 4 h (4.77%ID/g for DOTA-NAPamide). What happened to these peptides in the kidney remains unclear. 
It may not depend on the position of the chelate, as suggested earlier to inspire the synthesis of the 
derivative carrying the -Gly-Lys(DOTA) extension, as all three peptides carried the DOTA-moiety at a 
different position along their sequences and all three displayed the same kind of biodistribution profile. 
Additionally, the expected effect of dimerization (increasing the number of binding motifs in the vicinity of 
the target receptor) on tumor uptake was not observed in vivo, in contrast to the binding affinities found in 
vitro. Although the tumor uptake of DOTA-diHexa(CN-NC)-amide was quite high (9.08%ID/g), kidney 
uptake abolished all its benefits. The other two dimeric peptides displayed much lower tumor uptakes than 
DOTA-NAPamide. 
 
Although new modifications could be adopted, such as variation of the net charge of the peptide or its 
position along the sequence, insertion of unnatural amino acids in the sequence or synthesis of oligomers 
for example, it still appears that dimeric derivatives are not the method of choice to improve tumor-to-
kidney ratios of radiolabeled !-MSH analogs. Owing to their high receptor affinity, however, they may be 
useful in pretargeting strategies. Indeed, pretargeting involves the separation of the localization of the 
tumor, with an anticancer antibody for example, from the subsequent delivery of the imaging or therapeutic 
radionuclide by peptide haptens. With their excellent binding affinities, the studied dimeric derivatives could 
serve as “carriers” (for instance, instead of bsMAb (bispecific antibodies) typically used in pretargeting 
strategies) for other binding motifs, themselves becoming targets for (preferably) bivalent radiolabeled 
haptens. With pretargeting strategies using bsMAb, tumor-to-non-target-tissue ratios could be dramatically 
improved. Goldenberg et al. observed much faster blood clearance and measured tumor/blood and tissue 
ratios often &10:1 within 1 h of the radionuclide injection128. It is thus reasonable to think that an adaptation 
of the bsMAb-method to dimeric !-MSH analogs could enhance their pharmacokinetical profiles as well. 
This approach would be rather complex and time-consuming, but would probably be worth an attempt. 
 
Secondly, glycated derivatives were synthesized and tested. The purpose of glycation was to increase 
kidney excretion of the radiolabeled peptides thanks to an enhanced hydrophilicity, without reducing their 
affinity for tumor cells. In in vitro competitive binding assays, it was observed that receptor affinity was 
conserved, with slight variations, compared to the reference peptide DOTA-NAPamide. Indeed, receptor-
binding affinities (IC50s) ranged from around 2-fold lower to 3-fold better than the reference peptide (with 
just one peptide, DOTA-N-NAPamide-Glc, bearing a 3.3-fold lower affinity). It is noteworthy that all 
glycopeptides displayed competitive binding affinities in the low nanomolar range, thus confirming that 
glycation does not affect receptor affinity sufficiently to impair binding. 
Two main trends were observed in their in vivo pharmacokinetical profiles. Glycation at the C-terminal end 
increased the kidney uptake and above all the retention time (around 100% of the 4 h-values still present 
after 24h), although tumor uptake and retention remained quite comparable (slightly lower) to those of 
DOTA-NAPamide. Side-chain glycated peptides displayed similar profiles, with enhanced kidney uptake 
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and lower tumor uptake than the reference peptide. No extension of the retention time was observed in the 
kidney for these peptides. 
 
Peptides glycated at their N-terminal end exhibited more interesting profiles. Indeed, although DOTA-Glc-
NAPamide displayed a weaker profile (lower tumor uptake and similar uptake in the kidney as in the 
tumor), DOTA-Mtr-NAPamide and especially DOTA-Gal-NAPamide grabbed our attention. Their profiles 
were very comparable to the reference DOTA-NAPamide, displaying high tumor uptakes and low kidney 
uptakes. Analysis of their tumor-to-kidney ratio of the AUC (4-48h) showed all their potential: if DOTA-Mtr-
NAPamide was slightly weaker than DOTA-NAPamide (ratio of 0.99 vs. 1.11), DOTA-Gal-NAPamide 
exhibited a better ratio than the reference, with 1.34. This result, together with the overall analysis of the 
glycopeptides class, shows that N-terminal glycation is most likely more favorable than glycation at other 
positions, and that the introduction of a galactose moiety is advantageous over other carbohydrate 
moieties. From another point of view, this study also confirms previous reports102,103,237,273,281,301,303,323,324 
about the influence that carbohydration can have on pharmacokinetics of peptides. Indeed, dramatic 
variations were observed, depending on the type of carbohydrate used or its position. Small modifications 
such as the replacement of a glucose moiety by a galactose readily produce striking effects. The number of 
potential variations would be infinite, and the lack of methods to precisely forecast the efficiency of new 
molecules makes the testing of all possibilities unfeasible. Indeed, it was observed in this work that e.g. the 
results of competitive binding assays did not necessarily correlate with the in vivo pharmacokinetical profile 
of the molecules tested. Additionally, it is ethically and technically definitely not conceivable to test a very 
large panel of molecules (e.g. synthesized by HTS) in animal experiments. Therefore, the future of 
glycopeptides should be envisaged with slight modifications of the existing promising peptides, i.e. 
preferably DOTA-Gal-NAPamide. As the introduction of negative charges in the sequence exhibited very 
positive effects (see DOTA-phospho-MSH2-9), it would be interesting to determine if a synergy between the 
two methods could be exploited. An attractive candidate would be, for example, a derivative of DOTA-Gal-
NAPamide carrying the phosphate group of DOTA-phospho-MSH2-9, to investigate if the effect of both 
modifications on pharmacokinetics is additive.  
 
Further investigations on the effect obtained by attachment of various chemical entities would also be 
necessary to draw conclusions about structure-activity relationship parameters of radiolabeled !-MSH 
analogs. It would be interesting to observe the consequences of the substitution of a rather hydrophilic 
carbohydrate moiety by a lipophilic phenyl or benzyl group, for example. Is the positive effect of galactose 
in DOTA-Gal-NAPamide only due to the presence at its N-terminus of a sugar and its hydroxyl groups, or 
could another sterically bulky functional group display the same positive influence on the pharmacokinetic 
properties of the peptide? A tremendous number of derivations is theoretically mentioned before, it would of 
course definitively not be possible to test all options, but some preliminary experiments in this direction 
would certainly be of interest. 
 
Thirdly, two negatively charged peptides were synthesized. The reason for the adoption of this strategy 
was to enhance kidney excretion of the peptide, thanks to repulsive electrostatic forces between negatively 
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charged peptides and the negative charges present at the surface of tubular cells, resulting in an enhanced 
excretion of the tracers in the primary urine and a potential reduction of the kidney uptake. Earlier 
developments in our group studied the impact of a negative charge localized at the C-terminal end of the 
peptide, but yielded insufficient biodistribution data. In the peptides tested earlier in our group, the chelate 
was placed at their N-terminal end. A new peptide was tested that bore the chelate as well as two 
negatively-charged D-Asp at its C-terminal end, in order to increase kidney excretion of a potential 
Lys(DOTA)-NH2 metabolite observed previously (unpublished data). While its kidney uptake could not be 
reduced by this modification, the peptide also lost its affinity to the receptor and displayed a poor tumor 
uptake in vivo. It was suspected that localization of the negative charge was indeed a crucial parameter. 
Another peptide carrying a phosphotyrosine residue (negatively charged at physiological pH) towards its N-
terminus was evaluated. In vitro experiments exhibited slightly lower MC1R affinity of DOTA-phospho-
MSH2-9 than the reference peptide DOTA-NAPamide in murine cells (though still lying in the nanomolar 
range), but unexpectedly an affinity similar to the reference peptide in human cells. Internalization data 
showed very good results, with the peptide being almost totally internalized after 2 h. The biodistribution 
experiment with 111In-labeled DOTA-phospho-MSH2-9 displayed very promising results. Indeed, although 
the tumor uptake was not as high as for some of the peptides (6.12 ± 0.44 vs. 8.30 ± 1.22 for DOTA-Gal-
NAPamide), the kidney uptake was much lower (2.98 ± 0.20 vs. 4.43 ± 0.34 for DOTA-Gal-NAPamide), 
producing a very interesting tumor-to-kidney ratio of the AUC (4-48 h) of 1.42 (1.34 for DOTA-Gal-
NAPamide and 1.11 for DOTA-NAPamide). These results really confirmed findings from other groups about 
the promising effect of negative charges on the pharmacokinetic behavior of such molecules7,33,67,168,181. 
Therefore, it would be relevant to study this approach further, using a systematic modification of the 
quantity of negative charges and their position along the peptide sequence in order to determine structure-
activity relationships. As mentioned in the previous paragraph, introduction of an additional negative charge 
towards the N-terminus of DOTA-Gal-NAPamide would certainly represent one of the next logical steps in 
this quest, with regard to combining the results obtained with the two strategies. 
 
We are aware that our studies encompassed a limited panel of derivatives from each type of radiopeptide. 
The lack of adequate automated cellular assays unfortunately does not allow the development of high-
throughput screening methods, and is therefore a limiting factor for the study of further analogs bearing 
systematic structural modifications. Indeed, as small differences in e.g. the type of sugar coupled to the 
peptide or the position of a negative charge had such strong influences, testing of a large number of 
molecules would be necessary. In addition, it was observed that in vitro binding affinities were not 
predictive for the in vivo behavior of the peptides, making the step to biodistribution experiments almost 
mandatory. Nevertheless, some major trends could be observed among the peptides or peptide types 
developed in this work, providing valuable information for the elucidation of some structural requirements of 
!-MSH derivatives. These may help to focus upcoming research on precise structural features for further 
developments in this field. As mentioned, combination of negative charges and sugar moieties may have a 
synergistic or additive impact on pharmacokinetics. Introduction of more negative charges may contribute 
to the renal excretion of the radiopharmaceuticals. Replacement of carbohydrates by other non-amino acid 
functional groups, or new derivatives bearing more non-natural amino acid residues may improve the in 
GENERAL DISCUSSION AND CONCLUSION 
157
vivo behavior of radiolabeled !-MSH analogs. The use of NOTAGA as chelate could constitute another 
interesting alternative for the improvement of the pharmacokinetical behavior of !-MSH analogs. As 
mentioned earlier, NOTAGA-coupled peptides such as Tyr3-octreotide exhibited enhanced uptake in target 
tissues and a faster excretion, probably owing to the spacer function of one of its “arms”. 
 
The future of !-MSH analogs is still open for optimization and innovations. Future work will certainly have 
to concentrate on minor modifications, as many investigations about major requirements have been 
achieved to date. This work hopefully laid a further milestone by investigating some classes of 
modifications in depth. Their fine-tuning will certainly give birth to new candidates with improved 
pharmacokinetic profiles and, optimistically, to the valuable diagnostic and therapeutic tools urgently 
needed in the clinic. 
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